CONFIDENTIA L
The GlaxoSmithKline group of companies 205724
1Division :World wide Development
Information Type :Reporting and Anal ysis Plan
Title :Reporting and Anal ysis Plan for 450 Participant/6 Month 
Strategic Interim and Final Anal ysis for Study  205724: 
Randomi zed, Double -Blind (Sponsor Open), Placebo -
Cont rolled, Multi -centre, Dose Ranging Stud y to Evaluate 
the Efficacy  and Safet y of Danirixin Tablets Administered 
Twice Dail y Compared with Placebo for 24 Weeks in Adult 
Participants with Chronic Obs tructive Pulmonary  Disease
Compound Number :[COMPANY_004]1325756
Effective Date :30-OCT -2018
Description:
The purpose of this Reporting and Anal ysis Plan is to describe the planned 450 
participant/6 month strategic interim and final analy ses and output to be included in 
the Clinical Study  Report for Protocol 205724 .
RAP Author(s):
Approver Date Approval Method
25-OCT -[ADDRESS_984577] -2018 eTMF eSignatureDirector Clinical Pharmacology
Copy right 2018 the GlaxoSmithKline group of companies. All rights reserved.  
Unauthorised cop ying or use of this information is prohibited.
[COMPANY_003]
[COMPANY_003]
CONFIDENTIA L
205724
2RAP Team Approval s:
Approver Date Approval Method
26-OCT -[ADDRESS_984578] -2018 eTMF eSignature
[CONTACT_493653]:
Approver Date Approval Method
30-OCT -2018 eTMF eSignat ureStatistics Director (Respi[INVESTIGATOR_720785])
26-OCT -2018 eTMF eSignature [CONTACT_720880] (Respi[INVESTIGATOR_720786])
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CONFIDENTIA L
205724
3TABLE OF CONTENTS
PAGE
1.INTRODUCTION ................................ ................................ ................................ ......7
1.1. RAP Amendment ................................ ................................ .......................... 7
2.SUMMARY OF KEY PROTO COL INFORMATION ................................ .................. 9
2.1. Changes to the Protocol Defined Statistical Analysis Plan ............................ 9
2.2. Study Objectives and Endpoints ................................ ................................ .10
2.3. Study Design ................................ ................................ .............................. 12
2.4. Statistical Hypotheses ................................ ................................ ................. 13
3.PLANNED ANALYSES ................................ ................................ .......................... 14
3.1. Interim Analyses ................................ ................................ ......................... 14
3.1.1. Interim PK Analysis ................................ ................................ ......14
3.1.2. Futility Analysis ................................ ................................ ............ 14
3.1.3. Strategic Analysis ................................ ................................ ........ 14
3.1.4. Administrative Int erims ................................ ................................ .14
3.2. Final Analyses ................................ ................................ ............................ 15
4.ANALYSIS POPULATIONS ................................ ................................ ................... 16
4.1. Strategic Interim Analysis ................................ ................................ ........... 16
4.2. Final Analysis ................................ ................................ ............................. 17
4.3. Protocol Deviations ................................ ................................ ..................... 17
5.CONSIDERATIONS FOR D ATA ANALYSES AND DAT A HANDLING 
CONVENTIONS ................................ ................................ ................................ .....18
5.1. Study Treatment & Sub -group Display Descriptors ................................ .....18
5.2. Baseline Definitions ................................ ................................ .................... 18
5.3. Multicentre Studies ................................ ................................ ..................... 19
5.4. Examination of Covariates, Other Strata and Subgroups ............................ 19
5.4.1. Covariates and Other Strata ................................ ........................ 19
5.4.2. Examination of Subgroups ................................ ........................... 20
5.5. Multiple Comparisons and Multiplicity ................................ ......................... 20
5.6. Other Considerations for Data Analyses and Data Handling 
Conventions ................................ ................................ ................................ 20
6.STUDY POPULATION ANA LYSES ................................ ................................ .......21
6.1. Overview of Planned Study Population Analyses ................................ ........ 21
6.1.1. Demographic and Baseline Characteristics ................................ ..21
6.1.2. Prior and C oncomitant Medications ................................ ............. 21
6.1.3. Exposure and Treatment Compliance ................................ .......... 21
7.EFFICACY ANALYSES ................................ ................................ .......................... 22
7.1. Primary Efficacy Analyses ................................ ................................ .......... 22
7.1.1. Month 6 E -RS: COPD Total Score Dose -Response 
Analysis ................................ ................................ ....................... 22
[IP_ADDRESS]. Endpoint ................................ ................................ .....22
[IP_ADDRESS]. Summary Measure ................................ ..................... 23
[IP_ADDRESS]. Population of Interest ................................ .................. 23
CONFIDENTIA L
205724
[IP_ADDRESS]. Strategy for Intercurrent (Post -Randomization) 
Events ................................ ................................ ........ 23
[IP_ADDRESS]. Statistical Analyses / Methods ................................ ....23
[IP_ADDRESS].1. Statistical Methodology 
Specification ................................ ........... 23
7.1.2. E-RS: COPD Subscale Scores Dose -Response Analysis ............ 25
7.1.3. E-RS: COPD Total and Subscale Scores Longitudinal 
Analysis ................................ ................................ ....................... 25
[IP_ADDRESS]. Endpoint ................................ ................................ .....25
[IP_ADDRESS]. Summary Measure ................................ ..................... 25
[IP_ADDRESS]. Population of Interest ................................ .................. 25
[IP_ADDRESS]. Strategy for Intercurrent (Post -Randomization) 
Events ................................ ................................ ........ 26
[IP_ADDRESS]. Statistical Analyses / Methods ................................ ....26
[IP_ADDRESS].1. Bayesian MMRM Methodology 
Specification ................................ ........... 26
[IP_ADDRESS].2. Frequentist MMRM Methodology 
Specification ................................ ........... [ADDRESS_984579] Events ................................ ................................ ............. 29
[IP_ADDRESS]. Endpoint ................................ ................................ .....29
[IP_ADDRESS]. Summary Measure ................................ ..................... 29
[IP_ADDRESS]. Population of Interest ................................ .................. 29
[IP_ADDRESS]. Strategy for Intercurrent (Post -Randomization) 
Events ................................ ................................ ........ 29
[IP_ADDRESS]. Statistical Analyses / Methods ................................ ....29
[IP_ADDRESS].1. Statistical Methodology 
Specification ................................ ........... [ADDRESS_984580] Event .................. 31
[IP_ADDRESS]. Endpoint ................................ ................................ .....31
[IP_ADDRESS]. Summary Measure ................................ ..................... 31
[IP_ADDRESS]. Population of Interest ................................ .................. 31
[IP_ADDRESS]. Strategy for Intercurrent (Post -Randomization) 
Events ................................ ................................ ........ 31
[IP_ADDRESS]. Statistical Analyses / Methods ................................ ....32
[IP_ADDRESS].1. Statistical Methodology 
Specification ................................ ........... 32
7.2.3. E-RS: COPD Total and Subscale Scores Responder 
Analysis ................................ ................................ ....................... 33
[IP_ADDRESS]. Endpoint ................................ ................................ .....33
[IP_ADDRESS]. Summary Measure ................................ ..................... 33
[IP_ADDRESS]. Population of Interest ................................ .................. 33
[IP_ADDRESS]. Strategy for Intercurrent (Post -Randomization) 
Events ................................ ................................ ........ 33
[IP_ADDRESS]. Statistical Analyses / Methods ................................ ....33
[IP_ADDRESS].1. Statistical Methodology 
Specification ................................ ........... 33
7.2.4. SGRQ Total Score and CAT Score ................................ .............. 34
7.2.5. Rescue Use ................................ ................................ ................. 34
7.2.6. Physical Activity ................................ ................................ ........... 34
7.3. Exploratory Efficacy Analyses ................................ ................................ .....35
CONFIDENTIA L
205724
57.3.1. E-RS: COPD Total Score ................................ ............................. [ADDRESS_984581] ................................ ................................ ...37
8.4.4. Strategy for Intercurrent (Post -Randomization) Events ................ 38
8.4.5. Statistical Analyses / Methods ................................ ..................... 38
[IP_ADDRESS]. Frequentist MMRM Methodology Specification ........... 38
8.5. Other Safety Analyses ................................ ................................ ................ 39
9.PHARMACOKINETIC ANAL YSES ................................ ................................ ......... 39
9.1. Primary Pharmacokinetic Analyses ................................ ............................. 39
9.1.1 .Derived Pharmacokinetic Parameters ................................ .......... 39
9.1.2. Statistical Analyses / Methods ................................ ..................... 39
9.2. Exploratory Pharmacokinetic Analyses ................................ ....................... 40
9.2.1. Derived Pharmacokinetic Parameter s................................ .......... 40
9.2.2. Statistical Analyses / Methods ................................ ..................... 40
[IP_ADDRESS]. Statistical Methodology Specification .......................... 40
10.POPULATION PHARMACOK INETIC ANALYSES ................................ ................. 41
11.BIOMARKER ANALYSES ................................ ................................ ...................... 41
12.PHARMACOKINETIC / PH ARMACODYNAMIC ANALYS ES................................ .42
12.1. Statistical Analyses / Methods ................................ ................................ ....42
13.REFERENCES ................................ ................................ ................................ .......43
14.APPENDICES ................................ ................................ ................................ ........ 44
14.1. Appendix 1: Protocol Deviation Management and Definitions for Per 
Protocol Population ................................ ................................ ..................... 44
14.1.1. Exclusions from Per Protocol Population ................................ .....44
14.2. Appendix 2: Schedule of Activities ................................ .............................. 45
14.2.1. Protocol Defined Schedule of Events ................................ ........... 45
14.3. Appendix 3: Assessment W indows ................................ ............................. 51
14.4. Appendix 4: Study Phases ................................ ................................ .......... 52
14.4.1. Study Phases ................................ ................................ .............. 52
[IP_ADDRESS]. Study Phases for Diary Data ................................ ......52
[IP_ADDRESS]. Study Phases for Concomitant Medication ................. 52
[IP_ADDRESS]. Study Phas es for Event Data ................................ ......53
[IP_ADDRESS]. Study Phases for Other Data ................................ ......53
14.5. Appendix 5: Data Display Standards & Handling Conventions .................... 54
14.5.1. Reporting Process ................................ ................................ .......54
14.5.2. Reporting Standards ................................ ................................ ....54
CONFIDENTIA L
205724
614.5.3. Reporting Standards for Pharmacokinetic Data ........................... 56
14.6. Appendix 6: Derived and Transformed Data ................................ ............... 57
14.6.1. General ................................ ................................ ........................ 57
14.6.2. Study Population ................................ ................................ .......... 57
14.6.3. Efficacy ................................ ................................ ........................ 61
14.6.4. Safety ................................ ................................ .......................... 66
14.7. Appendix 7: Reporting Standards for Missing Data ................................ .....68
14.7.1. Premature W ithdrawals ................................ ................................ 68
14.7.2. Handling of Missing Data ................................ ............................. 68
[IP_ADDRESS]. Handling of Missing and Partial Dates ........................ 68
14.8. Appendix 8 : Values of Potential Clinical Importance ................................ ...69
14.8.1. Laboratory Values ................................ ................................ ........ 69
14.8.2. ECG ................................ ................................ ............................. 70
14.8.3. Vital Signs ................................ ................................ .................... 71
14.9. Appendix 9: Popula tion Pharmacokinetic Analyses ................................ .....72
14.9.1. Population Pharmacokinetic Dataset Specification ...................... 72
[IP_ADDRESS]. Handling Missing Demographic and Covariate 
Data ................................ ................................ ........... 72
[IP_ADDRESS]. Handling Missing Dose Times ................................ ....72
[IP_ADDRESS]. Handling Missing Times of PK Samples ..................... 72
[IP_ADDRESS]. Handling of PK Data Below the Lower Limit of 
Quantification ................................ ............................. 72
[IP_ADDRESS]. Data set Specification ................................ .................. 72
14.10. Appendix 10: Abbreviations & Trade Marks ................................ ................ 85
14.10.1. Abbreviations ................................ ................................ ............... 85
14.10.2. Trademarks ................................ ................................ ................. 86
14.11. Appendix 11: List of Data Displays ................................ .............................. 87
14.11.1. Data Display Numbering ................................ .............................. 87
14.11.2. Deliverables ................................ ................................ ................. 87
14.11.3. Study Population Tables ................................ .............................. 88
14.11.4. Study Population Figures ................................ ............................. 94
14.11.5. Efficacy Tables ................................ ................................ ............ 95
14.11.6. Efficacy Figures ................................ ................................ ......... 103
14.11.7. Safety Tables ................................ ................................ ............. 109
14.11.8. Safety Figures ................................ ................................ ........... 114
14.11.9. Pharmacokinetic Tables ................................ ............................. 115
14.11.10. Pharmacokinetic Figures ................................ ........................... 116
14.11.11. Pharmacokinetic / Pharmacodynamic Figure ............................. 119
14.11.12. Biomarker Tables ................................ ................................ ....... 120
14.11.13. Biomarker Figures ................................ ................................ .....121
14.11.14. ICH Listings ................................ ................................ ............... 122
14.11.15. Non-ICH Listings ................................ ................................ ........ 126
14.12. Appendix 12 : Example Mock Shells for Data Displays .............................. 130
CONFIDENTIA L
205724
71. INTRODUCTION
The purpose of this reporting and anal ysis plan (RAP) is to describe the 450 participant/6 
month strategic interim.  This RAP will also describe the final anal yses to be included in 
the Clinical Study  Report (CSR) for Protocol 205724.
Revision Chronology:
2016N293867_00 28-NOV -[ADDRESS_984582]- 2017 Adds a second, optional, detailed pharmacokinetic 
profiling at Visit 10 in a subset of participants to allow for 
a better understanding of danirixin pharmacokinetics. 
Removes the Participant Exit Interview from the 
exploratory endpoints. 
Provides additional information and clarification for the 
following: spi[INVESTIGATOR_31757], exclusion for cancers 
other than lung cancer, permitted use of supplemental 
oxygen, permitted uses of chronic steroids, participant 
numbering requirement for rescreening, additional text to 
explain the timing of the planned interim analysis and 
updates to the analysis populations.
1.1. RAP Amendment
Revision chronology : 
RAP Section Amendment Details
[COMPANY_004]1325756- 205724 Statistical Analysis Plan Reporting and Analysis Plan Version 001 (31 -Aug-
2018)
[COMPANY_004]1325756- 205724 Reporting and Analysis Plan Amendment 1_Final [Insert Date]
Approvals Removed  as she has left [COMPANY_004]. Added  
 replacement) as an additional approver
2.2 Study Objectives and 
EndpointsPK endpoints w erenot assessed in the strategic interim
3.1.3 Strategic Analysis Updated to past tense
3.2 Final Analysis Updated to reflect planned unblinding process
4.1 Strategic Interim 
Analysis ,[IP_ADDRESS].1 
Bayesian MMRM 
Methodology Specification
and [IP_ADDRESS].1 Statistical 
Methodology SpecificationITTand Symptomatic population snot used for final ana lysis. 
(PP) a dded to Per Protocol population in the definition table .
6.1.2 Prior and 
Concomitant MedicationsAdditional concomitant medication table at Month 6
7.1.1 Month 6 E -RS: COPD 
Total Score Dose -
Response AnalysisClarification of posterior predi ctive probability of success calculation used 
at the Strategic Interim
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CONFIDENTIA L
205724
8RAP Section Amendment Details
7.1.2 Month 2 -6 E-RS: 
COPD Total Score Dose -
Response Analysis and 
[IP_ADDRESS].[ADDRESS_984583] 
ANCOVA Methodology 
Specification and 14.6.3 
EfficacyMonth 2 -6 E:RS: COPD Dose Response Analysis not required
[IP_ADDRESS].1 Bayesian MMRM 
Methodology SpecificationUpdates to Bayesian model specifications to improve convergence and 
mixing
[IP_ADDRESS].[ADDRESS_984584] 
MMRM Methodology 
SpecificationAdditional plots of LS Mean and daily mean E -RS: COPD scores. Plots 
of empi[INVESTIGATOR_720787] E -RS: COPD Total Scores. 
[IP_ADDRESS].1 Statistical 
Methodology SpecificationAdditional table for HCRU exacerbations treated with antibiotics.
7.2.4 SGRQ Total Score 
and CAT ScoreAdditional plot of arithmetic me an and 90% CIs for SGRQ and CAT
7.2.5 Rescue Medication Additional plots daily rescue medication use
7.3.1 E -RS: COPD Total 
ScoreIdentify subgroups not required for final SAC
7.3.[ADDRESS_984585] 
Clinically Important 
Deterioration
8.3 Clinical Laborat ory 
AnalysisRemove urinalysis outputs because no PCI ranges are defined for 
urinalysis
[IP_ADDRESS] Frequentist MMRM 
Methodology SpecificationAdditional summaries of FEV1/FVC ratio and plots of arithmetic mean 
and 90% CIs for all spi[INVESTIGATOR_270942].
11 Bi omarker Analysis Additional tables and box plots in subjects with pneumonia
[IP_ADDRESS] Study Phases for 
Diary DataClarify that Diary data phases applies to EXACT events
14.6.2 Study Population Additional COPD medication combinations table at Month 6
14.6. 3 EfficacyClarify definitions for Season, time to first, raw annual rate and offset. 
Remove definition of CID as not reporting this exploratory endpoint.
14.6.4 SafetyClarify definition for character laboratory parameters .  Add definition of 
ICS use for pneumonia table.
14.11 Appendix 11: List of 
Data DisplaysUpdates to tables and figures .
Remove urinalysis outputs
Remove CID tables
CONFIDENTIA L
205724
92. SUMM ARY OF KEY PROTOCOL I NFORM ATION
2.1. Changes to the Protocol Defined Statistical A nalysis Plan
Changes from the original ly planned statistical analy sis specified in the protocol are 
outlined in Table 1.
Table 1 Changes to Protocol Defined A nalysis Plan
Protocol Reporting & Analysis Plan
Statistical Analysis Plan Statistical Analysis Plan Rationale for Changes
All Participants population All Subjects population R&D Clinical Data Standards Board 
(CDSB) recommendation to use the 
term 'Subjects' in all displays (Tables, 
Figures & Listings)
No Intent -to-treat ( ITT) 
population ITT population defined 
to be used for selected 
efficacy displaysUsed for key efficacy displays to 
enable phase III planning
No Per Protocol (PP) 
populationPP population defined 
and used for efficacy 
displaysRemove data from participant s who 
had a protocol deviation considered 
to impact efficacy during the 
treatment period.
No Symptomatic population Symptomatic 
population defined and 
used for selected study 
population and efficacy 
displaysUsed to explore the subgroup of 
symptomatic par ticipants. 
No PK2 population PK2 population defined 
and used for PK dry 
blood spot vs wet 
whole bloodUsed to compare dry blood spot with 
wet whole blood
mITT population used for 
efficacy endpointsPP population used for 
efficacy endpointsRemove data f rom participants who 
had a protocol deviation considered 
to impact efficacy during the 
treatment period.
The final Emax model will 
be repeated using months 
1-6 and months 3 -6.The final Emax model 
will be repeated using 
months 2 -6.Team decision to includ e most 
informative time period.
The protocol states that 
exacerbation rates for the 
danirixin and placebo 
groups, along with the ratio 
in exacerbation rates 
danirixin/placebo, will be 
estimated and 
corresponding 95% credible 
intervals will be produced.90% credible intervals 
will be produced for all 
Bayesian efficacy 
analyses including 
exacerbation rates.Inconsistency in protocol.  
CONFIDENTIA L
205724
102.2. Stud y Objectives and Endpoints
Objectives Endpoints Assessed in 
Strategic 
Interim
Primary Objectives Primary Endpoints
To characterize the dose 
response of danirixin 
compared with placebo on 
the incidence and severity 
of respi[INVESTIGATOR_720788] 
(COPD )Change from baseline in respi[INVESTIGATOR_720789] b y the Evaluat ing 
Respi[INVESTIGATOR_720790] (E -RS:
COPD) daily  diary : total score and 
subscales (i.e. breathlessness, cough and 
sputum, and chest sy mptoms)Yes
To compare the safety  of 
danirixin with placebo in 
participants with COPDAdverse events (AE), clinical 
laboratory  values, vital signs, 
electrocardiogram (ECG)Yes[1]
Secondary Objectives Secondary Endpoints
To characterize the dose 
response of danirixin 
compared with placebo on 
the annual rate of 
moderate/severe COPD 
exacerbations in 
participants with COP DHealthcare Resource Utilization 
(HCRU) -defined COPD exacerbationsYes
To further characterize 
the clinical activity  of 
danirixin compared to 
placebo in participants 
with COPDE-RS:COPD Responder Analy sis 
(including subscales)Yes
Number of Exacerbati ons of Chronic 
Pulmonary  Disease (EXACT) tool 
defined eventsNo
Time to first EXACT event No
EXACT event severity No
EXACT event duration for all events No
Time to first HCRU -defined COPD 
exacerbationYes
Time to first severe HCRU -defined 
COPD ex acerbationYes
HCRU -defined COPD exacerbation 
durationYes
Change from baseline for the St. 
George’s Respi[INVESTIGATOR_21606] 
(SGRQ) total score (derived from Yes
CONFIDENTIA L
205724
11Objectives Endpoints Assessed in 
Strategic 
Interim
SGRQ -C)
SGRQ responder anal ysis Yes
Change f rombaseline for the COPD 
Assessment Tes t (CAT) total scoreYes
CAT responder anal ysis Yes
Lung function ( forced expi[INVESTIGATOR_308206] 1 second [ FEV1 ], FEV1 % 
predicted, forced vital capacity  [FVC ], 
FEV1/FVC ratio)Yes
Rescue medication use Yes
Participant experience of phy sical 
activity  (subset of approximately  50% 
of participants) measured using Clinical 
Visit PROactive Phy sical Activity  in 
COPD T ool (C -PPAC)Yes[2]
To characterize the 
pharmacokinetics of 
danirixin in participants 
with COPDDanirixin concentration and standard 
pharmacok inetic (PK) parameters for 
danirixin (e.g. AUC, Cmax, Tmax), 
using dried blood spot dataNo
Exploratory Objectives Exploratory Endpoints
To further explore study  
participants ’experience 
with study  treatment and 
overall experience with 
the stud yTime t o first Clinically  Important 
Deterioration (CID)No
SGRQ domains Yes
To characterize the effect 
of danirixin on lung 
matrix 
destruction/remodellingBlood/serum/plasma biomarkers that 
are indicative of extracellular matrix 
turnover/remodelling (e.g. elas tin and 
collagen neo -epi[INVESTIGATOR_322])No
Comparison between 
dried blood spot and wet 
whole blood anal ysis of 
danirixin concentrations 
in partipants with COPDDanirixin concentration and standard 
pharmacokinetic parameters for 
danirixin (e.g. AUC, Cmax, Tmax)No
CONFIDENTIA L
205724
12Objectives Endpoints Assessed in 
Strategic 
Interim
 To characterise danirixin 
exposure -response 
relationships for various 
safet y parameters, if 
appropriateDanirixin sy stemic exposure and 
various efficacy /pharmacody namic 
(PD)/safet y parameters, if appropriateNo
[1]AEs, serious AEs (SAEs) ,drug-related A Es, AEs leading to withdrawal, AE s of 
special interest (AE SI),laboratory  data , ECG 
[2] Summary  of C -PPAC questionnaire responses only
2.3. Stud y Design
Overview of Study Design and Key Features
Design
FeaturesThis is a parallel group ,randomi zed, double -blind (sponsor open), 
placebo -controlled, multi -centre, dose ranging study .
Dosing Study  treatment will be administered twice dail y for 24 weeks.
Time & 
EventsRefer to Appendix 2 : Schedule of Activities
Treatment 
AssignmentParticipants will be randomized (1:1:1:1:1:1) to receive one of five dose 
strengths of danirixin (5 mg, 10 mg, 25 mg, 35 mg and 50 mg) or placebo.   
Randomization was stratified by  [CONTACT_282717].
Interim 
AnalysisThree specific interim analy seswere defined for the study , with the 
protocol allowing for additional administrative interims as required.  
An administrative interim was performed in October 2017 and included 
plots of E -RS: COPD total score (and subscale scores ) over time by  
[CONTACT_3148], to aid internal decision -making on the project.
The first protocol specified interim anal ysis was an evaluation of danirixin 
PK after 10 participants in each treatment group had completed Visit 3 
CONFIDENTIA L
205724
13Overview of Study Design and Key Features
(Day  1). This anal ysis was performed in December 2017.
A protocol specified futility  interim anal ysis based on the E -RS:COPD 
endpoint was conducted after approximately  [ADDRESS_984586] completed 6 months of 
treatment.  This strategic interim will be used to support GlaxoSmithKline 
([COMPANY_004]) decisions regarding additional investment and further development 
of danirix in. Itwill include endpoints as specified in Section 2.2and in the 
list of data display s in Appendix 1 1. No changes will be made to the study 
based on the results of this strategic interim anal ysisunless a safet y 
concern is identified.
Outputs containing unblinded treatment assignments will be created for all 
interim analy ses and will only  be made available to a limited number of 
[COMPANY_004] staff.  Full details will be included in the study  results dissemination 
plan (SRDP) .
2.4. Statistical Hy potheses
The primary  efficacy  endpoint is the change from baseline of E-RS:COPD total score at 
Month 6.  The primary  objective of the study  is to characterize the dose response of 
danirixin a nd select appropriate dose(s) for future drug development.
A model based probability  inference approach in Bay esian framework will be used to 
guide decision -making around dose selection. The posterior probability  that the change 
from baseline of E -RS:COPD total score for each active dose is less than placebo will be 
derived .
No formal statistical h ypothesis will be tested in the primary  efficacy  analy sis.
CONFIDENTIA L
205724
143. PLANNED ANALYSES
3.1. Interim Analyses
3.1.1. Interim PK A nalysis
After approximately  10 participants in the PK su bset for each treatment group h ad
completed Visit 3 (Day  1), an interim evaluation of danirixin PK parameters w as
undertaken.  The purpose of the interim PK anal ysis was to determine if danirixin 
exposures were within the expected range.   No formal HARP ou tputs were produced .
3.1.2. Futility Analysis
An interim anal ysis wasconducted to allow for the possibility  of stoppi[INVESTIGATOR_720791] y for 
futility after approximately  150 participants ha dcompleted 3 months of treatment .  This 
is described in a separate RAP.  Outputs fe aturing unblinded treatment assignments were 
created and shared with the study  team and those listed in the Study  Results 
Dissemination Plan ( SRDP ).
3.1.3. Strategic A nalysis
Whenapproximately 450 participants had completed 6 months of treatment , a further 
interim analy sis wasperformed for strategic planning purposes , as described in this RAP .  
This analy sis was planned to be used to aid in the planning of future studies and for a 
better understanding of benefit/risk profile of danirixin.  No changes were made t o the
study  based on the results of this strategic interim anal ysis.
The anal yses were performed after the completion of the following sequential steps:
1.The date of the planned Visit 10 for the 450thcompleted participant (01AUG2018) 
had been met.
2.All requ ired database cleaning activities had been completed b y Data Management 
(DM) on data collected up until 01AUG18.  Data collected between 02AUG2018 
and 5SEP2018 (DBR) for ongoing subjects was not cleaned.
3.Unblinded randomization schedules were released by  [CONTACT_720818].
Data wasreported in System Independent (SI) format. Outputs featuring unblinded 
treatment assignments were created for this strategic interim anal ysis, reviewed b y the 
study  team and shared with selective [COMPANY_004] personnel (to be inc luded in the SRDP ).
3.1.4. Administrative Interims
Administrative assessments of danirixin exposure , efficacy  and spi[INVESTIGATOR_720792]. No decisions 
regarding stud y conduct will be made based on these assessments.   The reporting team 
will have access to the unblinded participant treatment assignments.  The unblinded study  
team (as defined in the 205724 Study  Charter) will have access to unblinded aggregate 
data grouped b y stud y treatment assign ment.
CONFIDENTIA L
205724
15An administrative interim was performed in October 2017 and included plots of E -RS: 
COPD total score (and the subgroups) over time by [CONTACT_3148], to aid internal decision -
making on the project.
3.2. Final A nalyses
The final planned anal yses for this Clinic al Data Interchange Standards Consortium 
(CDI SC) study  will be performed after the completion of the following sequential steps:
1.All participants have completed the study  as defined in the protocol.
2. SI data to Study  Data Tabulation Model (SDTM) data conv ersion has been 
completed b y Accenture and quality control (QC) of blinded SDTM has been 
completed b y CDAD and DM. DM will provide the blinded SI  PC dataset to 
Accenture.
3.All required database cleaning activities have been completed and final SI Source 
Data Lock (SDL) has been declared by  [CONTACT_193875].
4.Study  is unblinded
Randomization schedules and container data are released in RANDALL NG.
SMS2000 data is released in HARP
5.The SDTMs (including the PK) are unblinded b y clinical p rogramming (or 
representative) using t he interim unblinding process. 
6.Database freeze (DBF) on unblinded SDTM datasets is declared b y DM.
CONFIDENTIA L
205724
164. ANALYSIS P OPUL ATIONS
4.1. Strategic Interim Analy sis
Population Definition / Criteria Analyses Evaluated
All Subjects 
(ALLSUB)All participants screened and for whom a 
record exists on the study database.Participant disposition
Reasons for withdrawal prior to 
randomization
Inclusion/exclusion/randomization 
criteria deviations for non -
randomized participants
AEs and SAEs for non -
randomized participants
Intent -to-treat 
(ITT)All randomized participants apart from those 
who were randomized in error (i.e. were also 
recorded as screen or run -in failures and did 
not receive a dose of study treatment).
Any participant who receives a treatment 
randomization number will be considered to 
have been randomized.
Randomized participants will be assumed to 
have received study medication unless 
definitive evidence to the contrary exists.
Data will be reported according to the 
randomized treatment.Selected efficacy displays as 
described in Section 7
Strategic Interim only
Modified 
Intent -To-
Treat (mITT)Same as the Intent -to-treat population, but 
this population will be ‘modified’ in that all 
data summaries and analyses for this 
popul ation will be based on the actual 
treatment received, if it is different to the 
randomized treatment.
If any participant received more than one 
treatment during a treatment period, their data 
will be reported according to the treatment 
they received for t he longest period of time.Study Population
Safety
Per Protocol
(PP)All participants from the mITT population who 
did not have a protocol deviation considered 
to impact efficacyEfficacy
Symptomatic All participants in the PP population who have 
Chronic Mucus Hypersecretion (CMH) 
according to baseline SGRQ (see Section 
14.6.2 ) and baseline E -RS:COPD total score 
(see Section 5.2) >=10.Study Population
Selected effi cacy displays as 
described in Section 7
Strategic Interim only
Refer to Appendix 1 1: List of Data Displays which details the population used for each display.
CONFIDENTIA L
205724
174.2. Final Analysis
The final analy sis will use the same populations as above, plus additional populations as 
defined below.
Population Definition / Criteria Analyses Evaluated
PK All participants in the mITT population who had at least 1 
non-missing PK assessment (Non -quantifiable [NQ] 
values will be considered as non -missing values) 
obtained and analysed whilst on treatment with danirixin.PK
PK2 All participants in the PK population who had at least 1 
non-missing PK assessment (NQ values will be 
considered as non -missing values) obtained and 
analysed whilst on treatment with danirixin from a dry 
blood spot sample and corresponding wet whole blood 
sample.PK Dry Blood Spot 
vs Wet Whole 
Blood
Refer to Appendix 1 1: List of Data Dis plays which details the population used for each display.
In the event one or more investigators are withdrawn from the stud y due to concerns over 
protocol deviation then a further population will be defined which will consist of all 
participant s in the PP population excluding participants from those investigative sites. 
This population will be used to perform additional sensitivity  anal ysis for the primary  
efficacy  endpoint only and will only  be defined if the combined enrolment at these sites 
exceeds ≥ 2% of the overall PP study  enrolment. No other anal yses will be repeated.
4.3. Protocol Deviations
Protocol Deviations ( PDs)will be tracked b y the study team throughout the conduct of 
the study  in accordance with the Proto col Deviation Management Plan (6JUL 2018, 
V2.0):
Data will be reviewed prior to SDL to ensure all important deviations are captured 
and categori sed on the protocol deviations dataset. 
Participants who received an incorrect treatment container will be captured as an 
important protocol deviation . Whether or not the incorrect container contained 
incorrect treatment will be identified following DBF in the analysis dataset and 
the PD will be flagged accordingl y. 
This dataset will be the basis for the summaries and listings of protocol 
deviations.
Important protocol deviations (including deviations related to study  
inclusion/exclusion criteria, conduct of the trial, participant management or 
participant assessment) will be summarised and listed.
A separate summary  and listing of all inclusion/exclusi on criteria deviations will 
also be provided. This summary  will be based on data as recorded on the 
inclusion/exclusion page of the electronic case report form ( eCRF ).
CONFIDENTIA L
205724
185. CONSIDERA TIONS FOR DATA ANALYSES ANDDATA
HANDLING CONVENTIONS
5.1. Stud y Treatment & Sub -group Display  Descriptors
Treatment Group Descriptions
RandAll NG Data Displays for Reporting 
Code Description Description Order in TLF 
D5 Danirixin 5mg DNX5mg 2
D10 Danirixin 10mg DNX 10mg 3
D25 Danirixin 25mg DNX 25mg 4
D35 Danirixin 35mg DNX 35mg 5
D50 Danirixin 50mg DNX 5 0mg 6
PO Placebo oval Placebo 1
PR Placebo round Placebo 1
Treatment comparisons will be display ed as in the danirixin dose column with the 
descriptor: Column vs Placebo .
5.2. Baseline Definition s
Any assessments made after t he start of stud y treatment will not be included in the 
derivation of baseline.  Assessments made on the same day  as the start of treatment are 
assumed to be taken prior to first dose .
If baseline data are missing, no derivation will be performed and basel ine will be set to 
missing.
Parameter Baseline Used in Data Display
E-RS: COPD total and 
subscale scoresMean score during a stable period between ( Latest of (7 days before Study 
treatment start date (Day 1) and day of Visit 1 (Screening)) and day befo re Day [ADDRESS_984587] (for 
determining EXACT 
events)Defined according to the EXACT User Manual v 8.0(Evidera ,2016a)
SGRQ total and 
domain scoresDay 1
CAT s core Day 1
Rescue use (diary card 
and sensor data, mean 
number of 
puffs/ occasions per 
day and percentage of 
rescue -free days)Mean score during a stable period between ( Latest of (7 days before Study 
treatment start date (Day 1) and day of Visit 1 (Screen ing)) and day before Day [ADDRESS_984588] 4 days.
PROactive score A PROactive Total Score and two domain scores (amount and difficulty) will be 
derived using d ata from the C -PPAC questionnaire on Day 1 and physical a ctivity 
CONFIDENTIA L
205724
19Parameter Baseline Used in Data Display
monitor worn between Visit 2 and Visit 3 (7 days) . The activity monitor must have 
been worn for at least 3 days with >=8 hours wearing (the 3 days do not need to 
be consecutive ). Further details of the derivation are describe d in S ection 14.6.3
and in the IMI PROactive user manual (14JUN16) . 
Blood pressure (BP) Latest pre -dose assessment with a non -missing value for both systolic and 
diastolic BP, including those from unscheduled visits
Pulse rate, lab oratory 
data, ECGLatest pre -dose assessment with a non -missing value for the individual 
assessment, including those from unscheduled visits
Post-bronchodilator 
(BD) FEV1, post -BD 
FVCDay [ADDRESS_984589] in statistical models and 
treatment b y countr y interaction investigated as described in Section 7and Section 8.  
Results will be presented for all countries combined except as specified in Section 7.
5.4. Examination of Covariates , Other Strata and Subgroups
5.4.1. Covariates and Other Str ata
The covariates and other strata listed below will be used in statistical models and 
treatment b y covariate/stratum investigated as defined in Section 7, Section 14.6.2 and
Section 14.6.3 .
Category Details
Strata Smoking s tatus
Covariates Treatment, visit /Month , baseline, smoking status at screening, country, gender,
exacerbation history (≤1, ≥2 moderate/severe), post-bronchodilator % predicted FEV1, 
CMH status at baseline , season of data collection .
CONFIDENTIA L
205724
205.4.2. Examination of Subgroups
The subgroup s listed below will be used in statistical anal ysesas described in Section 7.
Subgroup Categories 
Season Spring, Summer, Fall, Winter (see Section 14.6.3 )
Country Australia, Canada, [LOCATION_013], Korea, Netherlands, Poland, Romania, 
Spain, US
Exacerbation history History of ≥2 moderate/severe exacerbations vs <2 moderate/severe 
exacerbation
COPD medication at Baseline ICS+LABA+LAMA vs. ICS+LABA vs. LABA+LAMA vs. Other COPD 
medication
ERS10 Baseline E -RS:COPD Total Score <10, ≥10
CAT10 Baseline CAT Score <10, ≥10
Smoking status at Screening Current, Former
% predicted FEV1 at Screening <50%, ≥50%
CMH status at baseline CMH+, CMH -(see Section 14.6.2 )
5.5. Multiple Comparisons and Multiplicity
No multiplicity  adjustment will be mad e for this study , as the primary  objective of the 
study  is to model the danirixin dose response and use it to select Phase III dose(s).
5.6. Other Considerations for Data A nalyses and Data Handling 
Conventions
Other considerations for data anal yses and data han dling conventions are outlined in the 
appendices:
Section Component
14.3 Appendix 3 : Assessment Windows
14.4 Appendix 4 : Study Phases
14.5 Appendix 5 : Data Display Standards & Handling Conventions
14.6 Appendix 6: Derived and Transformed Data
14.7 Appendix 7 : Reporting Standards for Missing Data
14.8 Appendix 8 : Values of Potential Clinical Importance
CONFIDENTIA L
205724
216. STUDY POPULA TION ANALYSES
6.1. Overview of Planned Stud y Population Analyses
Study  population displays including anal yses of participant disposition, protocol 
deviations , demographic and baseline characteristics, prior and concomitant medications, 
and exposure and treatment compliance will be based on [COMPANY_004] Core Data Standards.  
Results will be presented for each treatment and overall.
Details of the planned display sinclud ing the population to be used for each display  and 
which display s are produced for the strategic interim are presented in Appendix 1 1.  
Additional details are provided below.
6.1.1. Demographic and Baseline Characteristics
The summary  of exacerbation history  at Screening will include the number and 
percentage of participants reporting mild, moderate, severe and moderate/severe 
exacerbations (0, 1, >=2 ; see Section 14.6.2 ) in the 1 2 months prior to screen ing.
6.1.2. Prior and Concomitant Medications
Non-COPD medication tables will report b y Anatomical Therapeutic Chemical (ATC) 
level 1 classification and ingredient. Multi -ingredient non -COPD medications will be 
presented according to their combination ATC classification rather than the 
classifications of the ingredients.
COPD medication tables will report by  [CONTACT_15206][INVESTIGATOR_720793] (RMC) and 
ingredient (See Section 14.6.2 ). The number and pe rcentage of participants taking each 
medication in the RMC categories (defined i n Section 14.6.2 ) will be presented. 
The number and percentage of subjects taking each medication in the RMC categories 
ICS, LABA, LAMA, PDE4 inhibitors, Xanthines , Anti -IgE, Anti -IL5and combinations 
of these RMCs on the day  of the Screening visit , at Baseline (Day  1)and at Month 6 will 
be presented.
6.1.3. Exposure and Treatment Compliance
Calculation of treatment compliance will be base d on the number of tablets dispensed and 
returned as described in Section 14.6.2 . Calculation of diary  compliance will be based on 
the number of day s with non -missing E -RS: COPD total score as described in Secti on 
14.6.2 .  Percentage treatment and diary  compliance will be summarized categoricall y and 
with descriptive statistics.
CONFIDENTIA L
205724
227. EFFICA CY ANALYSES
Details of the planned display s including the population to be used for e ach display  and 
which display s are produced for the strategic interim are presented in Appendix 1 1.  
Additional details are provided below.
For this study , no data were scheduled to be collected after discontinuation of study  
treatment, therefore accounting for non -recorded missing data following study  
withdrawal is addressed by  [CONTACT_720819].
7.1. Primary  Efficacy  Anal yses
7.1.1. Month 6 E-RS: COPD Total Score Dose -Response Analysis
The estimand is the effect of actual treatment in the population of participants who did 
not experience a protocol deviation considered to impact efficacy  and completed six 
months of treatment.
A Bay esian dose response model will be applied to the change from baseline to Month 6 
and used to estimate the treatment difference between placebo and each dose.
The dose -response model will be fitted using Bay esian techniques with non -informative 
priors for E0 and Emax and a functional uniform prior (FUP) for ED50 and the slope 
parameter, m (Bornkamp , 2014) . The rationale for this choice of inference is that the FUP 
shrinks the dose -response towards a flat line throughout the dose range, therefore 
providing more cons ervative estimates of the dose -response relationship compared to 
maximum likelihood.
For the strategic interim, the posterior predictive probability  of success (PPS) at the end 
of the study  will be calculated for each dose using the formula suggested by [CONTACT_720820]. (Spi[INVESTIGATOR_192636] , 2004) as follows:
Where m is the average number of participants with Month 6 data in the placebo and 
comparative dose arm, n is the average number of participants y et to be observed
(assuming 90% of participants , rounded to the nearest integer, in each treatment group 
will provid e month 6 data at end of stud y. If the actual number of participants at month 6 
exceeds this, the actual number will be used ), 
 is the posterior mea n difference from 
the fitted model, and 
 is the standard deviation (SD) of the posterior mean 
difference .
[IP_ADDRESS]. Endpoint
Change from baseline in Month 6 E -RS: COPD total score as defined in Section 14.6.3 .
CONFIDENTIA L
205724
[IP_ADDRESS]. Summary  Measure
For the strategic interim, the summary  measure is the posterior predictive probability  of 
success for each danirixin dose, where success is the probability  that a true difference 
from placebo is less than 0 is >95% at Month 6.
For the fin al anal ysis, the summary  measure is the posterior probability  that a true 
difference from placebo is less than 0 at Month 6 for each danirixin dose.
[IP_ADDRESS]. Population of Interest 
PP population.
[IP_ADDRESS]. Strategy  for Intercurrent (Post -Randomization) Events
For the primar y efficacy  anal ysis, the intercurrent event of interest is occurrence of a 
protocol deviation considered to impact efficacy  during the treatment period (see 
Appendix 1 ). An ‘as treated’ strategy  will be used to account for this event -only Month 
6 E-RS: COPD data (see Section 14.6.3 ) collected prior to the occurrence of a protocol 
deviation considered to impact efficacy  will be used in the anal ysis.
The intercurrent event of treatment discontinuation is accounted for in the endpoint 
definition as only  data at Month 6 will be used.
[IP_ADDRESS]. Statistical A nalyses / Methods
[IP_ADDRESS].1. Statistical Methodology Specification
Endpoint / Variables
Change from baseline in Month 6 E-RS: COPD total score
Model Specification
Bayesian dose response model:
Models of the following form will be considered:
Response=E0+ Emax* f(dose)
oLog-linear model: f(dose)=log(dose+0.01), where 0.01 is an offset to allow the 
model to fit for zero dose (placebo).
o3-parameter emax model: f(dose)=dose/(dose+ed50)
o4-parameter emax model: f(dose)=dose^m/(dose^m+ED50^m)
Where:
oE0 = the response at dose = 0 (placebo),
oEmax = the maximal response over placebo,
oED50= the dose that yields 50% of the maximal response,
om= dose -response s lope parameter.
The log -linear, 3 -parameter emax and 4 -parameter emax model will be fitted without adjusting 
for covariates. If possible, covariates (i.e., baseline, smoking status, country) will be included in 
the E0 and Emax terms of the model for the fi nal analysis
Normal non -informative priors will be used for the E0 and Emax parameters with mean 0 and 
SD 100. A FUP will be used for the ED50 and m parameters (Bornkamp , 2014) , where the 
CONFIDENTIA L
205724
24prior density for the FUP i s based on all the parameters in the model.  An inverse -gamma prior 
with shape of 0.001 and scale of 0.001 will be used for the residual variance.
Parameters will be blocked such that the MCMC procedure samples from E0 and Emax first, 
then the ED50 and m parameters and then finally the residual variance parameter. 
For the functional uniform priors, the density will be calculated for values of dose from 0.0001 
to 50 in steps of 5 (i.e. 0.0001, 5.0001, 10.0001,…, 50.0001).
3 MCMC chains will be fitted using the following starting values (as required for the parameters 
in each particular model):
Parameter Chain 1 Chain 2 Chain 3
E0 Posterior mean for placebo from 
MMRM at Month 6 (See Section 7.1.3 )-15 15
Emax Posterior mean for 50mg dose from 
MMRM at Month 6 (See Section 7.1.3 )15 -15
ED50 25 10 50
M 1 2 4
Residual variance 6 8 10
100,[ADDRESS_984590] -
burn-in samples from the 3 chains will be used for inference. The number of samples 
generated and the thin may be increased to reduce the ratio of the MCS E to the posterior SD, 
as deemed necessary.
The seeds used to forthe three chains w eregenerated using the ranuni function in SAS and 
are listed in Section 14.5.2 .
The best fitting model will be the model with the smallest average DIC over the [ADDRESS_984591] sfor 
covariates, all outputs will be presented adjusting for the mean in the observed covariate. 
Production and QC will be deemed to have agreement if the QC value is the following range:
if a number is reported to 0dp and there is a difference of 1(number of participant s must 
agree)
if a number is reported to 1dp and there is a difference of 0.1
if a number is re ported to 2dp and there is a difference of 0.01
if a number is reported to 3dp and there is a difference of 0.001
if a number is reported to 4dp and there is a difference of 0.0001
Model Checking & Diagnostics
Posterior density plots and plots of t he posterior samples (chains) will be produced for all the 
parameters in the model.
The posterior density for the adjusted mean change from baseline in E -RS:COPD total score 
in each treatment group and differences versus placebo for each danirixin dose wi ll be plotted.
The Gelman -Rubin R estimate from the three chains will be calculated for all parameters in the 
model and the differences from placebo for each danirixin dose.
Model Results Presentation
The following will be presented for each analysis bas ed on the best fitting model using all post -burn 
in samples available.
The posterior mean, median, SD and 90% credible interval (CrI) for the change from baseline 
in E-RS:COPD total score for each treatment group.
The posterior mean and 90% CrI for the di fference from placebo for each danirixin dose.
CONFIDENTIA L
205724
25The posterior probability that difference from placebo is less than 0 ,-0.5, -1, -1.5 and -2for 
each danirixin dose.
For the strategic interim, the posterior predictive probability of success for each danirix in dose, 
where success is the probability that the difference from placebo is less than 0 is >95%.
A figure of the fitted mean dose response model with the 90% CrI for all possible doses in the 
dose range, overlaid with the Month 6 adjusted posterior means and 90% CrI from the 
longitudinal model in Section 7.1.3 .
Sensitivity and Supportive Analyses
At the strategic interim, a supportive analysis will be conducted to estimate the effect of actual 
treatment in th e population of participants who were confirmed as having CMH according to 
SGRQ, were symptomatic at baseline, did not experience a protocol deviation considered to 
impact efficacy, and completed six months of treatment.  The population used will be the 
Symptomatic population; all other details will be the same as for the primary analysis.
7.1.2. E-RS: COPD Subscale Scores Dose -Response A nalysis
The primary  analysis described in Section 7.1.1 will be repeated for the three E-RS:
COPD subscale score s of breathlessness, cough and sputum and chest sy mptoms .
7.1.3. E-RS: COPD Total and Subscale Scores Longitudinal A nalysis
The estimand is the effect of actual treatment in the population of participants who did 
not experience a pr otocol deviation considered to impact efficacy .  A supportive anal ysis 
will be performed to assess the effect of randomized treatment in all randomized and 
dosed participants .
A Bayesian mixed effects analy sis with repeated measures (MMRM) will be performe d 
on the monthly  E-RS:COPD total and subscale scores.
A frequentist MMRM analy sis will be performed on the monthly  E-RS:COPD total 
scores and repeated to assess the impact of various covariates.
[IP_ADDRESS]. Endpoint
Change from baseline in monthly  mean E -RS:COPD to tal and subscale scores as defined 
in Section 14.6.3 .
[IP_ADDRESS]. Summary  Measure
For the Bay esian MMRM the summary  measure is the adjusted posterior mean difference 
from placebo for each danirixin dose .
For the frequentist MMRM the summary  measure is the adjusted mean difference from 
placebo for each danirixin dose .
[IP_ADDRESS]. Population of Interest
PPpopulation.
CONFIDENTIA L
205724
[IP_ADDRESS]. Strategy  for Intercurrent (Post -Randomization) Events
A ‘hypothetical’ strategy will be used to account for the intercurre nt event sof occurrence 
of a protocol deviation considered to impact efficacy  during the treatment period (see 
Appendix 1 )and treatment discontinuation, to estimate the effect if participants had not 
deviated from the protocol and remained on treatment . Only  E-RS: COPD data prior to 
the occurrence of a protocol deviation considered to impact efficacy or treatment 
discontinuation will be used in the anal ysis. Subsequent data up to Month 6 will be 
assumed to be missing a t random (MAR). 
[IP_ADDRESS]. Statistical A nalyses / Methods
[IP_ADDRESS].1. Bayesian MMRM Methodology Specification
Endpoint / Variables
Change from baseline in monthly E -RS:COPD total and subscale scores
Model Specification
Bayesian mixed models repeated measures approach.
The m odel will include treatment*visit, baseline*visit, country and smoking status parameters.   
Note that the model will not include an intercept.  Visit will consist of six levels (Month 1 -Month 
6), and Treatment will consist of six levels (placebo and 5 acti ve doses). If the model does not 
run, the country covariate will be removed.
The priors for the mean vector for each of the parameters (i.e covariates) will each follow a 
normal distribution with mean 0 and SD 1000.  The prior for the variance -covariance w ill follow 
an inverse Wishart distribution with degrees of freedom equal to the number of visits and an 
identity scale array.  1 50,000 samples will be generated with a thin of 75 after a burn -in of 
10,000 samples.  The number of samples or thin may be incr eased as needed to reduce the 
MCSE/SD<0.01 as deemed necessary.
Three chains will be used to calculate the gelman -rubin R statistic:
oChain 1: The starting value for all cov ariates in the model will be 0.
oChain 2: The starting value for all covariates in th e model will be 2.
oChain 3: The starting value for all covariates in the model will be -2.
The seeds used to for the three chains were generated using the ranuni function in SAS and 
are listed in Section 14.5.2 .
All post -burn-in samples will be used when creating outputs.
Model Checking & Diagnostics
Posterior density plots and plots of the posterior samples (chains) will be produced for all the 
parameters in the model.
The posterior density for the adjusted me an change from baseline in E -RS: COPD score in 
each treatment group and differences versus placebo for each danirixin dose will be plotted.
The Gelman -Rubin R estimate from the three chains will be calculated for all parameters in the 
model and the differe nces from placebo for each danirixin dose.
Distributional assumptions underlying the model used for analyses using MMRM will be 
examined by [CONTACT_19201] a normal probability plot of the residuals and a plot of the residuals 
versus the fitted values (i.e. chec king the normality assumption and constant variance 
assumption of the model respectively) to gain confidence that the model assumptions are 
CONFIDENTIA L
205724
27reasonable. Plots of residuals versus covariates and baseline versus response will also be 
examined.
Model Results Presentation
The adjusted posterior mean change from baseline and the associated 90% equi -tailed CrI for 
each Month for each treatment.
The adjusted mean difference from placebo and the associated 90% equi -tailed CrI for each 
Month for each danirixin dose .
The probability that each treatment difference is less than 0 ,-0.5, -1, -1.5 and -2for each 
month for each danirixin dose.
A figure of t he posterior mean and 90% equi -tail CrI for each Month for each treatment.
Sensitivity and Supportive Analyses
At the strategic interim a supportive analysis of monthly E -RS:COPD total score will be 
conducted to estimate the effect of actual treatment in the population of participants who were 
confirmed as having CMH according to SGRQ, were symptomatic at baseline, a nd did not 
experience a protocol deviation considered to impact efficacy.  The population used will be the 
Symptomatic population; all other details will be the same as for the primary analysis.
At the strategic interim a further supportive analysis will be conducted to estimate the effect of 
the randomized treatment.  The population used will be the ITT (according to randomized 
treatment). A ‘treatment policy’ strategy will be used to account for the intercurrent event of 
occurrence of a protocol deviatio n considered to impact efficacy during the treatment period 
(see Appendix 1 ). All E-RS: COPD data up the time of treatment discontinuation or Month 6 
(see Section 14.6.3 ) will be used in the analysis, regardless of any protocol deviation. A 
‘hypothetical’ strategy will be used to account for the intercurrent event of treatment 
discontinuation. D ata after treatment discontinuation will be considered MAR.
[IP_ADDRESS].2. Frequentist MMRM Meth odology Specification
Endpoint / Variables
Change from baseline in monthly E -RS:COPD total score
Model Specification
The following covariates will be included in the model: baseline, country, smoking status at 
screening, treatment, Month, Month*baselin e and Month*treatment interactions, where Month 
is nominal. Month will consist of six levels (Month 1 -Month 6), and treatment will consist of six 
levels (placebo and 5 active doses)
Two models will be fitted; one with a response variable of E -RS:COPD Tota l Score, and one 
with a response variable of change from baseline in E -RS:COPD Total Score.
An unstructured covariance structure for the R matrix will be used by [CONTACT_312424] ‘type=UN’ on 
the REPEATED line.
The Kenward and Roger method for approximating the denominator degrees of freedom and 
correcting for bias in the estimated variance -covariance of the fixed effects will be used. If this 
method does not run, the residual method will be used instead
The OM option will be used to derive the least square ( LS)means using coefficients which are 
based on the participants used in the analysis. The OM option requires an OM dataset which 
has a row for every participant -visit combination that contains all of the covariates used in the 
model and a macro variable cont aining the mean baseline for the participants used in the 
CONFIDENTIA L
205724
28analysis.
Model Checking & Diagnostics
Distributional assumptions underlying the model used for analyses using MMRM will be 
examined by [CONTACT_19201] a normal probability plot of the residuals and a plot of the residuals 
versus the fitted values (i.e. checking the normality assumption and constant variance 
assumption of the model respectively) to gain confidence that the model assumptions are 
reasonable. Plots of residuals versus covariates and baselin e versus response will also be 
examined.
Model Results Presentation
LS mean and LS mean changes from baseline with their corresponding standard errors (SEs) 
for each Month and each treatment
Estimated treatment differences from placebo and corresponding 90% confidence intervals 
(CIs) and p -values for each Month and each danirixin dose.
A figure of LS mean changes from baseline and 9 0% CIs for each treatment by [CONTACT_720821].
A figure of LS mean and 90% CIs for each treatment by [CONTACT_720822].
The type III tests of fixed effects from the model will be presented.
Summary Results Presentation
A figure of daily mean E -RS: COPD total and subscale scores over time (Days -7 to 168) for 
the PP population.
A figure of daily mean E -RS: COPD tot al and subscale scores over time by [CONTACT_720823] 
(Days -7 to 168) for the PP population.
A figure of daily mean change from baseline E -RS:COPD total and subscale scores over time 
for the PP population.
A figure of daily mean (SE) change from baselin e E-RS:COPD total and subscale scores 
over time for each dose and placebo in a separate panel.  This figure will be produced for the 
PP and Symptomatic populations (Strategic interim only) .
A figure of daily mean ( SE) E -RS: COPD total and subscale score s over time (Days -7 to 
168) for each dose and placebo in a separate panel.  This figure will be produced for the PP 
population.
Summary statistics for baseline E -RS:COPD total and subscale scores for each treatment and 
overall for participants with non -missing score for each Month, for the PP and Symptomatic
(Strategic interim only) population.
Summary statistics for raw and change from baseline m onthly mean E -RS:COPD total and 
subscale score sfor each month for each treatment , for the PP and Symptomatic population
(Strategic interim only) .
Empi[INVESTIGATOR_720794] E -RS: COPD Total Scores at Baseline and at Month 6.
7.2. Secondary  Efficacy A nalyses
The estimand is the effect of actual treatment in the population of participants who did 
not expe rience a protocol deviation considered to impact efficacy .
CONFIDENTIA L
[ADDRESS_984592] 
Events
[IP_ADDRESS]. Endpoint
Annual rate of moderate/severe HCRU exacerbations as defined in Section 14.6.[ADDRESS_984593] events as defined in Section 14.6.3 .  
[IP_ADDRESS]. Summary  Measure
Rate ratio (also expressed as percentage rate reduction) for each danirixin dose vs. 
placebo
[IP_ADDRESS]. Population of Interest
PP population
[IP_ADDRESS]. Strategy  for Intercurrent (Post -Randomization) Events
The intercurr ent event sof interest are occurrence of a protocol deviation considered to 
impact efficacy  during the treatment period (see Appendix 1 )and treatment 
discontinuation . An ‘as treated’ strategy  will be used to account f or theseevents to 
estimate the effect if participants had not deviated from the protocol and remained on 
treatment . Onl y HCRU exacerbations/EXACT events prior to the occurrence of a 
protocol deviation considered to impact efficacy  will be used in the anal ysis.
[IP_ADDRESS]. Statistical A nalyses / Methods
[IP_ADDRESS].1. Statistical Methodology Specification
Endpoint / Variables
Annual rate of On-treatment moderate/severe HCRU exacerbations
Annual rate of On-treatment EXACT events
Model Specification
Bayesian g eneralized linear model assuming a negative binomial distribution for the 
underlying exacerbation rate with a log link function
Terms in the model:
oResponse: number of on -treatment, moderate/severe HCRU exacerbations or EXACT 
events per partic ipant.
oCategorical: treatment group, gender, exacerbation history ( ≤1, ≥2 moderate/severe),
smoking status (screening), country
oContinuous: post -bronchodilator % predicted FEV1 (Screening)
oAn offset to account for the length of time on treatment for each participant will be 
CONFIDENTIA L
205724
30included in the model as log e(length of time) as defined in Section 14.6.3 .
oNon-informative priors will be used for all modelling parameters. Wherever possible 
conjugate priors will be utilised.
oAll the terms in the model will follow a normal distribution wi th a mean of 0 and a SDof 
100, except for dispersion which follows a gamma distribution with shape and inverse 
scale of 0.001. 
Three chains will be used to calculate the gelman -rubin R statistic:
oChain 1: The starting value for all covariates in the mode l will be the maximum 
likelihood estimation (MLE), except dispersion which will be 0.1.
oChain 2: The starting value for all covariates in the model will be 130% of the MLE, 
except for dispersion which will be 0.2 .
oChain 3: The starting value for all covari ates in the model will be 70% of the MLE, 
except for dispersion which will be 0.4 .
The seeds used to for the three chains were generated using the ranuni function in SAS and 
are listed in Section 14.5.2 .
Burn -in2000, thin 5, and 10,000 MCMC samples will be generated for 2000 retained samples
Model Checking & Diagnostics
The fit of the regression models will be examined using “Q -Q” plots of the standardized 
residuals. Interpretation of these plots will be aided by [CONTACT_720824] ( Atkinson ,1985).
The Gelman -Rubin R estimate will be calculated for all parameters in the model and the rate 
ratios vs. placebo for each danirixin dos e.
Autocorrelation plots will be visually inspected to assess degree of autocorrelation (should 
decline rapi[INVESTIGATOR_720795]).
Model Results Presentation
Model estimated median exacerbation /event rate and associated 90% C rI for each t reatment 
group
Median r ate ratio and associated 90% C rI, percent reduction in annual exacerbation /event rate 
and associated 90% CI for each danirixin dose vs. placebo
The probability that the true exacerbation rate ratio is less than 1 , 0.9 and 0.8 for eac h danirixin 
dose will be presented
A figure of the rate ratios and associated 90% C rIs for each danirixin dose vs. placebo
Summary Results Presentation
For HCRU exacerbations:
Number and percent of participants reporting an exacerbation ( mild, moderate, severe and
moderate/severe), number and percent of participants with each number of moderate/severe
exacerbations (0, 1, ≥2), the total number of exacerbations per treatment and annual raw
exacerbation rate (as defined in Section 14.6.3 ).  This table will be repeated for HCRU 
exacerbations that were treated with Antibiotics and wi ll include the number and percentage of 
participants who were receiving ICS treatment at the time of the exacerbation.
For each moderate/severe exacerbation, the outcome, severity, duration, whether the
exacerbation led to hospi[INVESTIGATOR_059], systemic/oral co rticosteroids being taken, antibiotics being 
taken, or emergency room visit.
For EXACT events:
Number and percent of participants reporting an EXACT -defined event, number and percent of 
CONFIDENTIA L
[ADDRESS_984594] -defined events (0, 1, ≥2), the number of EXACT -
defined events and annual raw event rate (as defined in Section 14.6.3 ) will be summarized for 
all events and for recovered, censored and persistent worsening events separately for each 
treatment group.  The duration and severity (indicated by [CONTACT_720825]) will be reported for all events.  
Sensitivity and Supportive Analyses
At the strategic interim a supportive analysis of HCRU exacerbations will be conduct ed to 
estimate the effect of the randomized treatment.  The population used will be the ITT 
(according to randomized treatment) . A ‘treatment policy’ strategy will be used to account for 
the intercurrent event of occurrence of a protocol deviation consider ed to impact efficacy during 
the treatment period (see Appendix 1 ). All on-treatment exacerbation sup the time of treatment 
discontinuation will be used in the analysis, regardless of any protocol deviation. An ‘as tre ated’ 
strategy will be used to account for the intercurrent event of treatment discontinuation –no 
exacerbations will be recorded after treatment discontinuation/study withdrawal.
7.2.2. Time to First HCRU Exacerbation and EXACT Event
[IP_ADDRESS]. Endpoint
Time to first mod erate/severe HCRU exacerbation as defined in Section 14.6.[ADDRESS_984595] event as defined in Section 14.6.3 .  
[IP_ADDRESS]. Summary  Measure
Hazard ratio (also expressed as percentage risk reduction) for each danirixin dose vs. 
placebo)
[IP_ADDRESS]. Population of Interest 
PP population
[IP_ADDRESS]. Strategy  for Intercurrent (Post -Randomi zation) Events
The intercurrent event sof interest are occurrence of a protocol deviation considered to 
impact efficacy  during the treatment period (see Appendix 1 )and treatment 
discontinuation . An ‘as treated’ strate gy will be used to account for th eseevents to 
estimate the effect if participants had not deviated from the protocol and remained on 
treatment . Onl y first exacerbations/EXACT events prior to the occurrence of a protocol 
deviation considered to impact effi cacy will be used in the anal ysis.
CONFIDENTIA L
205724
[IP_ADDRESS]. Statistical A nalyses / Methods
[IP_ADDRESS].1. Statistical Methodology Specification
Endpoint / Variables
Time to first On-treatment moderate/severe HCRU exacerbation
Time to first On-treatment severe HCRU exacerbation
Time to first On-treatment EXACT event
Model Specification
Bayesian proportional hazards model
Terms in the model:
oResponse: time to first on -treatment, moderate/severe HCRU exacerbation or EXACT 
event
oCategorical: treatment group, gender, exacerbation history ( ≤1, ≥2 moderate/severe), 
smoking status (screening), country
oContinuous: post -bronchodilator % predicted FEV1 (Screening)
oNon-informative priors will be used for all modelling parameters. Wherever possible 
conjugate priors will be utilised.
oAll the terms i n the model will follow a normal distribution with a mean of 0 and a SD of 
100
The ‘exact ’method will be used for handling ties. If the analysis will not run using the ‘exact ’
method, then the ‘Efron ’method for handling ties will be used instead.
Three c hains will be used to calculate the gelman -rubin R statistic:
oChain 1: The starting value for all covariates in the model will be the MLE, except 
dispersion which will be 0.1.
oChain 2: The starting value for all covariates in the model will be 130% of the MLE, 
except for dispersion which will be 0.2.
oChain 3: The starting value for all covariates in the model will be 70% of the MLE, 
except for dispersion which will be 0.4.
The seeds used to for the three chains were generated using the ranuni function in SA S and 
are listed in Section 14.5.2 .
Burn -in 2000, thin 5, and 10,000 MCMC samples will be generated for 2000 retained samples
Kaplan -Meier survivor functions will be obtained for each treatment group using PROC 
LIFETEST with a TIME statement.
Model Checking & Diagnostics
The proportional hazards assumption will be examined by [CONTACT_720826] -Meier 
estimates of the survival function S(t) over time separately for each treatment group. In 
addition, the ln { -ln[S(t)]} plot will be produced.
Model Results Presentation
Hazard ratio and the percent reduction in risk for each danirixin dose compared with placebo 
with associated 90% C rI.
The probability of having an event, 90% C rI and first quartile and median tim e to event for each 
treatment group will be presented.
The probability that the true hazard ratio is less than 1 for each danirixin dose will be 
presented .
CONFIDENTIA L
205724
33Kaplan -Meier curves showing the probability of having an event over time for each treatment 
group se parately plotted on the same figure
7.2.3. E-RS: COPD Total and Subscale Scores Responder A nalysis
[IP_ADDRESS]. Endpoint
Response according to E -RS: COPD total score, subscale scores, SGRQ total score or 
CAT score as defined in Section 14.6.3 .
[IP_ADDRESS]. Summary  Measure
Ratio of odds of being a responder vs. not for each danirixin dose vs. placebo
[IP_ADDRESS]. Population of Interest 
PPpopulation
[IP_ADDRESS]. Strategy  for Intercurrent (Post -Randomization) Events
A ‘hypothetical’ strategy will be used to account for t he intercurrent event sof occurrence 
of a protocol deviation considered to impact efficacy  during the treatment period (see 
Appendix 1 )and treatment discontinuation, to estimate the effect if participants had not 
deviated from the protocol and remained on treatment . Only  response data prior to the 
occurrence of a protocol deviation considered to impact efficacy  or treatment 
discontinuation will be used in the anal ysis. Subsequent data up to Month 6 will be 
assumed to b e missing at random (MAR). 
[IP_ADDRESS]. Statistical A nalyses / Methods
[IP_ADDRESS].1. Statistical Methodology Specification
Endpoint / Variables
Response according to E -RS: COPD total score, subscale scores, SGRQ total score or CAT 
score
Model Specification
Generalized linear mix ed model
Terms in the model:
oDependent : response (yes/no)
oCategorical : treatment group, smoking status (screening), country, visit/month
oContinuous : baseline
oInteraction : baseline*visit/month, treatment group*visit/month
The model will be fit with an unstructured variance -covariance matrix with one single model to 
include all visits /months where the assessment in question is scheduled to be performed.
Computation of confidence intervals for the odds ratios is based on the individual Wald tests.
CONFIDENTIA L
205724
34Model Checking & Diagnostics
Pearson residuals will be plotted by [CONTACT_720827]=PEARSONPANEL option for the model 
statement in SAS.
Model Results Presentation
Number and percentage of responders and non -responders for each treatment at each 
visit/month
Odds rat io for comparison of each danrixin dose with placebo, with associated 90% C Iand p -
value
7.2.4. SGRQ Total Score and CA T Score
SGRQ total score and CAT score at each visit will be anal ysed using the same 
methodology  as for E -RS:COPD total and subscale scores longitudinal analy sis (as 
described in Section [IP_ADDRESS].1 ).  Visit will be substituted for Month. A figure of mean and 
90% CI s for each treatment over time will be generated for SGRQ Total Score and CAT 
Score.
7.2.5. Resc ue Use
The monthly  mean number of puffs of rescue use per day  according to diary  card data 
and the monthly  mean number of occasions of rescue use per day  according to sensor 
data and the monthl y percentage of rescue -free day s according to diary  card data a nd 
according to sensor data will be anal ysed using the same methodology  as for E -RS:
COPD total and subscale scores longitudinal analy sis (as described in Section [IP_ADDRESS].2 ).
A figure of daily  mean number of puf fs of rescue medication per day  using diary  data 
over time and dail y mean number of occasions of rescue medication per day using sensor 
data over time will be generated for the PP population.
Additional analy sis of rescue use according to sensor data may  be performed and will be 
defined in a separate RAP.
7.2.6. Physical A ctivity
Assessment of ph ysical activity  during clinical visits (C -PPAC) has been developed to 
capture experience of phy sical activity  in partic ipants with COPD. This physical activity  
data will be combine dwith activity  monitor data to assess phy sical activity experience 
according to the IMI PROactive User G uide (14JUN16) . A PROactive Total Score and 
two domain scores (amount and difficulty ) will be derived.  
Raw and change from baseline PROacti ve Total Score and Domain scores (Amount and 
Difficulty ) will be sum marized.
For the strategic interim, the responses to the C -PPAC questions at each visit will be 
summarized.
Additional analy sis of activity  monitor data may  be performed and will be define d in a 
separate RAP.
CONFIDENTIA L
205724
357.3. Exploratory  Efficacy  Analyses
7.3.1. E-RS: COPD Total Score
For the final anal ysis the list of subgroups may  be amended.
Exploratory Statistical Analyses
Model Specification
For the PP population, an assessment of whether the effect of trea tment on E -RS:COPD Total Score is 
modified by:
[CONTACT_720828] E-RS:COPD Total Score (continuous) (Strategic Interim only)
oSmoking Status at Screening 
oCountry (Strategic Interim only)   
will be made by [CONTACT_720829], identical to th e MMRM model described in 
Section [IP_ADDRESS].[ADDRESS_984596] of treatment on E -RS:COPD Total Score i s modified 
by [CONTACT_15006] (as defined in Section 5.4.2 ):
oPercent Predicted FEV1 at Screening (continuous)
oBaseline CAT Score (continuous)
oExacerbation history (Strategic Interim only)
oCOPD Medication a t Baseline (Strategic Interim only)
oCMH status at baseline (Strategic Interim only)
oSeason (Strategic Interim only)
This will be made by [CONTACT_720829], identical to the model described above 
but also including additional terms f or the factor and the treatment by [CONTACT_720830].
If an interaction from these analyses is significant at the 10% level it implies that the effect of treatment on 
E-RS:COPD Total Score is modified by [CONTACT_139739]. The analysis will be run by [CONTACT_720831] (excluding any groups with sparse data):
oBaseline E -RS:COPD Total Score <10, ≥10(Strategic Interim only)
oSmoking Status at Screening -Former, Current 
oCountry (Strategic Interim only)
oPercent Predicted FEV1 at Screening <50, ≥50
oBaseline CAT Score <10, ≥10
oExacerbation history ( history of ≥2 moderate/severe exacerbations, <2 moderate/severe 
exacerbation) (Strategic Interim only)
oCOPD Medication at Baseline (ICS+LABA+LAMA vs. ICS+LABA vs. LABA+LAMA vs. Other 
COPD medication )(Strategic Interim only)
oCMH +, -(Strategic Interim only)
oSeason (The estimates from this model will be presented for each season.) (Strategic 
Interim only)
Model Checking & Diagnostics
Distributional assumptions underlying the model used for analyses using MMRM will be examined by 
[CONTACT_19201] a normal probability plot of the residuals and a plot of the residuals versus the fitted values 
(i.e. checking the normality assumption and constant variance assumption of the model respectively) 
to gain confidence that the model assumptions are reasonable.  Plots of residuals versus covariates 
and ba seline versus response will also be examined.
CONFIDENTIA L
205724
36Exploratory Statistical Analyses
Model Results Presentation
The interaction p -values from the interactions of treatment with the factors above will be presented.
Comparisons of each danirixin dose with placebo for each level of each categori cal subgroup.
LS Mean changes from baseline estimates for each treatment by [CONTACT_765] (except for season) along with 
90% CIs will be obtained for each level of the subgroup.
LS Mean changes from baseline estimates for each treatment along with 90% CIs will be obtained 
for each level of the season subgroup.  
LS Mean changes from baseline estimates and 90% CIs will be plotted against treatment in separate 
panels for each level of the factor for Month 6 (except for season).LS Mean changes from baseline 
estimates and 90% CIs will be plotted by [CONTACT_720832].     
If an interaction between treatment and factor is significant at the 10% level an additional plot of LS 
Mean changes from baseline and 90% CIs against treatment by [CONTACT_720833] a 
separate plot for each level of the factor (except for season) .
7.3.2. CAT Score
CAT score will be anal ysed using the same methodology  as for E -RS:COPD total scores 
exploratory  statistical analy sis (as described in Section 7.3.1 ).  
7.3.3. Time to First Clinically Important Deterioration
Following the Strategic Interim, the study  team decided not to report this exploratory  
endpoint.
7.3.4. SGRQ Domain Scores
Raw and change from baseline SGRQ domain scores wil l be summarized.
7.3.5. Participant Global A ssessments
Participant global assessments of severit y, change in severity, activity limitation and 
change in activity  limitation will be summarized.
CONFIDENTIA L
[ADDRESS_984597] of Standardize d Medical Dictionary  for Regulatory  Activities 
(MedDRA) Queries (SMQs) and other groupi[INVESTIGATOR_720796] 14.6.[ADDRESS_984598] 
mITT population.
CONFIDENTIA L
205724
388.4.4. Strategy  for Intercurrent (Post -Randomization) Events
The intercurrent event of interest is treatment discontinuation . A ‘hy pothetical’ strategy  
will be used to account for this event. All recorded data up to the time of treatment
discontinuation will be included in the anal ysis. Subsequent data up to Day  168 will be 
assumed to be missing at random (MAR). 
8.4.5. Statistical A nalyses / Methods
[IP_ADDRESS]. Frequentist MMRM Methodology Specification
Endpoint / Variables
Change from baseline in post-BDFEV1
Change from baseline in post-BD FVC
Model Specification
The following covariates will be included in the model: baseline, country, smoking status at 
screening, treatment, Visit, Visit *baseline and Visit *treatment interactions, where Visit is 
nomi nal. Visit will consist of two levels (Day 84 and 168), and treatment will consist of six levels 
(placebo and 5 active doses)
Two models will be fitted; one with a response variable (FEV1 or FVC), and one with a 
response variable of change from baseline (F EV1 or FVC).
An unstructured covariance structure for the R matrix will be used by [CONTACT_312424] ‘type=UN’ on 
the REPEATED line.
The Kenward and Roger method for approximating the denominator degrees of freedom and 
correcting for bias in the estimated varianc e-covariance of the fixed effects will be used. If this 
method does not run, the residual method will be used instead
The OM option will be used to derive the least square (LS) means using coefficients which are 
based on the participants used in the analys is. The OM option requires an OM dataset which 
has a row for every participant -visit combination that contains all of the covariates used in the 
model and a macro variable containing the mean baseline for the participants used in the 
analysis.
Model Check ing & Diagnostics
Distributional assumptions underlying the model used for analyses using MMRM will be 
examined by [CONTACT_19201] a normal probability plot of the residuals and a plot of the residuals 
versus the fitted values (i.e. checking the normality assum ption and constant variance 
assumption of the model respectively) to gain confidence that the model assumptions are 
reasonable. Plots of residuals versus covariates and baseline versus response will also be 
examined.
Model Results Presentation
LS mean an d LS mean changes from baseline with their corresponding standard errors (SEs) 
for each visit and each treatment
Estimated treatment differences from placebo and corresponding 90% confidence intervals 
(CIs) and p -values for each visit and each danirixin do se.
A figure of LS mean changes from baseline and 90% CIs for each treatment by [CONTACT_720834].
The type III tests of fixed effects from the model will be presented.
CONFIDENTIA L
205724
39Summary Results Presentation
Summary statistics for baseline post -BD FEV1 , FVC and FEV1/FVC for each treatment and 
overall for participants with non -missing assessments for each Visit, for the mITT population.
Summary statistics for raw and change from baseline post -BD FEV1 ,FVC and FEV1/FVC for 
each visit for each treatment, for the mITT population.
A figure of mean and 90% CIs for each treatment by [CONTACT_765] (including baseline, Day 84 and Day 
168) will be generated for post -BD FEV1, FVC and FEV1/FVC.
8.5. Other Safety  Analyses
The anal yses ofnon-laboratory  safet y test results including E CGsand vital sign swill be 
based on [COMPANY_004] Core Data Standards , unless otherwise specified.
9. PHA RMACOKINETIC A NALYSES
9.1. Primary  Pharmacokinetic A nalyses
9.1.1. Derived Pharmacokinetic Parameters
PK parameters will be calculated b y standard non -compartmental analy sis according to 
current working practices and using the currently supported version of WinNonlin . All 
calculations of non -compartmental parameters will be based on actual sampling times. 
PK parameters listed will be determined from the blood concentration -time (dry blood 
spot) data at Visit [ADDRESS_984599] -dose.
Parameter Parameter Description
AUC(0 -t) Area under the concentration -time curve fr om time zero to the time of the last quantifiable 
concentration (C(t)) will be calculated using the linear trapezoidal rule for each incremental 
trapezoid and the log trapezoidal rule for each decremental trapezoid.
Cmax Maximum observed concentration, de termined directly from the concentration -time data.
Tmax Time to reach Cmax, determined directly from the concentration -time data.
Tlast Time of last quantifiable concentration
NOTES:
Additional parameters may be included as required.
9.1.2. Statistical A nalyses / Methods
No formal statistical analysis of the dry  blood spot PK concentrations or PK parameters 
will be performed. Details of the planned display s are provided in Appendix [ADDRESS_984600] anda rds and statistical principles.
CONFIDENTIA L
205724
409.2. Exploratory Pharmacokinetic Analyses
9.2.1. Derived Pharmacokinetic Parameters
Note: Approximately  20% of the wet whole blood samples collected at Visit 3 will be 
analysed for danirixin concentrations to provide an anal ytical compa rison between dried 
blood spot and wet whole blood sample results. The expectation is that samples selected 
will mainly  come from those samples provided by  [CONTACT_720835] -set (i.e .
collecting samples over 12 hours) and be distributed across danirixin treatment groups.
PK parameters will be calculated b y standard non -compartmental analy sis according to 
current working practices and using the currently  supported version of WinNonlin .All 
calculations of non -compartmental parameters will be based o n actual sampling times. 
PK parameters listed will be determined from the blood concentration -time (wet whole 
blood) data at Visit 3 , as data permits.
Parameter Parameter Description
AUC(0 -t) Area under the concentration -time curve from time zero to the t ime of the last quantifiable 
concentration (C(t)) will be calculated using the linear trapezoidal rule for each incremental 
trapezoid and the log trapezoidal rule for each decremental trapezoid.
Cmax Maximum observed concentration, determined directly fro m the concentration -time data.
Tmax Time to reach Cmax, determined directly from the concentration -time data.
Tlast Time of last quantifiable concentration
NOTES:
Additional parameters may be included as required.
9.2.2. Statistical A nalyses / Methods
Details of the planned display s are provided in Appendix 1 1and will be based on [COMPANY_004] 
Data Standards and statistical principles.
Unless otherwise specified, endpoints / variables defined in Section 9.2.1 will be 
summarised using descriptive statistics, graphically presented (where appropriate) and 
listed.
[IP_ADDRESS]. Statistical Methodology  Specification
An extension of the Bland and Altman approach [ Bland ,1986; Bland , 1999] will be used 
to quantify  the agreement between the assay  methods using log -transformed data, 
including hematocrit in the model. Age and weight will also beadded one at a time in a 
model building ap proach and their significance in the model will be assessed. L imits of 
agreement and the coefficient of variation will be assessed to determine the agreement of 
the assay  methods and whether wet whole blood assay  is comparable to dry blood spot
assay . 
A sensitivity  anal ysis will be performed excluding dry blood spot concentrations above 
the assay  higher level of quantification of 1000 ng/mL .
CONFIDENTIA L
205724
41Endpoint / Variables
Log-transformed Danirixin blood concentration and pharmacokinetic parameter (Cmax and 
AUC(0 -t)) data
Model Specification
The Bland and Altman method will be used.
The following covariates will be included in the model: haematocrit, age and weight.
Model Results Presentation
Separate outputs will be produced for Danirixin concentration and pharm acokinetic parameters 
(although both will be analyzed using the same model)
Estimates of intercept and slope on log -scale for Danirixin concentration and pharmacokinetic 
parameters, bias at concentration is 0, %CVw, geometric means and limit of agreement a t 
concentration is 0.
Comparative plots of individual blood concentration and pharmacokinetic parameter data.
Supportive SAS output from statistical analysis.
Sensitivity and Supportive Analyses
A sensitivity analysis excluding dry blood spot concentrati ons above the assay HLOQ of 1000 
ng/mL will be performed.
10. POPULA TION PHARM ACOK INETIC A NALYSES
PK data from this study  may  be combined with historic data for the purposes of
population PK (PopPK) modelling which would be the subject of a separate anal ysisplan 
andwould be presented separately  from the main CSR.
To support this analy sis a PopPK dataset will be generated. The details for the dataset 
specifications are provided in Appendix 9.
11. BIOM ARKER ANALYSES
C-reactiv e protein and fibrinogen data will be summarized in the same way  as laboratory  
data. Summary  tables and boxplots for each treatment by  [CONTACT_765] (including screening, 
baseline, Day  84 and Day  168) will be generated for the mITT populations and also for 
the sub set of subjects who have an event in the ‘Infective pneumonia’ SMQ.
Exploratory  biomarker analy sis will be the subject of a separate RAP.
CONFIDENTIA L
[PHONE_15025]. PHARMACOKINETIC /PHA RMACODYN AMIC
ANALYSES
Graphical assessment of the relationship between individual danirixin expos ureand PD 
endpoints will be conducted.
Contingent on an y PK/PD relationship(s) being identified from the graphical assessment 
a PK/PD dataset will be generated. The details for the methodology  and dataset 
specifications will be provided in a separate docu ment after review of the graphical 
assessment of the relationship between PK and PD endpoints.
12.1. Statistical A nalyses / Methods
Details of the planned display sare provided in Appendix 1 1and will be based on [COMPANY_004] 
Data S tandards and statistical principles.
CONFIDENTIA L
[PHONE_15026]. REFERENCES
Atkinson, AC. (1985) Plots, Transformations and Regression. Clarendon Press.
Bland JM, Altman DG. (1986). Statistical methods for assessing agreement between two
methods of clinical measurement. Lancet, i, 30 7-310
Bland JM, Altman DG. (1999). Measuring agreement in method comparison studies.
Statistical Methods in Medical Research 1999; 8: 135 -160.
Bornkamp, B. (2014). Practical considerations for using functional uniform prior 
distributions for dose -response estimation in clinical trials. Biometrical Journal, 947 –962.
Chong J, Leung, B and Poole P. Phosphodiesterase [ADDRESS_984601]. Rev. 2013; I ssue 11
Crim C, Dransfield MT, Bourbeau J, et al. Pneu monia risk with inhaled fluticasone 
furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann. Am. 
Thorac. Soc. 2015; 12(1): 27 -34
Drummond MB, et al. Inhaled corticosteroids in patients with stable chronic obstructive 
pulmonary  disease: a systemic review and meta -analy sis. JAMA. 2008; 300(20): 2407 -
16
EMA press release. PRAC reviews known risk of pneumonia with inhaled corticosteroids 
for chronic obstructive pulmonary  disease. 2016
Evidera (2016a) The Exacerbations of Chronic Pulmo nary Disease Tool (EXACT) 
Patient -Reported Outcomes (PRO), User Manual (Version 8.0).
Evidera (2016b) Evaluating Respi[INVESTIGATOR_244774] (E -RS™) in COPD (E -RS™: COPD), 
User Manual (Version 5.0) 
IMI PROactive in COPD Daily and Clinical Instruments D -PPAC and C-PPAC User 
Guide (14JUN16)
Jones PW and Forde Y. (2016) St. Georges Respi[INVESTIGATOR_312391], version 1.3
Spencer S, Karner C, Cates CJ, Evans DJ. I nhaled corticosteroids versus long -acting 
beta2 -agonists for chronic obstructive pulmonary  disease. Cochrane Database of 
Systematic Reviews 2011, I ssue 12. 
Spi[INVESTIGATOR_192636], D. J., Abrams, K. R., & My les, J. P. (2004). Bay esian approaches to 
clinical trials and health -care evaluation. John Wiley  & Sons.
CONFIDENTIA L
[PHONE_15027]. APPENDICES
14.1. Appendix 1: Protocol De viation Management and Definitions 
for Per Protocol Population
14.1.1. Exclusions from Per Protocol Population
A participant meeting any  of the following criteria will be excluded from the Per Protocol 
population:
Number Exclusion Description
01 Inclusion # 2–FEV1/FVC ratio >=0.70 or% predicted FEV1 <40% at Screening
02Inclusion #4 –<2 historical exacerbations or one historical exacerbation with screening 
fibrinogen <3 g/L
03 Inclusion #5 -Smoking history of <10 pack years at Screening
04Exclusion #4 -Screening visit is less than 14 days since the completion of a course of 
antibiotics or oral steroids for a COPD exacerbation
05 Exclusion #14 -Use of PDE4 inhibitors within 30 days of Screening
06 Exclusion #26 -Oxygen use that is not PRN at Screening
At the strategic interim a participant meeting an y of the following criteria will be 
excluded from the Per Protocol population:
Number Exclusion Description
07 Xanthines at any time between the day after screening and end of treatment
08 PDE4 inhibitors at any time between screening and end of treatment
09Chronic use (more than 3 months )of erythromycin or azithromycin for between screening 
and end of treatment
[ADDRESS_984602] data 
excluded from the time of the deviation.  If a prohibited medication is taken prior to 
randomisation the participant will be excluded from the Per Protocol population.
Number Exclusion Description
07 Xanthines at any time between the day after screening and end of treatment
08 PDE4 inhibitors at any time between screening and end of treatment
09Chronic use (more than 3 months) of erythromycin or azithromycin between s creening and 
end of treatment
10Participants who stopped study medication for more than 14 days will be excluded from the 
PP analyses from the time they stopped taking study medication.
11 Data excluded from date of breaking of blind.
CONFIDENTIA L
[PHONE_15028].2. Appendix 2: Sch edule of A ctivities
14.2.1. Protocol Defined Schedule of Events
ProcedurePre-
Screeninga
(Visit 0)Screeninga
(Visit 1)Study Visits
2 3 4 5 6 7 8 9 10Early 
WithdrawalFollow Up
(up to [ADDRESS_984603] dose) Study Day -7 1 14 28 56 84 112 140 168
Assessment Window -30 d  
0d+
3d
3d  
3d  
3d  
3d  
3d   
3d  
3d
Eligibility 
Informed consent X
Genetic Sample 
Informed ConsentbX
Dem ography X
COPD Exacerbation 
HistoryX
Pre-Screeni ng 
FibrinogencX
Smoking HistorydX
Smoking StatusdX X
Inclusion and 
Exclusion criteriaX
Medical historyeX
Full physical 
examination including 
height and w eightX
CONFIDENTIA L
205724
46ProcedurePre-
Screeninga
(Visit 0)Screeninga
(Visit 1)Study Visits
2 3 4 5 6 7 8 9 10Early 
WithdrawalFollow Up
(up to [ADDRESS_984604] dose) Study Day -7 1 14 28 56 84 112 140 168
Assessment Window -30 d  
0d+
3d
3d  
3d  
3d  
3d  
3d   
3d  
3d
Chest x -ray (CXR)fX
HIV, Hepatitis B and 
C screeninggX
Pulse Oximetry X
Additional Eligibility and In Study Assessments
Verify EligibilityhX X
Brief Physical X X X X X
Urine or serum
pregnancy testiX X X X X X X X X
Laboratory 
assessments (clinical 
chemistry (includes 
liver chemistries), 
hematology, 
urinalysis) X X X X X X
Additional Liver 
chemistries onlyX X X
12-lead ECG X X X X X X
Vital signsXX X X X X X
Spi[INVESTIGATOR_038] X X X X X
Randomization X
CONFIDENTIA L
205724
47ProcedurePre-
Screeninga
(Visit 0)Screeninga
(Visit 1)Study Visits
2 3 4 5 6 7 8 9 10Early 
WithdrawalFollow Up
(up to [ADDRESS_984605] dose) Study Day -7 1 14 28 56 84 112 140 168
Assessment Window -30 d  
0d+
3d
3d  
3d  
3d  
3d  
3d   
3d  
3d
Dispense Study 
MedicationX X X X X X
Dispense log pad and 
provide trainingX
Dispense MDI sensors 
and provide trainingX
Dispense physical 
activity monitor and 
provid e trainingX
Study treatment===================================== 
Study treatment 
compliance (ediary)===================================== 
Collect IP ============================  X X
Collect MDI sensors X X
Collec t physical 
activity monitorX X
Collect log pad X X
Adverse Event (AE) 
review=====================================  X X
Serious Adverse 
Event (SAE) review================================================================  X X
CONFIDENTIA L
205724
48ProcedurePre-
Screeninga
(Visit 0)Screeninga
(Visit 1)Study Visits
2 3 4 5 6 7 8 9 10Early 
WithdrawalFollow Up
(up to [ADDRESS_984606] dose) Study Day -7 1 14 28 56 84 112 140 168
Assessment Window -30 d  
0d+
3d
3d  
3d  
3d  
3d  
3d   
3d  
3d
Concomitant 
medication reviewX X X X X X X X X X X X X
Clinical Outcomes Assessments
COPD Exacerbations===========================================  X X
EXACT -PROj=========================================== 
Rescue Medication 
Usek===================== ====================== 
SGRQ -CX X X X
COPD Assessment 
TestX X X X
PROactive 
QuestionnairelX X X
Physical Activity 
MonitorlX X X
Participant Global 
Impression of COPD 
SeverityX
Participant Impre ssion 
of Change in COPD 
SeverityX X X X X X X X
CONFIDENTIA L
205724
49ProcedurePre-
Screeninga
(Visit 0)Screeninga
(Visit 1)Study Visits
2 3 4 5 6 7 8 9 10Early 
WithdrawalFollow Up
(up to [ADDRESS_984607] dose) Study Day -7 1 14 28 56 84 112 140 168
Assessment Window -30 d  
0d+
3d
3d  
3d  
3d  
3d  
3d   
3d  
3d
Participant Global 
Impression of Activity 
LimitationX
Participant Impression 
of Change in Activity 
LimitationX X X X X X X X
Genetic, Pharmacokinetic and Biomarker Blood Collection s
Blood sample for 
GeneticsX
Blood sample for 
pharmacokinetics 
(PK)mX X X X
Blood sample for 
FibrinogenX X X X
Blood sample for CRP X X X X
Blood Sample for 
Exploratory
BiomarkersX X X X
CONFIDENTIA L
205724
50ProcedurePre-
Screeninga
(Visit 0)Screeninga
(Visit 1)Study Visits
2 3 4 5 6 7 8 9 10Early 
WithdrawalFollow Up
(up to [ADDRESS_984608] dose) Study Day -7 1 14 28 56 84 112 140 168
Assessment Window -30 d  
0d+
3d
3d  
3d  
3d  
3d  
3d   
3d  
3d
a. Pre-screening and screening visits may be completed on the same day.
b. Agreeing to the genetic sample consent is not required for study participation.
c. A pre -screening plasma fibrinogen measurement is only required for participants with 1 COPD exacerbation in t he prior year.
d. Smoking status /history assessed at screening: smoking status rechecked at Visit [ADDRESS_984609] and present medical conditions and family history of premature CV disease.
f. See inclusion/exclusion criteria for CXR s creening requirement
g. Hepatitis B (HBsAg) and Hepatitis C (HepC antibody) testing is required. If testing otherwise performed within [ADDRESS_984610] dose of 
study treatment, testing at screening is not required.  Hepatitis C RNA testing is o ptional; how ever a confirmatory negative Hepatitis C RNA test must 
be obtained, to be able to enrol participants with positive Hepatitis C antibody due to prior resolved disease.
h. Participant’s clinical status should be review ed.
i. Pregnancy testing onl y required for w omen of child bearing potential (WOCBP).  A positive urine pregnancy test requires confirmation with a serum 
pregnancy test.
j. E-RS:COPD is a subset of EXACT -PRO and is not a separate assessment.
k. Rescue medication use will be assessed via e -diary and MDI sensor.
l. The Clinic Visit PROactive Physical Activity in COPD tool w ill be assessed in a subset of approximately 50% of study particip ants
m. Pre-dose PK samples will be collected in all participants at Visits 3, 6, 7, and 10.  In a subset of participants (approx. 50 participants at each dose 
level) at Visit 3, PK samples will be collected at pre -dose, 0.5, 1, 2, 4, 6, 8, 10, [ADDRESS_984611] -dose.  In a subset of participants (approx.. 50 
participants at each dose level) at Visit 10, PK samples will be collected at pre -dose, 0.5. 1. 2. 4. 6, 8, 10, [ADDRESS_984612] -dose.
CONFIDENTIA L
[PHONE_15029].3. Appendix 3: A ssessment Windows
In general, data will be reported according to the nominal time of clinic visits and 
assessments as specified in the protocol. For example , if a participant recorded values for 
the Day  [ADDRESS_984613] all 
questionnaires that are scheduled to be performed at the Earl y Withdrawal (EW) Visit, 
eDiary data is reported as a nEW Visit. I f the date of the EW diary  asses sment is the 
same as the date of a scheduled visit date from the eCRF and there is no diary  data 
present at the scheduled visit in question, the EW diary  data will be listed, summarized 
and anal ysed as part of the scheduled visit (if the diary  data was sch eduled to be 
performed at the visit in question).
CONFIDENTIA L
[PHONE_15030].4. Appendix 4: Study  Phases
14.4.1. Study Phases
Assessments and events collected outside scheduled study  visits will be classified into 
study  phases according to the time of occurrence relative to the start and/or st op date of 
study  treatment.   The ‘worst case -post baseline ’derivation for summaries will consider 
all scheduled and unscheduled measurements that have been assigned a treatment phase 
of ‘On-treatment ’.
[IP_ADDRESS]. Study  Phases for Diary Data
Diary  data (including EXA CT events) treatment states are specified in Section 14.6.3 .
[IP_ADDRESS]. Study  Phases for Concomitant Medication
COPD medication combinations taken at screening will include all COPD medications 
that were taken on the day o f the screening visit, excluding medications that stopped on 
the day  of the screening visit.
Treatment phases for summaries of COPD and non -COPD concomitant medications will 
be assigned as follows:
Study Phase Definition
Prior Medications taken on or befo re the day before treatment start date defined as:
(conmed start date < treatment start date or ‘Taken prior to study?’ is ‘Yes’ or study 
treatment not started or conmed start date is missing)
Note: prior concomitant medication data will only be summarized for COPD 
medications. All screening data will be listed.
On-treatment If study treatment stop date > study treatment start date then this includes medications 
taken between the study treatment start date and study treatment stop date -1 
(inclusive) defi ned as follows:
(conmed start date < study treatment stop date or conmed start date is missing) and 
(conmed stop date >= study treatment start date or (conmed stop date is completely 
missing and study treatment start date is non -missing))
If study treatme nt stop date = study treatment start date then this includes medications 
taken on the study treatment start date (which is equal to the study treatment stop 
date) defined as follows.
(conmed start date <= study treatment stop date or conmed start date is m issing) and 
(conmed stop date >= study treatment start date or (conmed stop date is completely 
missing and study treatment start date is non -missing))
Post-treatment If study treatment stop date > study treatment start date then this includes medications 
taken after the study treatment stop date defined as follows:
(conmed stop date >= study treatment stop date or (conmed stop date is completely 
missing and study treatment stop date is non -missing))
If study treatment stop date = study treatment start dat e then this includes medications 
taken after the study treatment stop date + 1 defined as follows.
(conmed stop date > study treatment stop date or (conmed stop date is completely 
missing and study treatment stop date is non -missing))
CONFIDENTIA L
205724
53NOTES: 
A concomita nt medication will be classed in every period of the study in which it was taken.
See Section [IP_ADDRESS] for handling of partial dates.
 If the study treatment stop date is missing, it will be imputed as described in Section 14.6.1 .
[IP_ADDRESS]. Study  Phases for Event Data 
Classification of a HCRU exacerbation/AE as having onset on -treatment will be made 
with reference to the study treatment start and stop dates and the event onset date. If the 
event onset date is missing, then the event will be considered on -treatment. 
Study Phase Definition
Pre-treatment If onset date is prior to treatment start date
Start Date < Study Treatment Start Date
On-treatment If onset date is on or aft er treatment start date & on or before treatment stop date + 3.
Study Treatment Start Date ≤ Start Date ≤ Study Treatment Stop Date + [ADDRESS_984614]-treatment If onset date is after treatment stop date + 3.
Start Date > Study Treatment Stop Date + 3 days
Note: assume on -treatment unless there is evidence to the contrary 
[IP_ADDRESS]. Study  Phases for Other Data 
All d ata collected at scheduled study  visitsafter Day  1 will be considered on -treatment. 
Any data collected at unscheduled visits (ie, l aboratory  data, vital si gns, ECGs, 
spi[INVESTIGATOR_038] , CAT and SGRQ )will be classified as on -treatment based on the study  
treatment start date (and time, if available) and study  treatment stop date and the date 
(and time, if available) of the visit/assessment. I f the visit/assessment da te is missing, 
then the event will be considered on -treatment. 
Study Phase Definition
Pre-treatment If assessment/visit date (and time) is on or prior to treatment start date (and time)
Assessment/Visit Date (and time) ≤ Study Treatment Start Date (and t ime)
On-treatment If assessment/visit date (and time) is after treatment start date (and time) & on or 
before treatment stop date + 3.
Study Treatment Start Date (and time) < Assessment/Visit Date (and time) ≤ Study 
Treatment Stop Date + [ADDRESS_984615]-treatment If assessment/visit date is after treatment stop date + 3.
Assessment/Visit Date > Study Treatment Stop Date + 3 days
Note: assume on -treatment unless there is evidence to the contrary 
CONFIDENTIA L
[PHONE_15031].5. Appendix 5: Data Display  Standards & Handling 
Conventions
14.5.1. Repor ting Process
Software
The currently supported versions of SAS software will be used .
Reporting Area
HARP Server : uk1salx00175
HARP Compound : [COMPANY_004]1325756
Analysis Datasets 
Analysis datasets will be created according to Legacy [COMPANY_004] A&R dataset standar dsfor the strategic 
interim and CDISC standards (SDTM IG Version 3.2& ADaM IG Version 1.1].
Generation of RTF Files
RTF files will be generated for strategic interim and final reporting efforts
14.5.2. Reporting Standards
General
The current [COMPANY_004] Integrated D ata Standards Library (IDSL) will be applied for reporting , unless 
otherwise stated (IDSL Standards Location: 
https://spope.gsk.com/sites/IDSLLibrary/SitePages/Home.aspx) :
4.03 to 4.24: General Principles
5.01 to 5.08: Principles Relat ingto Data Listings
6.01 to 6.11: Principles Related to Summary Tables
7.01 to 7.13: Principles Related to Graphics 
Formats
[COMPANY_004] IDSL Statistical Principle 4.24 for decimal places (DP’s) will be adopted for reporting of data based 
on the raw dat a collected , unless otherwise stated.
Numeric data will be reported at the precision collected on the eCRF.
The reported precision from non eCRF sources will follow the IDSL statistical principles but may be
adjust ed to a clinically interpretable number of DP’s .
oE-RS:COPD and SGRQ wi ll have a min and max to 1 decimal places ( dp)and then follow 
IDSL standards for reporting other summary statistics.
oCAT will have a min and max to 0 dp and then follow IDSL standards for reporting other 
summary statistics. 
Categories will be based on ro unded values to the precision collected on the eCRF , i.e., categories of 
% predicted FEV1 will be based on the rounded (to 1 dp) values of the variable FEV1PDPC
Summaries of continuous data will include number of participant s, mean, SD, median, minimum and
maximum and for C -RP and fibrinogen outputs the 25 thand 75 thpercentile .
Percentages between 1% and 99%, inclusive, will be rounded to integers. Percentages greater than 
0%, but less than 1%, will be reported as <1%, and percentages greater than 99%, but less than 100%, 
will be reported as >99%.
Planned and Actual Time
Reporting for tables, f igures and formal s tatistical analyses:
Planned time relative to dosing will be used in figures, summaries, statistical analyses and 
calculation of any derived para meters, unless otherwise stated.
CONFIDENTIA L
205724
55Actual time will be used for calculation of times to events and Kaplan -Meier plots.
Reporting for Data Listings: 
Planned and actual time relative to study drug dosing will be shown in listings (Refer to IDSL 
Statistical Pr inciple 5.05.1).
Unscheduled or unplanned readings will be presented within the participant’s listings. 
Unscheduled Visits
Unscheduled visits will not be included in summary tables and/or figures except as part of a 
maximum/minimum/worst case post -basel ine assessment or if they are assigned as the baseline 
assessment as detailed in Section 5.2.
All unscheduled visits will be included in listings.
Cardiovascular Event Reports
Laboratory results, ECG results/f indings and vital signs measurements collected as part of 
cardiovascular event reports will not be included in any tables, listings or any minimum/maximum post -
baseline assessments.
Time to Event Results
For all time to event analyses, the first quartile and median time to event will be presented. If less than 
25% of participant s experienced the event within a treatment group then the first quartile will be 
displayed as NA (not applicable) for that treatment. If less than 50% of participant s experienced t he 
event within a treatment group then the median will be displayed as NA for that treatment.
Descriptive Summary Statistics
Continuous Data Refer to IDSL Statistical Principle 6.06.1
Categorical Data N, n, frequency, %
Graphical Displays
Refer to IDSL Statistical Principals 7.01 to 7.13.
Seeds for Bayesian Analyses
The seeds used to for the Bayesian analyses were generated using the ranuni function in SAS.  The 
same seeds should be applied for all endpoints and populations. 
Chain Seed
1 2619
2 413
3 9243
CONFIDENTIA L
[PHONE_15032].5.3. Reporting Standards for Pharmacokinetic Data
Pharmacokinetic Concentration Data
PC Windows Non -
Linear (WNL) FilePC W NL file (CSV format) for the non -compartmental analysis by [CONTACT_720836]_51487 and PKOne documents . 
Note: Concentration values will be imputed as per GUI_51487
Descriptive Summary 
Statistics, Graphical 
Displays and ListingsRefer to IDSL PK Display Standards.
Refer to IDSL Statistical Principle 6.06. 1.
Note: Concentration values will be imputed as per GUI_51487 for descriptive 
summary statistics/analysis and summarized graphical displays only. 
Additionally, include geom etric mean and 9 0% CI for the summary of blood 
concentration data.
NONMEM/Pop PK 
FilePopPK file (CSV format) for the PopPK analysis by [CONTACT_720837] 9.
Pharmacokinetic Parameter Deri vation
PK Parameter to be 
Derived by 
[CONTACT_720838]. 
Descriptive Summary 
Statistics, Graphical 
Displays and ListingsRefer to IDSL PK Display Standards.
CONFIDENTIA L
[PHONE_15033].6. Appendix 6:Derived and Transformed Data
14.6.1. General
Multiple Measurements at One Analysis Time Point
Mean of the measurements will be calculated and used in any derivation of summary statistics but if 
listed, all data will be presented .
Participants having both High an d Low values for Potential Clinical Importance criteria at any post -
baseline visit for safety parameters will be counted in both the High and Low categories of “ Worst case
post-baseline” row of related summary tables. 
Study Day
Calculated as the number of days from First Dose Date:
Ref Date = Missing              → Study Day = Missing 
Ref Date < First Dose Date → Study Day = Ref Date –First Dose Date
Ref Data ≥ First Dose Date → Study Day = Ref Date –(First Dose Date) + 1
Study Treatment Stop Date
If the study treatment stop date is missing, it will be imputed as follows:
If any of EW Visit date, Visit 10 (Day 168) date or date of death are non -missing then the study 
treatment stop date will be imputed as the minimum of (EW Visit date, Visit 10 (Day 168) date, date 
of death, date that all study treatment containers were returned).
For all other missing treatment stop dates, the last recorded exposure start or stop date will be 
used.
For ongoing participants at the strategic interim, treatment stop da te will be imputed as 5SEP2018
Study Completion Definition
A participant is considered to have completed the study if they have not withdrawn and attended Visit 
10. 
14.6.2. Study Population
Demographics
Age
[COMPANY_004] standard IDSL algorithms will be used for calcu lating age where birth date will be imputed as 
follows:
oAny participant with a missing day will have this imputed as day ‘15’. 
oAny participant with a missing date and month will have this imputed as ‘30th June’.
Birth date will be presented in listings as ‘YYYY’.
Age will be calculated based on the Pre -screening visit date .
Age group categories are 18 -64, 65 -74, 75 -84, >=85
Body Mass Index (BMI)
Calculated as Weight (kg) / [Height (m) 2]
CONFIDENTIA L
205724
58Baseline Characteristics
% Predicted Normal FEV1 at Screening
The following categories will be derived: <50%, >=50%
Smoking Status
If the last smoked date (SUSMLSDT) is missing and a partial date (SUSMLSD) is not missing, then the 
following imputation should be applied to the partial smoking date for use in the recla ssification of 
smoking status calculation:
'01' will be used for the day and 'Jan' will be used for the month.
Former smokers will be reclassified as current smokers if screening date –last smoked date < 183 days.
Chronic Mucus Hypersecretion
 A particip ant is considered to have CMH ( CMH+ )if baseline SGRQ Q1(cough) = Most or several 
days a week AND baseline SGRQ Q2 (phlegm) = Most or several days a week. 
 A participant is considered not to have CMH ( CMH -)if baseline SGRQ Q1(cough) not equal to 
Most or s everal days a week OR baseline SGRQ Q2(phlegm) not equal to Most or several days a week 
and both questions are non -missing at baseline.
 Otherwise participants are considered to have a missing CMH status.
Baseline E -RS: COPD Total Score Categories
 The fol lowing categories will be derived for baseline E -RS: COPD Total Score
o<8, >=8
o<10, >=10
o <12, >=12
Exacerbation History Categories
 Exacerbations (historical) will be classified as follows:
 Mild: Managed without oral/systemic corticosteroids and/or antibio tics (not involving 
hospi[INVESTIGATOR_11956]) 
 Moderate: Requiring oral/systemic corticosteroids and/or antibiotics (not involving hospi[INVESTIGATOR_11956]) 
 Severe: Requiring hospi[INVESTIGATOR_11956] 
 Moderate/severe: Requiring oral/systemic corticosteroids and/or antibiotics or ho spi[INVESTIGATOR_11956].
 The total number of moderate/severe exa cerbations will be categorized as ≤1, ≥2 for inclusion as 
a covariate in statistical models.
GOLD Grade 1 -4 at Screening
 Participants will be classified into Global Initiative on Obstructive Lung Disease (GOLD) Grades 
1-[ADDRESS_984616] -bronchodilator pe rcent predicted FEV1 assessment at Screening: 
oGOLD Grade 1 (Mild):  percent predicted FEV1 80%
oGOLD Grade 2 (Moderate): 50% percent predicted FEV1 <80%
oGOLD Grade 3 (Severe):  30% percent predicted FEV1 <50%
o GOLD Grade 4 (Very Severe): percent predicte d FEV1 <30%   
GOLD Grade A -D at Screening
Participants will be classified into GOLD Grades A -D definitions as follows:
A. Low risk, less symptoms: baseline CAT < 10 AND GOLD Grade 1 -2 AND ≤1
exacerbation; (no hospi[INVESTIGATOR_720797]), prior year.
B. Low risk, more symptoms: baseline CAT >= 10 AND GOLD Grade 1 -2 AND ≤1
exacerbation (no hospi[INVESTIGATOR_720797]), prior year
C. High risk, less symptoms: baseline CAT < 10 A ND either GOLD Grade 3 -4 OR ≥2
exacerbations, prior year OR >=1 exacerbation leading to hospi[INVESTIGATOR_059], prior
year
D. High risk, more symptoms: baseline CAT >= 10 AND either GOLD Grade 3 -4 OR ≥2
exacerbations, prior year OR >=1 exacerbation leading to h ospi[INVESTIGATOR_059], prior year
CONFIDENTIA L
205724
59Baseline Characteristics
Participant Disposition
For Kaplan -Meier plots of study withdrawal over time, censoring will be performed as follows:
oParticipant s are represented from their Day 1 date to the date of early withdrawal from the study (or 
date o f death). Participant s that completed the study are censored at the earliest of the date of 
completion and Day 168.
Medical Conditions and Concomitant Medications
Respi[INVESTIGATOR_720798]
COPD concomitant medications will be grouped into the follow ing RMCs based on pre -defined code lists 
derived from ATC classifications:
oAndrogens and Estrogens
oAnti-IgE, Anti -IL5
oAnticholinergic
oAntiinfectives (antibiotics, antiseptics only)
oAntimycotics
oAntivirals
oBeta [ADDRESS_984617]
oCorticosteroid –Inhaled
oCorticoster oid –Depot
oCorticosteroid –Systemic, oral, parenteral and intra -articular
oCorticosteroid –Other
oLeukotriene Receptor Antagonist
oLong -acting anticholinergic
oLong -acting beta -[ADDRESS_984618]
oXanthine
oOther medication given for exacerbation
oOther COPD medication
COPD Medication Combination
COPD medications will be summarized at the following time points:
oAt Screening: T aken on the day of the Screening visit excluding medications that stopped 
on the day of the Screening visit
oAt Baseline: Taken on the day of start of treatment
oAt Month 6: Taken during Month 6 (Study Day [ADDRESS_984619] of (Study day 168 and day 
before study treatment stop date) )
Medication combinations of all RMC categories will be derived.  Medications will be summarized based 
on individual and combinations of the following RMC categories, with or without other medications :
oICS
oLABA
oLAMA
oXanthine
oPDE4 inhibitor
o Anti-IgE, Anti-IL5
CONFIDENTIA L
205724
60Medical Conditions and Concomitant Medications
Cardiovascular Risk Factors
Subjects with at least one of the following current or past medical conditions at Screening will be classed 
as having cardiovascular (CV) risk factor at screening.  The number of CV risk factors at Screening (0, 1, 
or >=2) will be derived.
oCoronary artery disease
oMyocardial infarction
oArrithymia
oCongestive heart failure
oHypertension
oCerebrovascular accident
oHypercholesterolemia
o Diabetes mellitus
Compliance
Treatment Compliance
Compliance= (tablets issued –tablets returne d) x 100 / 2 x (treatment stop date –treatment start date +1)
If any count of tablets returned is missing overall compliance will be set to missing.
Compliance will be categorized as follows:
< 80 %
80 % to < 95 %
95 % to 105 %
>105 % to 120 %
>120 %
If a participant received a treatment other than the randomized treatment during the study, the 
compliance will still be calculated using data from all containers received and overall treatment start and 
stop dates.
Daily Diary Compliance
Overall c ompliance= ( number of days with non -missing data between study treatment start and the earliest of 
(Study day 168 and day before study treatment stop) ) x 100 / ( Earliest of (Study day 168 and day before 
study treatment stop date)–treatment start date +1)
Overall c ompliance will be categorized as follows:
< 50 %
50 % to < 60 %
60 % to < 70 %
70 % to < 80 %
80 % to < 90 %
90 % to 100 %
Baseline and Monthly compliance= number of days with non -missing data between periods defined in 
Section 14.6.3   
Baseline compliance will be categorized as follows: Number of days completed < 4, 4
Monthly compliance will be categorized as follows: Number of days completed <10, 10 -20, >20
CONFIDENTIA L
205724
61Exposure
Exposure to Study Tr eatment
Duration of exposure to study treatment is calculated as (treatment stop date –treatment start date +1) .
The following exposure categories will be derived:
≥1 day, ≥4 weeks, ≥8 weeks, ≥12 weeks, ≥16 weeks, ≥20 weeks and ≥24 weeks. An additional 
category of 23 -25 weeks will also be summarized.
14.6.3. Efficacy
Daily eDiary endpoints
General
Participants were instructed to complete the daily eDiary in the evening (typi[INVESTIGATOR_720799]).  The 
parameters collected include rescue use and EXACT -PRO scores.
The tables below show which daily eDiary records are used to calculate the daily eDiary parameters for each 
period.  Any diary data collected after the minimum of ( Day 168 and the day before study treatment stop 
date) will not be slotted. 
To be used for rescue use endpoints and E -RS:COPD total and subscale scores:
Period First day Last day
Baseline [1]Latest of (7 days before Study 
treatment start date (Day 1) and 
day of Visit 1 (Screening))Day before Day 1 of study 
treatment
Month 1 [1]Study day 1 Study day 28
Month 2[1]Study day 29 Study day 56
Month 3[1]Study day 57 Study day 84
Month 4[1]Study day 85 Study day 112
Month 5[1]Study day 113 Study day 140
Month 6[1]Study day [ADDRESS_984620] of (Study day 168 and day 
before study treatment sto p date )
[1] The denominator for baseline and monthly mean scores is the number of days with a non -missing 
score; this is also used to determine whether or not a baseline (>=4 days) or monthly mean (>=10 
days) is calculated.
EXACT PRO
The EXACT -PRO ( Evidera , 2016 a) is a 14 -item daily diary (typi[INVESTIGATOR_720800]) 
The daily E -RS: COPD total score (and subscales) will be computed according to the E -RS in COPD 
user manual (Evidera , 2016 b). 
The monthly mean for E -RS: COPD total score , and the subscale score s RS -Breathlessness, RS -Cough 
and Sputum, and RS -Chest Symptoms will be calculated as the mean of the daily scores in the monthly 
intervals defined above.
Mean m onthly score = (sum of daily scores/# diary days completed).
A participant must have at least 10 days of diary data in any month to contribute a non -missing monthly 
mean of daily values; otherwise the monthly mean for that month will be considered missing.
A participant must have at least 4 days of diary data in the 7 days prior to treatment start date to 
contribute a non -missing mean of daily values for baseline; otherwise baseline will be considered 
missing.
If missing values occur for individual items, t he E-RS: COPD total score and E -RS: COPD subscale 
CONFIDENTIA L
205724
62Daily eDiary endpoints
score that contain the item will be set to missing on that day.
Responders according to E -RS: COPD Total and Subscale Scores
A participant will be considered as a responder according to E -RS:COPD total s core if their monthly 
mean change from baseline E -RS: COPD total score ≤ -2.0.
A participant will be considered as a non -responder according to E -RS:COPD total score if their monthly 
mean change from baseline E -RS:COPD total score > -2.0.
A participant will be considered as a responder according to E=RS: COPD breathlessness score if their 
month mean change from baseline E -RS:COPD breathlessness score ≤ -1.0.
A participant will be considered as a non -responder according to E -RS:COPD breathlessness score i f 
their monthly mean change from baseline E -RS: COPD breathlessness score > -1.0.
A participant will be considered as a responder according to E -RS: COPD cough & sputum score if their 
monthly mean change from baseline E -RS: COPD cough & sputum score ≤ -0.70.
A participant will be considered as a non -responder according to E -RS: COPD cough & sputum score if 
their monthly mean change from baseline E -RS:COPD cough & sputum score > -0.70.
A participant will be considered as a responder according to E -RS:COPD ch est symptoms score if their 
monthly mean change from baseline E -RS:COPD chest symptoms score ≤ -0.70.
A participant will be considered as a non -responder according to E -RS:COPD chest symptoms score if 
their monthly mean change from baseline E -RS: COPD chest symptoms score > -0.70.
If the monthly mean E -RS: COPD score is m issing then response status will be missing.
Season
For each participant and each month, season will be assigned based on the firstdate with a non -missing 
daily score in the monthly mean E -RS:COPD total score. 
Australia will add [ADDRESS_984621] day of the monthly mean E -RS:COPD total score before season 
is assigned.
If the month of the first day of the monthly mean score period is:
Dec, Jan or Feb then season is Winter
Mar, Apr or May then season is Spring
Jun, Jul or Aug then season is Summer
Sep, Oct or Nov then season is Fall
Mean Number of Rescue Puffs per Day and Percentage Rescue Free Days
If a participant has more than one daily diary record for any given day, the worst case response on that 
day for each endpoint will be used in the summ aries and analyses. i.e. the maximum number of puffs of 
rescue use reported will be counted for the day in question and used to determine if it was a recue -free 
day.
A rescue -free day is defined as a day where the total puffs is 0.
For each summary period, the mean number of puffs per day and the percentage of rescue free days, 
will be calculated, using the number of days with non -missing values for the endpoint as denominator.
Rescue use will be summarized over the periods defined above.
CONFIDENTIA L
205724
63HCRU Exacerbatio ns
Duration
The duration of the exacerbation will be calculated as (exacerbation resolution date or date of death -
exacerbation onset date + 1).
Severity
Each HCRU exacerbation will be categorized based on severity as follows:
oMild: no treatment with oral/systemic corticosteroids and/or antibiotics and not involving 
hospi[INVESTIGATOR_11956], an emergency room visit or resulting in death  
oModerate: required treatment with oral/systemic corticosteroids and/or antibiotics (not 
involving hospi[INVESTIGATOR_11956], an emerge ncy room visit or resulting in death).
oSevere: required in -patient hospi[INVESTIGATOR_059], an emergency room visit, or resulted in death
Time to First Exacerbation
The time to first on -treatment Moderate/Severe HCRU exacerbation will be calculated as exacerbati on 
onset date of first on -treatment moderate or severe on -treatment exacerbation –date of start of 
treatment +1
Participants will be represented from their treatment start date to their first on-treatment moderate or 
severe exa cerbation or date of censori ng.
For the strategic interim analysis, participants that have not experienced an on -treatment exacerbation 
are censored at the earliest of (treatment stop date + 3, date of death, or the interim cut -off date, 
1AUG2018). 
For the final analysis, participan ts that have not experienced an on -treatment exacerbation are censored 
at the earliest of (treatment stop date + 3, date of death , date of exclusion from the per protocol 
population (if analysis is in Per Protocol population) )
Raw Annual Rate
Raw annual rate is the event rate per 1000 participant -years, calculated as the number of events x 1000, 
divided by [CONTACT_720839] (minimum(treatment stop date + 1, date of death , date of exclusion 
from the per protocol population (if analysis is in Per P rotocol population) ) –treatment start date + 1).
Offset Variable
For analyses of exacerbation rate, the offset variable will be defined as the logarithm of the ((minimum 
(date of end of study treatment + 3, date of death , date of exclusion from the per protocol population (if 
analysis is in Per Protocol population) ) –date of start of treatment + 1)/365.25 )
EXACT Events
General
The daily EXACT -PRO scores will be computed according to the EXACT -PRO user manual ( Evidera , 
2016a) and used to identify EXACT -defined events, including the frequency, duration and severity of the 
events.
Events will be categorized as recovered, censored, or persistent worsening (according to the manual).
Time to First Event
The time t o first on -treatment EXACT event will be calculated as the onset date of the first on -treatment 
EXACT event –date of start of treatment +1
Participants will be represented from their treatment start date to their first EXACT event or date of 
censoring. 
For the final analysis, participants that have not experienced a nEXACT event are censored at the 
earliest of ( Day 168, treatment stop date -1, date of death, or date of final EXACT -PRO assessment , 
date of exclusion from the per protocol population (if ana lysis is in Per Protocol population) )
CONFIDENTIA L
205724
64Raw Annual Rate
Raw annual rate is the event rate per [ADDRESS_984622] -
defined events x 1000, divided by [CONTACT_720839] (minimum( Day 168, treatment stop dat e -1, 
date of death, date of final EXACT -PRO assessment , date of exclusion from the per protocol population 
(if analysis is in Per Protocol population) ) –treatment start date + 1).
Offset Variable
For analyses of EXACT event rate, the offset variable w ill be defined as the logarithm of the ((minimum 
(Day 168, treatment stop date -1, date of death, date of final EXACT -PRO assessment , date of 
exclusion from the per protocol population (if analysis is in Per Protocol population) ) –date of start of 
treatm ent + 1)/365.25 )
CAT
CAT Score
The CAT consists of eight items each formatted as a six -point differential scale: 0 (no impact) to 5 (high 
impact). A CAT score will be calculated by [CONTACT_720840] -missing scores on the eight items.  The 
score can have values ranging from 0 to 40. 
If one item is missing, then the score for that item is set as the average of the non -missing items. If more 
than one item is missing, then the CAT score will be set to missing. 
If the language of the CAT conducted at a post -baseline visit is different to the language used at 
baseline, the CAT score for that visit and all subsequent visits will be set to missing.
If there is more than one response to a question at a visit or duplicate questionnaires, the CAT score for 
that vis it will be set to missing.
Responders according to CAT Score
A participant will be considered as a responder according to CAT score if their change from baseline 
CAT score ≤ -2.0.
A participant will be considered as a non -responder according to CAT score if their change from baseline 
CAT score > -2.0.
If CAT score is missing at a visit, the response status will be missing at that visit.
Season
For each participant and each visit, season will be assigned based on visit date. 
Australia will add 6 months to the visit date before season is assigned.
If the month of the visit is:
Dec, Jan or Feb then season is Winter
Mar, Apr or May then season is Spring
Jun, Jul or Aug th en season is Summer
Sep, Oct or Nov then season is Fall
SGRQ
SGRQ Domain and Total Score s
The SGRQ -C contains 14 questions with a total of 40 items grouped into three domains (Symptoms, 
Activity and Impacts). 
Details for how to score the SGRQ -C, inclu ding handling of missing data or multiple responses to 
questions, are outlined in the SGRQ -C manual ( Jones , 2016).
SGRQ -C domains and total scores will be converted to SGRQ scores as described in the manual.
Changes f rom baseline in domain and total score will be calculated for the converted scores.
If the language of the SGRQ -C conducted at a post -baseline visit is different to the language used at 
baseline, all SGRQ scores at that visit and all subsequent visits will be set to missing.
CONFIDENTIA L
205724
65Responders according to SGRQ Total Score
A participant will be considered as a responder according to SG RQ total score if their change from 
baseline SGRQ total score ≤ -4.0.
A participant will be considered as a non -responder accordin g to SGRQ total score if their change from 
baseline SGRQ total score > -4.0.
If SGRQ total score is missing at a visit, the response status will be missing at that visit.
Change from baseline SGRQ total score will be rounded to 1dp prior to assigning respon der status.
Rescue Use via Sensor
Mean Number of Occasions and Percentage Rescue Free Days via Sensor
The mean number of occasions of rescue per day and the percentage of rescue -free days will be 
calculated over the same time periods and using the same assumptions as rescue use via diary .
Rescue -free Days -days within the diary data collection period with no recorded rescue inhaler usage 
by [CONTACT_720841] a rescue inhaler usage of 0. 
PROactive
General
A PROactive Total Score and two domain scores (amount and difficulty) are derived using data from the 
C-PPAC questionnaire and a physical activity monitor worn for 7 days prior to the questionnaire . 
To derive the PROactive score at each visit the following is required:
oResponse to valid (i.e., no missing items) C -PPAC questionnaire
oMedian values of steps/day and VMU/min on at least 3 days of the 7 days prior to the 
C-PPAC questionnaire with >=8 hours wearing (the 3 days do not need to be 
consecutive).
The C -PPAC questionnaire contains 14 items (12 questions and 2 scores from the activity monitor 
outputs) each scored from 0 to 4.
The amount domain is calculated using 2 items from the C -PPAC questionnaire (amount of walking 
outside and chores outside) and 2 activity monitor outputs (vector magnitude units per minute (VMU/min) 
and steps/day).
The difficulty domain is calculated using 10 items from the C -PPAC questionnaire.
Each domain score is based on the addition of items (0-15 for amount and 0 -40 for difficulty) and then 
scaled from 0 -100.
The total score is calculated as (amount+difficulty)/2
Further details for how to score and scale the domain and total scores are outlined in the IMI PROactive 
user guide (14JUN16).
CONFIDENTIA L
[PHONE_15034].6.4. Safety
Adverse Events
AEsofSpecial Interest
AESI are defined as ev ents in the ‘Infective pneumonia’ SMQ in the MedDRA version current at the time of 
reporting.
Subjects receiving ICS (RMC -Corticosteroid –Inhaled) for at least 7 days at the time of Pneumonia onset.
Maximum/Minimum Post -Baseline and Worst -Case Post -Baseline
Definition Reporting Details
Maximum post -baseline
(QTcF, QTc B, PR interval, ECG 
heart rate, pulse rate, systolic BP, 
diastolic BP and laboratory tests)Change from baseline of m aximum value over all time -points after Day [ADDRESS_984623] -baseli ne
(Diastolic BP and laboratory tests 
that do not have a lower limit = 0)Change from baseline of m inimum value over all time -points after Day [ADDRESS_984624] -baseline
(ECG findings)‘Abnormal’ if any on -treatment assessment is evaluated as 
‘Abnormal’
‘Unable to evaluate’ if all on -treatment assessments are ‘Unable to 
evaluate’
‘Normal’ if any on -treatment assessment is evaluated as ‘Normal’ 
and there are no on -treatment assessments evaluated as 
‘Abnormal’
NOTES :
The treatment phase definitions spe cified in Section [IP_ADDRESS] will be used and only assessments within the on -
treatment period will be considered in assessment of minimum/maximum/worst -case post -baseline.
Assessment of minimum/maximum/worst -case post-baseline will include on-treatment data from scheduled, 
unscheduled and study treatment discontinuation visits (if applicable) 
Laboratory Parameters
General
NQ laboratory results will be treated as missing in summary displays.  However, the resul ts will be listed 
as received (e.g. ‘<x’ or ‘>x’).
If numeric laboratory results are missing but a character result has been recorded, ie. <X, (the numeric 
part of the character value)/2 will be used to assign the PCI ranges. 
A ‘worst case post-baseline’ change classification will be derived, in which participant s will be counted in 
the ‘to low’ and ‘to high’ categories if they reported a change from a n‘in range ’ baseline to a value 
below or above the PCI criteria (respectively) at any scheduled or unsche duled on -treatment visit. 
Participant s who did not report a change to a value outside the PCI criteria at any visit after the start of 
study treatment will be counted in the ‘to w/in range or no change’ category. 
Multiple Measurements for On-Treatment Visits for Safety
Participant s having both high and low values relative to PCI criteria at post -baseline visits for safety 
parameters will be counted in both the high and low categories of the “ worst case post-baseline” row of 
related summary tables.
CONFIDENTIA L
205724
67ECG
General
The QTc data was collected via machine derived values (QTCB/QTCF) or manually derived values 
(QTCBC/QTCFC). For the purposes of reporting the following variable should be combined:
-Combine QTCF with QTCFC 
If both QTCF and QTCFC are missing (and QT and RR are non -missing then the QTcF interval will be 
derived as follows:
-QTcF interval (msec) = QT/[(RR/1000)**(1/3)]
-If RR interval is not collected and the corrected QT interval by [CONTACT_35019]’s method (QTcB) is collected, 
then RR interval (msec) will be derived prior to deriving QTcF as follows: RR interval (msec) = 
1000*[(QT/QTcB)**2]
If QTcF intervals are collected they will not be rederived.
ECG Categories
Maximum and maximum increase in d QTcF values will be reported in categories as below . In subje cts who 
have QTc above 450 at baseline, decreases that result in a QTc that remains above 450 will be considered 
No Change.
ECG Parameter Units Category
Absolute
Absolute QTcF Interval msecNo Change or Decrease to <=450
Increase To >450 to <=480
Increase To >480 to <=500
Increase To >500
Change from Baseline
Change from Baseline QTcF msecIncrease of <=30 ms
Increase of 31 -60 msec
Increase of >[ADDRESS_984625] -baseline will include on -treatment data from scheduled, un scheduled and 
study treatment discontinuation visits (if applicable)
CONFIDENTIA L
[PHONE_15035].7. Appendix 7: Reporting Standards for Missing Data
14.7.1. Premature Withdrawals
Element Reporting Detail
General Participant study completion (i.e. as specified in the protocol) was defined as 
completion of all phases of the study including the last study visit and the last 
scheduled procedure shown in the Schedule of Activities ( Appendix 2 ). 
For the purposes of reporting, a participant is considered to have completed the study if 
they have not withdrawn and attended Visit 10.
Withdrawn participants were not replaced in the study.
All available data from participants who were withdrawn from the study will be listed 
and all available planned data will be includ ed in summary tables and figures, unless 
otherwise specified.
Data from the Early Withdrawal visit will not be included in any summaries or analyses 
except as part of a worst case post -baseline assessment.
14.7.2. Handling of Missing Data
Element Reporting Detai l
General Missing data occurs when any requested data is not provided, leading to blank fields on 
the collection instrument:
oThese data will be indicated by [CONTACT_2224] a “blank” in participant listing displays. 
Unless all data for a specific visit are mis sing in which case the data is excluded 
from the table. 
oAnswers such as “Not applicable” and “Not evaluable” are not considered to be 
missing data and should be displayed as such.
Outliers If outliers are identified, analyses may be repeated excluding th e outlying data.
Any participants /data excluded from summaries and/or statistical analyses will be 
documented along with the reason for exclusion in the clinical study report.
[IP_ADDRESS]. Handling of Missing and Partial Dates
Element Reporting Detail
General Partial dates will be displayed as captured in participant listing displays.
Adverse 
EventsCompletely missing start or end dates will remain missing, with no imputation applied. 
Consequently, time to onset and duration of such events will be missing.
Concomita nt 
MedicationsPartial dates for any concomitant medications recorded in the CRF will be imputed 
using the following convention:
oIf the partial date is a start date, a '01' will be used for the day and 'Jan' will be 
used for the month
oIf the partial date i s a stop date, a '28/29/30/31' will be used for the day 
(dependent on the month and year) and 'Dec' will be used for the month.
The recorded partial date will be displayed in listings.
CONFIDENTIA L
[PHONE_15036].8. Appendix 8: Values of Potential Clinical Importance
14.8.1. Laboratory  Values
The following table identifies a range of potential clinical importance (PCI) for each 
laboratory  anal yte.  Limits with an ‘x’ are multipliers of the central laboratory  normal 
range.  Values above and below this range will be considered of PCI.
Hematology Analyte 
(units)Effect COPD Patients
Low High
Platelet Count (x10 9/L) 0.90x 1.10x
Red Blood Cell Count 
(x1012/L)0.93x 1.07x
White Blood Cell Count 
(x109/L)0.70x 1.60x
Reticulocyte Count (%) >4%
Hemoglobin (g/L)Males 0.85x 1.20x
Females 0.85x 1.20x
Hematocrit (Ratio of 1)Males 0.50x 1.30x
Females 0.50x 1.30x
MCV (fL) 0.25x 2.00x
MCH (pg) 0.85x 1.20x
MCHC (g/dL) 0.85x 1.10x
Neutrophils (%) 0.65x 1.50x
Lymphocytes (%) 0.80x 1.20x
Monocytes (%) 0.80x 1.60x
Eosinophils (%) 2.00x
Basophils (%) 5.00x
Note: Multipliers are identified by “x”, otherwise actual comparison values are provided with units.
CONFIDENTIA L
[ADDRESS_984626] COPD Patients
Low High
BUN (mmol/L) 0.70x 1.60x
Creatinine ( mol/L)1.30x
(or >27 mol/L inc rease from 
baseline)
Glucose fasting (mmol/L) <0.6x >4x
Sodium (mmol/L) 0.80x 1.15x
Potassium (mmol/L) 0.75x 1.30x
Chloride (mmol/L) 0.90x 1.10x
Bicarbonate (mmol/L) <18 mmol/L >32 mmol/L
Calcium (mmol/L) 0.85x 1.08x
GGT (U/L) 0.85x 1.10x
Uric Acid (mg/dL)Males <2.1 mg/dL >8.5 mg/dL
Females <2.0 mg/dL >7.0 mg/dL
Albumin (mmol/L) 0.90x 1.50x
Total Protein (mg/dL) 1.25x
Note: Multipliers are identified by “x”, otherwise actual comparison values are provided with units.
Liver Function Test Analyte Effect PCI Range Unit
ALT/SGPT High ≥ 3x ULN U/L
AST/SGOT High ≥ 3x ULN U/L
Alkaline Phosphatase High ≥ 2x ULN U/L
Total Bilirubin High ≥ 2x ULN mol/L
Direct Bilirubin High ≥ 2x ULN mol/L
Total Bilirubin + ALT High≥ 2x ULN Total Billirubin
+
≥ 3x ULN ALTmol/L
U/L
14.8.2. ECG
ECG Parame ter PCI Range Unit
Absolute QTc Interval (QTcB, QTcF) >530 msec
Increase from Baseline QTc >60 msec
QT Interval <300 or >500 msec
PR Interval <120 or >240 msec
QRS Interval <70 or >125 msec
RR Interval <375 or >1714 msec
Heart Rate <35 or >120 bpm
CONFIDENTIA L
[PHONE_15037].8.3. Vital Signs
Vital Sign Parameter PCI Range Unit
Systolic BP <90 or >160 mmHg
Diastolic BP <40 or >110 mmHg
Heart Rate <35 or >120 bpm
Respi[INVESTIGATOR_26452] <8 or >30breaths 
/min
CONFIDENTIA L
[PHONE_15038].9. Appendix 9: Population Pharmacokinetic Analyses
14.9.1. Population Pharmacokinetic D ataset Specification
[IP_ADDRESS]. Handling Missing Demographic and Covariate Data 
Missing demographic and covariate data will not be imputed. 
[IP_ADDRESS]. Handling Missing Dose Times
Missing dose time information will be handled on a case b y case basis b y imputing this 
informatio n based on prior dosing times or based on recorded PK collection times. The 
details of these imputations will be described in the report.
[IP_ADDRESS]. Handling Missing Times of PK Samples
Missing times for PK will be handled on a case b y case basis b y imputing this 
information based on the dose time and/or times of other PK. The details of these 
imputations will be described in the report.
[IP_ADDRESS]. Handling of PK Data Below the Lower Limit of Quantification
Any PK data below the lower limit of quantification will be set to missi ng.
[IP_ADDRESS]. Dataset Specification
General description and rules:
Missing or unknown values in covariates, if not to be imputed, will be assigned -99.
The dataset is sorted b y STUD, SUBJ ID, DATE, RTFD , EVID descending.
The data items (columns) in the anal ysis-readydata file will be provided in the same 
order as follows.
NQ concentration values will be included as detailed for the CONC variable.
Non-numerical concentration values (such as NS, NR, NA) will not be included.
Placebo participants will not be included.
The dataset will be a comma delimited ASCII text file and will be named:
oNM.compound.study .PK.v1.csv
oWhere “compound” is the compound name (e.g. [COMPANY_004]1234567) and “study ” is 
the study  number (e.g. 205724 ).
CONFIDENTI AL
205724
73Variable Label 
(Variable 
description)Type Units Missing 
valueCodes/Derivation/Notes
ID NONMEM 
participant
identifierInteger None Never Sequential participant identifier 
across study after data is sorted 
by [CONTACT_720842], SUBJID, DATE, RTFD , 
EVID.
Numbering to start at 1.
To be entered in all rows for each 
partic ipant .
STUDYID Unique 
identifier for a 
studyChar None Never [ADDRESS_984627] one 
measurable drug concentration.
To be entered in all rows for each 
participant .
COUNTRY Coun try Char None Never Country of the investigational site 
in which the participant
participated in the trial; e.g. [LOCATION_003].
To be entered in all rows for each 
participant .
SITEID Unique 
identifier for a 
study siteChar None Never e.g.  any lead zero shou ld 
not be included.
To be entered in all rows for each 
participant .
CONC Drug 
Concentration Num ng/mL Never CONC=0 for 
DOSE _[COMPANY_004]1325756 records.
No sample (NS), insufficient 
sample (IS) and no result (NR) 
records will be excluded from 
dataset.
CONC=’.’ for PK_[COMPANY_004]1325756 
records < LOQ (i.e. if drug conc is 
NQ).
LNCONC Natural log of 
CONC 
column Num ng/mL Never Natural log of CONC column.
If CONC=0, then LNCONC=’.’.
LLQ Lower Limit of 
quantificationNum ng/mL Never LLQ=5 or from source data if 
different.
To be entered in all rows for each 
participant .
[COMPANY_003]
CONFIDENTI AL
205724
74Variable Label 
(Variable 
description)Type Units Missing 
valueCodes/Derivation/Notes
LNLLQ Natural log of 
LLQ columnNum ng/mL Never Natural log of LLQ column.
If LLQ=0, then LNLLQ=’.’.
MATRIX Sample matrix Num None Never MATRIX=1 (blood).
MATRTEXT Sample matrix 
textChar None Never Text c orresponding to code for 
MATRIX. 
Enter ‘Blood’ for all rows.
LABL Label 
describing the 
recordChar None Never LABL explains the type of 
measurement for CONC for the 
current record.
LABL=DOSE_[COMPANY_004]1325756 for 
dose record. 
LABL=PK_[COMPANY_004]1325756 for 
blood conce ntration record.
DATE Date of 
Record MM/DD/YYYY None Never Date of record.
DATETIME Date and time 
of recordMM/DD/YYYY 
HH:MM:SSNone Never Date and time of record.
DAY Study day 
number of 
recordNum None Never Day of study relative to first IP 
dose.
NDAY Nominal day Num day Never Schedule visit day of study 
relative to first IP dose.
NOMT Nominal time 
since FIRST 
IP doseNum h Never Nominal time of study relative to 
first IP dose.
NOMT=[ADDRESS_984628] IP dose prior to sample. 
NOMTLD=[ADDRESS_984629] dose of IP 
prior to sample.
When 
LABL=DOSE_[COMPANY_004]1325756, 
RTLD=0.
For pre -dose PK sample Visit 6, 7 
and 10, RTLD is relative to the 
previous dose. 
DOSE Dose amount Num mg Never DOSE= 5, 10, 25, 35 or 50 per 
treatment administered .
To be entered in all rows for each 
participant .
DRUG Name [CONTACT_720881]=[COMPANY_004]1325756.
To be entered in all rows for each 
participant .
CONFIDENTI AL
205724
75Variable Label 
(Variable 
description)Type Units Missing 
valueCodes/Derivation/Notes
REG Dosing 
Regimen Integer None Never REG=2 for BD.
To be entered in all rows for each 
participant .
REGTEXT Participant
dose regimen 
textChar None Never REGTXT=BD, text corresponding 
to code for REG. 
To be entered in all rows for each 
participant .
ROUT Route of 
administrationInteger None Never ROUT=1 for PO.
To be entered in all rows for each 
participant .
ROUTTEXT Participant
route of 
administration 
textChar None Never ROUTTEXT=PO, text 
corresponding to code for ROUT.
To be entered in all rows for each 
participant .
CNC NONMEM 
Country codeInteger None Never Australia, Canada, [LOCATION_013], 
Korea, Netherlands, Po land, 
Romania, Spain, US. 
Assign integer as appropriate for 
each country. Eg. 1=US
To be entered in all rows for each 
participant .
CMT NONMEM 
Compartment 
codeInteger None Never CMT=1 for DOSE_[COMPANY_004]1325756 
records.
CMT=2 for PK_[COMPANY_004]1325756 
records.
EVID NONMEM 
Event IDInteger None Never EVID=1 for LABL= 
DOSE_[COMPANY_004]1325756.
EVID=0 for LABL= 
PK_[COMPANY_004]1325756.
AMT NONMEM 
Amount of 
drug 
administeredNum mg Never AMT=0 for LABL= 
PK_[COMPANY_004]1325756 records.
AMT= 5, 10, 25, 35or 50 (ass 
appropriate) for LABL= 
DOSE_[COMPANY_004]13257 56 records.
II NONMEM 
Inter-dose 
intervalInteger h Never II=0 for LABL= PK_[COMPANY_004]1325756.
II=12 for LABL= 
DOSE_[COMPANY_004]1325756, except
II=0 for LABL= 
DOSE_[COMPANY_004]1325756 on Day 1 
only.
SS Steady -state 
data itemInteger None Never SS=0 for LABL= 
PK_[COMPANY_004]1325756 record s.
SS=1 for LABL= 
DOSE_[COMPANY_004]1325756 records, 
except
SS=0 for LABL= 
DOSE_[COMPANY_004]1325756 records on 
Day 1 only.
CONFIDENTI AL
205724
76Variable Label 
(Variable 
description)Type Units Missing 
valueCodes/Derivation/Notes
RATE NONMEM 
Rate of drug 
infusionInteger None Never RATE=0 for LABL= 
PK_[COMPANY_004]1325756 records.
RATE= -2 for LABL= 
DOSE_[COMPANY_004]1325756 records.
MDV NONMEM 
Missing data 
valueInteger None Never MDV=1 for LABL= 
DOSE_[COMPANY_004]1325756 records.
MDV=0 for LABL= 
PK_[COMPANY_004]1325756 records.
MDV=1 for LABL= 
PK_[COMPANY_004]1325756 records < LOQ 
(NQ).
VIS Visit number Integer None Never From source data.
POP Population Integer None Never POP=1, for COPD.
To be entered in all rows for each 
participant .
POPTEXT Participant
population 
textChar None Never POPTEXT=COPD, text 
corresponding to code for POP.
To be entered in all rows for each 
participant .
COH Cohort Integer None Never COH=1.
To be entered in all rows for each 
participant .
AGE Participant
AgeInteger year If missing 
impute 
with -99From source data.
To be entered in all rows for each 
participant .
SEX Participant
gender Integer None Never 0=Male, 1=Female
To be entered in all ro ws for each 
participant .
SEXTEXT Participant
gender textChar None Never Text corresponding to code for 
SEX, e.g. MALE or FEMALE). To 
be entered in all rows for each 
participant .
BMI Baseline Body 
Mass IndexNum kg/m 2If missing 
impute 
with -99Ensure co nsistent with S&P 
formula. E.g. Formula: 
Weight(kg)/(height(m)**2)
To be entered in all rows for each 
participant .
BSA Baseline Body 
Surface AreaNum m2If missing 
impute 
with -99Formula: BSA (m 2) = 0.024265 • 
Height(cm) 0.3964• Weight(kg) 0.5378
Ensure c onsistent to with S&P 
formula.
To be entered in all rows for each 
participant .
WT Baseline 
Participant
weightNum kg If missing 
impute 
with -99From source data.
To be entered in all rows for each 
participant .
CONFIDENTI AL
205724
77Variable Label 
(Variable 
description)Type Units Missing 
valueCodes/Derivation/Notes
HT Baseline 
Participant
heightNum m If miss ing 
impute 
with -99From source data.
To be entered in all rows for each 
participant .
RACE1 Participant
race code1Integer None Never From source data e.g.
1=African American / African 
Heritage
2=American Indian or Alaska 
Native
3=Asian –Central / Sout h Asian 
Heritage
4=Asian –East Asian Heritage
5=Asian –Japanese Heritage
6=Asian –South East Asian 
Heritage
7=Asian –Mixed Race
8=Native Hawaiian or other 
Pacific Islander
9=White –Arabic / North African 
Heritage
10=White –White / Caucasian / 
Europea n Heritage
11=White –Mixed Race
12=Mixed Race
To be entered in all rows for each 
participant .
RACE1TXT Participant
race 1 textChar None Never Text corresponding to code for 
RACE1
To be entered in all rows for each 
participant .
RACE2 Participant
race co de2Integer None Never 1=East Asian: Asian –East Asian 
Heritage & Asian –Japanese 
Heritage
2=White: White –Arabic / North 
African Heritage White –White / 
Caucasian / European Heritage
3=African: African American / 
African Heritage; 
4=Other: American Indian or 
Alaska Native; Asian –Central / 
South Asian Heritage; Asian –
South East Asian Heritage; Asian 
–Mixed Race; Native Hawaiian 
or other Pacific Islander; White –
Mixed Race & Mixed Race
To be entered in all rows for each 
participant .
CONFIDENTI AL
205724
78Variable Label 
(Variable 
description)Type Units Missing 
valueCodes/Derivation/Notes
RACE2TXT Participant
race 2 textChar None Never Text corresponding to code for 
RACE2
To be entered in all rows for each 
participant .
ETHN Participant
ethnicityNum None Never From source data definition. 
E.g 1=Hispanic or Latino, 2=Non -
Hispanic
To be entered in al l rows for each 
participant .
ETHNTEXT Participant
ethnicity textChar None Never Text corresponding to code for 
ETHN.
To be entered in all rows for each 
participant .
REGN Region for 
participantNum None Never 1 = East Asia (to include Japan, 
South Korea and Taiwan)
2 = Rest of the World (to include 
all other countries)
To be entered in all rows for each 
participant .
SMOK Participant
smoking 
statusInteger None Never 0=Non -smoker, 1=Smoker, 
2=Former smoker
To be entered in all rows for each 
participant .
SMOKTEXT Participant
smoking 
status textChar None Never Text corresponding to code for 
SMOK.
To be entered in all rows for each 
participant .
CMED1 COPD 
conmeds 
identifierNum None Never 0 = no concomitant use
1 = intermittent use
2 = continuous use
To be entered in all rows for each 
participant .
CMED1TXT Participant
CMED1 textChar None Never Text corresponding to code for 
CMED1.
To be entered in all rows for each 
participant .
CRCL Baseline 
Creatinine 
Clearance Num mL/min If missing 
impute 
with -99From source data.
OR Specify appropriate formula 
e.g.
Creatinine Clearance will be 
calculated based on the 
Cockcroft -Gault equation.
CrCL (ml/min) = [140 –
AGE (in 
years)]*Weight(kg)*0.85 
(for female particpants ) / 
CONFIDENTI AL
205724
79Variable Label 
(Variable 
description)Type Units Missing 
valueCodes/Derivation/Notes
[72* Serum Creatinine 
(micromol/L) * 0.011 3
CrCL (mL/min) = (140 –
Age (yr)) * IBW (kg) / (72 
• SCr (µmol/L) * 0.0113) 
* [0.85 if female], where 
IBW (kg) = 50 (kg) [ -4.5 
(kg) if female]+ 2.3 (kg) * 
(HT (inch) -60)
Delete one as 
appropriate and ensure 
consistency with S&P 
formula
To be entered i n all rows 
for each participant .
CMED2 Gastric acid 
reducing 
conmeds 
identifierNum None Never 0 = no concomitant use
1 = intermittent use
2 = continuous use
To be entered in all rows for each 
participant .
CMED2TXT Participant
CMED2 textChar None Never Text corresponding to code for 
CMED2.
To be entered in all rows for each 
participant .
CMED3 Identifier for 
on-treatment 
gastric acid 
increasing 
concomitant 
medicationNum None Never 0 = no concomitant use
1 = intermittent use
2 = continuous use
To be ente red in all rows for each 
participant .
CMED3TXT Participant
concomitant 
medication 
textChar None Never Text corresponding to code for 
CMED3.
To be entered in all rows for each 
participant .
CMED4 P-gp inhibitor 
conmed s 
identifierNum None Never 0 = no con comitant use
1 = intermittent use
2 = continuous use
To be entered in all rows for each 
participant .
CMED4TXT Participant
CMED4 textChar None Never Text corresponding to code for 
CMED4.
To be entered in all rows for each 
participant .
CMED5 Identifier fo r 
on-treatment 
p-gp inducer 
concomitant 
medicationNum None Never 0 = no concomitant use
1 = intermittent use
2 = continuous use
To be entered in all rows for each 
participant .
CONFIDENTI AL
205724
80Variable Label 
(Variable 
description)Type Units Missing 
valueCodes/Derivation/Notes
CMED5TXT Participant
concomitant 
medication 
textChar None Never Text correspo nding to code for 
CMED5.
To be entered in all rows for each 
participant .
ALB Baseline
AlbuminNum Specify If missing 
impute 
with -99Baseline defined in the source 
dataset
To be entered in all rows for each 
participant .
TBIL Baseline Total 
bilirubinNum Specify If missing 
impute 
with -99Baseline defined in the source 
dataset
To be entered in all rows for each 
participant .
TFIB Baseline 
FibrinogenNum Specify If missing 
impute 
with -99Baseline defined in the source 
dataset
To be entered in all rows for each 
participant .
Current Therapi[INVESTIGATOR_685242]: CMED1
Therapy Efficacy Claims Main Safety Concerns
Long -acting β 2-agonists (LABAs)
Formoterol
Indacaterol
Salmeterol
OlodaterolBronchodilator treatment to 
relieve symptoms in patients 
with COPD. Not use d alone, 
generally in combination 
with inhaled corticosteroids 
and LAMAs. Adverse reactions related to β 
receptor agonist pharmacology 
e.g.tremor, tachycardia, 
hypokalaemia, hyperglycaemia. 
Use of indacaterol has been 
associated with post -inhalation 
coug h.
Hypersensitivity reactions can 
occur with ICS, LAMA and LABAs, 
but are unlikely to affect the 
majority of patients. 
Cardiovascular effects have also 
been associated with use of 
muscarinic antagonists and β 2
agonists in patients with COPD.
CONFIDENTI AL
205724
81Therapy Efficacy Claims Main Safety Concerns
Long acting anti-muscarinic antagonists (LAMAs)
Tiotropi[INVESTIGATOR_720801]. Same as 
above.Adverse reactions related to anti -
muscarinic pharmacology. The 
most commonly reported adverse 
effects include dry mouth, GI 
effects and upper respi[INVESTIGATOR_720802].
Hypersensitivity reactions can 
occur with ICS, LAMA and LABAs, 
but are unlikely to affect the 
majority of patients
Cardiovascular effects have also 
been associated with use of 
muscarinic antagonists and β2
agonists in patients with COPD. 
Long acting combination bronchodilators
Albuterol/ipratropi[INVESTIGATOR_720803]/umeclidinium 
Olodaterol/tiotropi[INVESTIGATOR_720804]/glycopyrrolate
Formoterol/glycopyrrolat e
Formoterol/aclidiniumBronchodilator treatment 
superior to LABA or 
LAMA alone relieving 
symptoms in patients with 
COPD.Adverse reactions related to β 
receptor agonist and anti -
muscarinic pharmacology
Methylxanthines
Theophylline
AminophyllineBronchod ilator effects and 
claimed anti -inflammatory 
effects.Dose -related toxicity including the 
development of atrial and 
ventricular arrhythmias and grand 
mal seizures. 
Inhaled glucocorticosteroids 
Beclomethasone
Budesonide
Fluticasone propi[INVESTIGATOR_720805] e furoate
MometasoneAnti-inflammatory effects; 
normally used in 
combination with LAMAs 
and LABAsThe class effects of inhaled 
corticosteroids can include oral 
candidiasis, hoarse voice, skin 
bruising and increased risk of 
pneumonia. Systemic 
corticostero id class effects 
including hypothalamic -pi[INVESTIGATOR_2117] -
adrenal (HPA) axis suppression, 
decrease in bone mineral density 
and ocular disorders ( e.g. 
glaucoma and cataracts).
Pneumonia is a recognized class 
CONFIDENTI AL
205724
82Therapy Efficacy Claims Main Safety Concerns
risk with the use of inhaled 
corticosteroid (ICS) in COP D 
[Spencer , 2011; Drummond , 
2008], however, the benefit of ICS 
continue to outweigh the risks 
[EMA , 2016]
Hypersensitivity reactions can 
occur with ICS, LAMA and LABAs, 
but are unlikely to affect the 
majority of patients.
Inhaled glucocorticosteroids (ICS, in combination with inhaled bronchodilators)
Formoterol/budesonide
Salmeterol/Fluticasone 
propi[INVESTIGATOR_720806]/Fluticasone Furoate
Form oterol/beclomethasone
Formoterol/mometasoneAn inhaled corticosteroid 
combined with a LABA is 
more effective than the 
individual components in 
reducing exacerbations and 
improving lung function and 
health status.As described for LABAs and 
inhaled glucoco rticosteriods 
above.
Crim et al. (2015) pneumonia was 
shown to be more frequent in 
patients who received 
fluticasone/vilanterol than those 
who received vilanterol alone. 
Inhaled glucocorticosteroids (ICS, in combinat ion with inhaled LABA and LAMA)
Fluticasone 
Furoate/Umeclidium/VilanterolAdding a LAMA to existing 
LABA/ICS improves lung 
function and patient 
reported outcomes in 
particular, exacerbation risk. As described for LABAs, LAMAs 
and inhaled corticosteroids above. 
Phospodiesterase -[ADDRESS_984630] improvement in 
FEV1 (versus placebo) and 
small improvements in 
SCRQ and COPD -related 
systems. No significant 
changes in exercise 
tolerance with PDE4 
inhibitors. Unclear benefit on 
modifying FEV1 decline, 
hospi[INVESTIGATOR_720807]. [ Chong J et al. 
2013].  Weight loss, abdominal pain, 
diarrhoea, nausea, headache and 
sleep disturbances. Caution f or 
use is advised in patients with 
depression.
CONFIDENTI AL
205724
83Therapy Efficacy Claims Main Safety Concerns
Antibiotics
Macrolides (e.g. azithromycin, 
erythromycin)Regular use of may reduce 
exacerbation rate. 
Azithromycin or 
erythromycin for one year in 
patients prone to 
exacerbations reduced the 
risk of exacerb ations 
compared to usual care.Azithromycin use associated with 
increased incidence of bacterial 
resistance and impaired hearing.
CMED2: Gastric acid reducing conmeds

CONFIDENTI AL
205724
84NDAY : For der iving the nominal day  which is the planned day , DAY specific 
information is not available in EXPOSURE dataset. VI SIT variable and the time and 
events table might have to be taken into account to find the exact plan of events.
NOMT: It is twice dail y dosing with inter -dose interval given to be [ADDRESS_984631] to be considered.
NOMTLD : In case of PK_[COMPANY_004]1325756 records, the planned time point variable will 
give the value of this variable for all the post -dose records. For the pre -dose records, this 
variable will have missing values since there is no fixed time point since the previous 
dose for pre -dose records.
RTFD : The time difference b etween the first dose of the subject and the current dose 
(when LABL=DOSE_[COMPANY_004]1325756) should be calculated in hours. The time difference 
between the first dose of the subject and the PK sample collection time (when 
LABL=PK_[COMPANY_004]1325756) should be calculated in hours.
RTLD : The latest dose prior to the PK sample collection time will have to be found out 
and the time difference between that dose and the PK sample collection time will be 
calculated in hours.
CONFIDENTI AL
[PHONE_15039].10. Appendix 1 0: Abbreviations & Trade Marks
14.10.1. Abbrev iations
Abbreviation Description
AE Adverse Event
AESI Adverse Event of Special Interest
ALLSUB All Subjects
ALT Alanine aminotransferase
AST Aspartate aminotransferase
ATC Anatomical Therapeutic Chemical Classification
BD Bronchodilator
BP Blood Pressure
BUN Blood urea nitrogen
C-PPAC Clinical Visit PROactive Physical Activity in COPD
CAT COPD Assessment Test
CDISC Clinical Data Interchange Standards Consortium
CI Confidence Interval
CID Clinically Important Deterioration
CMH Chronic Mucus Hypersec retion
CrI Credible Interval
COPD Chronic Obstructive Pulmonary Disease
CSR Clinical Study Report
DBF Database Freeze
DM Data Management
DP Decimal Places
E-RS: COPD Evaluating Respi[INVESTIGATOR_720808] e Record Form
EW Early Withdrawal
EXACT Exacerbations of Chronic Pulmonary Disease Tool
FEV1 Forced Expi[INVESTIGATOR_1814] [ADDRESS_984632] Error
MCV Microtic cell volume
MedDRA Medical Dictionary for Regulatory Activities
mITT Modified Intent -to-treat
CONFIDENTI AL
205724
86Abbreviation Description
MLE Maximum likelihood estimate
MMRM Mixed Model Repeated Measures
NQ Non-quantifiable
PCI Potential Clinical Importance 
PD Pharmacodynamic
PK Pharmacokinetic
PopPK Population PK
QC Quality Control
RAP Reporting & Analysis Plan
RMC Respi[INVESTIGATOR_720809]. George’s Respi[INVESTIGATOR_312402] -C SGRQ for COPD patients
SI System Independent
SMQ Standardized MedDRA Query
SRDP Study Results Dissemination Plan
ULN Upper limit of normal
14.10.2. Trademarks
Trademarks of the GlaxoSmithKline 
Group of CompaniesTrademarks not owned by [CONTACT_720843]
[PHONE_15040].11. Appendix 1 1: List of Data Display s
14.11.1. Data Display  Numbering
The followin g numbering will be applied for RAP generated display s:
Strategic Interim Statistical Analysis Complete
Section Tables Figures
Study Population 1.1 to 1. 20
Efficacy 2.1 to 2.52 2.1 to 2.35
Conditional Efficacy 2.36 to 2.xx
Safety 3.1 to 3.23 3.1 to 3.6
Pharmacokinetic
Pharmacokinetic / Pharmacodynamic
Biomarker 6.1 to 6. 2 6.1 to 6.2
Section Listings
ICH Listings 1 to 1
Other Listings 2 to 2
Final Statistical Analysis Complete (Including Post SAC)
Section Tables Figures
Study Population 1.1 to 1. 43 1.1 
Efficacy 2.1 to 2. 49 2.1 to 2. 32
Conditional Efficacy 2.33to 2.xx
Safety 3.1 to 3.3 7 3.1 to 3. 11
Pharmacokinetic 4.1 to 4.8 4.1 to 4. 13
Pharmacokinetic / Pharmacodynamic 5.1 to 5.4
Biomarker 6.1 to 6. 4 6.1 to 6. 4
Section Listings
ICH Listings 1 to 3 6
Other Listings 37to 69
14.11.2. Deliverable s
In all display s the term "Subjects" is used to refer to “Participants”.
Delivery [Priority] Description
StInt Strategic Interim Statistical Analysis Complete
SAC Final Statistical Analysis Com plete
Post SAC Additional outputs provided after SAC
CONFIDENTIA L
[PHONE_15041].11.3. Study Population Tables
Study Population Tables
StInt
No.SAC
No.Population IDSL / Example Shell Title Programming NotesDeliverable 
[Priority]
Participant Disposition
1.11.[ADDRESS_984633]/Clinical 
OperationsSAC
1.21.4mITT NS1Summary of Number of Subjects by [CONTACT_720844], SAC
1.31.5PP NS1Summary of Number of Subjects by [CONTACT_720844], SAC
1.4 1.6 mITT Summary of Attendance at Each Clinic Visit StInt, SAC
Protocol Deviation
1.7 mITT DV1 Summary of Important Protocol Deviations ICH E3 SAC
1.8
All Subjects IE2Summary of Inclusion/ Exclusion/ Randomization 
Criteria D eviations for Screen or Run -in failuresAdd a row “Number of 
Screen Failures” above 
“any criteria deviations”.
Percentage will be based 
on number of screen 
failuresSAC
CONFIDENTIA L
205724
89Study Population Tables
StInt
No.SAC
No.Population IDSL / Example Shell Title Programming NotesDeliverable 
[Priority]
1.9
mITT IE1Summary of Inclusion/ Exclusion/ Randomization 
Criteria Deviations for t he Modified Intent -to-treat 
PopulationSAC
Population Analysed
1.51.10
All Subjects SP1 Summary of Study PopulationsIDSL
Number of participants who 
were in the All Participants 
population, who were 
randomized, the number in 
the ITT population
(Strate gic interim only) , the 
number in the mITT 
population.  Of those in the 
mITT, the number and 
percentage of participants 
in the PP, Symptomatic
(Strategic interim only) , PK 
and PK2 populationsStInt, SAC
1.11mITT SP2 Summary of Exclusions from the Per Pr otocol 
PopulationIDSL SAC
Demographic and Baseline Characteristics
1.[ADDRESS_984634] SAC
1.15mITT DM6 Summary of Race and Racial CombinationsICH E3, FDA, FDAAA, 
EudraCTSAC
CONFIDENTIA L
205724
90Study Population Tables
StInt
No.SAC
No.Population IDSL / Example Shell Title Programming NotesDeliverable 
[Priority]
1.16All Subjects EMA Table 1Summary of Number of Subjects Enrolled by 
[CONTACT_720845]. 
Macro: EMA_COUNTRYSAC
1.17All Subjects EMA Table 2Summary of Number of Subjects Enrolled by [CONTACT_720846]. 
Macro: EMA_AGEGRPSAC
1.81.18
mITT SU1Summary of Smoking History and Smoking Status at 
ScreeningInclude smoking status, 
smokin g pack years, 
cigarettes smoked/dayStInt, SAC
1.9 1.19PP SU1Summary of Smoking History and Smoking Status at 
ScreeningInclude smoking status, 
smoking pack years, 
cigarettes smoked/dayStInt, SAC
1.10 Symptomatic SU1Summary of Smoking History and Sm oking Status at 
ScreeningInclude smoking status, 
smoking pack years, 
cigarettes smoked/dayStInt
1.20 mITT SP_T12 Summary of COPD History at Screening SAC
1.111.21mITT SP_T13Summary of HCRU Exacerbation History at 
ScreeningSee notes in Section 14.6.3 StInt, SAC
1.121.22PP SP_T13Summary of HCRU Exacerbation History at 
ScreeningSee notes in Section 14.6.3 StInt, SAC
1.13 1.23mITT Summary of Screening Spi [INVESTIGATOR_720810]-BD FEV1 (L), Post -BD 
FEV1 (L), Predicted normal 
FEV1 (L), Percent 
predicted normal post -BD 
FEV1 (% ), Percent 
predicted normal post -BD 
FEV1: <50%, >=50%, Post -
BD FVC (L), Post -BD 
FEV1/FVCStInt, SAC
CONFIDENTIA L
205724
91Study Population Tables
StInt
No.SAC
No.Population IDSL / Example Shell Title Programming NotesDeliverable 
[Priority]
1.141.24PP Summary of Screening S pi[INVESTIGATOR_720810]-BD FEV1 (L), Post -BD 
FEV1 (L), Predicted normal 
FEV1 (L), Percent 
predicted normal post -BD 
FEV1 (% ), Percent 
predicted normal post -BD 
FEV1: <50%, >=50%, Post -
BD FVC (L), Post -BD 
FEV1/FVCStInt, SAC
1.25mITT Summary of GOLD Stages at Screening GOLD 1 -4 and GOLD A -D SAC
1.15 1.26mITT Summary of Baseline Symptomatic CharacteristicsProportion of participants 
with CMH according to 
SGRQ, with baseline E -RS: 
COPD total score </>=10, 
with baseline CAT Score 
</>=10, with 
ICS+LABA+LA MA vs. 
ICS+LABA vs. 
LABA+LAMA vs. Other 
COPD medication StInt, SAC
CONFIDENTIA L
205724
92Study Population Tables
StInt
No.SAC
No.Population IDSL / Example Shell Title Programming NotesDeliverable 
[Priority]
1.161.27PP Summary of Baseline Symptomatic CharacteristicsProportion of participants 
with CMH according to 
SGRQ, with baseline E -RS: 
COPD total score </>=10, 
with baseline CAT Scor e 
</>=10, with 
ICS+LABA+LAMA vs. 
ICS+LABA vs. 
LABA+LAMA vs. Other 
COPD medication StInt, SAC
Prior and Concomitant Medications
1.28mITT CM1Summary of COPD Concomitant Medications Taken 
Pre-treatmentUse RMC instead of ATC 
Level 1SAC
1.[ADDRESS_984635]-treatmentUse RMC instead of ATC 
Leve l 1SAC
1.31mITT CM1Summary of On -treatment COPD Concomitant 
Medications Given for an ExacerbationUse RMC instead of ATC 
Level 1SAC
1.17 1.32mITTSummary of COPD Concomitant Medication 
Combinations Taken at ScreeningNumber and percentage of 
participants taking each 
medication in the RMC 
combination defined in 
Section 14.6.2StInt, SAC
CONFIDENTIA L
205724
93Study Population Tables
StInt
No.SAC
No.Population IDSL / Example Shell Title Programming NotesDeliverable 
[Priority]
1.181.33mITTSummary of COPD Concomitant Medication 
Combinations Taken at BaselineNumber and percentage of 
particip ants taking each 
medication in the RMC 
combination defined in 
Section 14.6.2StInt, SAC
1.[ADDRESS_984636] Medical Conditions ICH E3 SAC
1.38 mITT MH4 Summary of Current Medical Conditions SAC
1.39
mITTTable 1.23
Study 
[COMPANY_004]283442 5/CTT116853Summary of Cardiovascular History/Risk Factors SAC
CONFIDENTIA L
205724
94Study Population Tables
StInt
No.SAC
No.Population IDSL / Example Shell Title Programming NotesDeliverable 
[Priority]
1.201.40mITT FH1Summary of Family History of Cardiovascular Risk 
FactorsStInt, SAC
Exposure and Treatment Compliance
1.41mITT IP1 Summary of Treatment Compliance SAC
1.42mITT Summary of Daily Diary Compliance SAC
1.43mITT EX1 Summary of Exposure to Study Treatment ICH E3 SAC
14.11.4. Study Population Figures
Study Population Figures
SAC
No.PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Dispositio n of Subject s
1.1. mITT Kaplan -Meier Plot of Time to Study Withdrawal SAC
CONFIDENTIA L
[PHONE_15042].11.5. Efficacy  Tables
Efficacy: Tables
StInt
No.SAC
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
E-RS:COPD
2.1 2.1
PP PD4 Summary of Baseline E -RS: COPD ScoresEndpoints: E -RS: COPD total and 
subscale scores
Include total columnStInt, SAC
2.2
Symptomatic PD4 Summary of Baseline E -RS: COPD ScoresEndpoints: E -RS: COPD total and 
subscale scores
Include total columnStInt
2.3 2.2
PP PD4Summary o f Monthly Mean E -RS: COPD 
ScoresEndpoints: E -RS: COPD total and 
subscale scores
Include raw and change from baseline 
scores for participants with non -missing 
E-RS data for each monthStInt, SAC
2.4
Symptomatic PD4Summary of Monthly Mean E -RS: COPD 
ScoresEndpoints: E -RS: COPD total and 
subscale scores
Include raw and change from baseline 
scores for participants with non -missing 
E-RS data for each monthStInt
2.5 2.3PPBayesian Dose Response Analysis of Change 
from Baseline E -RS: COPD Score sat Month 6Endpoint: Month 6 E -RS: COPD total and 
subscale scoresStInt, SAC
2.6
SymptomaticBayesian Dose Response Analysis of Change 
from Baseline E -RS: COPD Total Score at 
Month 6Endpoint: Month 6 E -RS: COPD total 
scoreStInt
CONFIDENTIA L
205724
96Efficacy: Tables
StInt
No.SAC
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.7 2.4
PPBayesian Analysis o f Change from Baseline 
Monthly Mean E -RS: COPD Score sup to 
Month 6Bayesian MMRM on Change from 
Baseline 
Endpoints: E -RS: COPD total and 
subscale scoresStInt, SAC
2.8
SymptomaticBayesian Analysis of Change from Baseline 
Monthly Mean E -RS: COPD Scoresup to 
Month 6Bayesian MMRM on Change from 
Baseline 
Endpoints: E -RS: COPD total and 
subscale scoresStInt
2.9
ITTBayesian Analysis of Change from Baseline 
Monthly Mean E -RS: COPD Score sup to 
Month 6Bayesian MMRM on Change from 
Baseline 
Endpoints : E-RS: COPD total and 
subscale scoresStInt
2.10 2.5PPAnalysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month 6Frequentist MMRM 
Endpoints: E -RS: COPD total scoreStInt, SAC
2.11 2.6
PP Type III Tests of Fixed Effects for Analysis of 
Change from Baseline Monthly Mean E -RS:
COPD Total Score up to Month 6Frequentist MMRM 
Endpoints: E -RS: COPD total scoreStInt, SAC
2.12 2.7
PPAnalysis of Proportion of Responders 
According to Monthly Mean E -RS: COPD
Scores up to Month 6Responder Analysis
Generalized linear model
Endpoints: E -RS: COPD total and 
subscale scoresStInt, SAC
2.13 2.8
PPAnalysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month 6: 
Interaction of Treatment with Other FactorsFrequentist MMRM 
Endpoints: E -RS: COPD total scoreStInt, SAC
CONFIDENTIA L
205724
97Efficacy: Tables
StInt
No.SAC
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.14 PP Analysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month 6 
by [INVESTIGATOR_31975] E -RS: COPD Total Score (<10, 
>=10)Frequentist MMRM 
Endpoints: E -RS: COPD total scoreStInt
2.15 2.9 PP Analysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month 6 
by [CONTACT_720847] (Current, 
Former)Frequentist MMRM 
Endpoints: E -RS: COPD total scoreStInt, SAC
2.16 PP Analysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month [ADDRESS_984637] MMRM 
Endpoints: E -RS: COPD total scoreStInt
2.17 2.10 PP Analysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month 6 
by % Predicted FEV1 at Screening (<50, >=50)Frequentist MMRM 
Endpoints: E -RS: COPD total scoreStInt, SAC
2.18 2.11 PP Analysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month 6 
by [CONTACT_720848] (<10, >=10)Frequentist MMRM 
Endpoints: E -RS: COPD total scoreStInt, SAC
2.19 PP Analysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month 6 
by [CONTACT_720849] (>=2 moderate/severe 
vs. 1 moderate/severe, prior year)Frequentist MMRM 
Endpoints: E -RS: COPD total scoreStInt
2.20 PP Analysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month 6 
by [CONTACT_720850][INVESTIGATOR_720811] 
(ICS+LABA+LAMA, ICS+LABA, LABA+LAMA, 
Other)Frequentist MMRM 
Endpoints: E -RS: COPD total scoreStInt
CONFIDENTIA L
205724
98Efficacy: Tables
StInt
No.SAC
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.21 PP Analysis of Change from Baseline M onthly 
Mean E -RS:COPD Total Score up to Month [ADDRESS_984638] MMRM 
Endpoints: E -RS: COPD total scoreStInt
2.22 PP Analysis of Change from Baseline Monthly 
Mean E -RS:COPD Total Score up to Month [ADDRESS_984639] MMRM 
Endpoints: E -RS: COPD total scoreStInt
2.12
Summary of Responders to E-RS: COPD Total 
Score, SGRQ and CAT at Month 6Include categories for E -RS, SGRQ, 
CAT, E -RS+SGRQ, E -RS+CAT. 
SGRQ+CAT, E -RS+SGRQ+CAT, None, 
MissingPost SAC
Exacerbations
2.232.13 PP Summary of On-treatment HCRU
ExacerbationsStInt, SAC
2.14 PP Summary of On-treatment Details of 
Moderate/Severe HCRU ExacerbationsSAC
2.[ADDRESS_984640] SAC
2.242.16 PP Bayesian Analysis of On-treatment 
Moderate/ Severe HCRU Exacerbations Bayesian generalized linear model StInt, SAC
2.25ITT Bayesian Analysis of On-treatment 
Moderate/ Severe HCRU Exacerbations Bayesian generalized linear model StInt, 
2.262.[ADDRESS_984641] On-treatment Moderate/Severe HCRU
ExacerbationBayesian proportional hazards model StInt, SAC
CONFIDENTIA L
205724
99Efficacy: Tables
StInt
No.SAC
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.272.[ADDRESS_984642] EventsBayesian proportional hazards modelSAC
SGRQ
2.28 2.22 P[COMPANY_003]4 Summary of Baseline SGRQ ScoresInclude total column
Total and domain scoresStInt, SAC
2.29 2.23 P[COMPANY_003]4 Summary of SGRQ ScoresInclude raw and change from baseline
Total and domain scoresStInt, SAC
2.30 2.24 PPBayesian Analysis of Change from Baseline
SGRQ Total Score up to Month 6Bayesian MMRM on Change from 
Baseline 
Endpo ints: SGRQ Total ScoreStInt, SAC
2.31 2.25 PP Analysis of Proportion of Responders 
According to SGRQ Total Scores up to Month 6Responder Analysis
Generalized linear modelStInt, SAC
CAT
2.32 2.26 PP PD4 Summary of Baseline CAT Score Include total col umn StInt, SAC
2.33 2.27 PP PD4 Summary of CAT Score Include raw and change from baseline StInt, SAC
CONFIDENTIA L
205724
100Efficacy: Tables
StInt
No.SAC
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.342.28 PPBayesian Analysis of Change from Baseline 
CAT Score up to Month 6Bayesian MMRM on Change from 
Baseline 
Endpoints: CAT ScoreStInt, SAC
2.35 2.29 PP Analysis of Proportion of Responders 
According to CAT Score up to Month 6Responder Analysis
Generalized linear modelStInt, SAC
2.36 2.30
PPAnalysis of Change from Baseline CAT Score 
up to Month 6: Interaction of Treatment with 
Other Facto rsFrequentist MMRM 
Endpoints: CAT ScoreStInt, SAC
2.37PP Analysis of Change from Baseline CAT Score 
up to Month 6 by [INVESTIGATOR_31975] E -RS: COPD Total 
Score (<10, >=10)Frequentist MMRM 
Endpoints: CAT ScoreStInt
2.38 2.31 PP Analysis of Change from Base line CAT Score 
up to Month 6 by [CONTACT_720847] 
(Current, Former)Frequentist MMRM 
Endpoints: CAT ScoreStInt, SAC
2.[ADDRESS_984643] MMRM 
Endpoints: CAT ScoreStInt
2.40 2.32 PP Analysis of Change from Baseline CAT Score
up to Month 6 by % Predicted FEV1 at 
Screening (<50, >=50)Frequentist MMRM 
Endpoints: CAT ScoreStInt, SAC
2.41 2.33 PP Analysis of Change from CAT Score up to 
Month 6 by [CONTACT_720848] (<10, >= 10)Frequentist MMRM 
Endpoints: CAT ScoreStInt, SAC
2.42 PP Analysis of Change from CAT Score up to 
Month 6 by [CONTACT_720849] (>=2 
moderate/severe vs. 1 moderate/severe, prior 
year)Frequentist MMRM 
Endpoints: CAT ScoreStInt
CONFIDENTIA L
205724
101Efficacy: Tables
StInt
No.SAC
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.43 PP Analysi s of Change from Baseline CAT Score
up to Month 6 by [CONTACT_720850][INVESTIGATOR_720812] (ICS+LABA+LAMA, ICS+LABA, 
LABA+LAMA, Other)Frequentist MMRM 
Endpoints: CAT ScoreStInt
2.[ADDRESS_984644] MMRM 
Endpoints: CAT ScoreStInt
2.45PP Analysis of Change from Baseline CAT Score
up to Month [ADDRESS_984645] MMRM 
Endpoints: CAT ScoreStInt
Rescue Use
2.46 2.34PP PD4Summary of Baseline Mean Number of Puffs of 
Rescue Medication per Day using Diary DataInclude total column StInt, SAC
2.47 2.35 PP
PD4Summary of Monthly Mean Number of Puffs of 
Rescue Medication per Day using Diary Data 
up to Month 6Include raw and change from baseline StInt, SAC
2.48 2.36 PP Analysis of Change from Baseline in Monthly 
Mean Number of Puffs of Rescue Medication 
per Day using Diary Data up to Month 6MMRM on Change from Baseline StInt, SAC
2.49 2.37 P[COMPANY_003]4Summary of Baseline Percentage Rescue -free 
Days using Diary DataInclude total column StInt, SAC
2.502.38 P[COMPANY_003]4Summary of Percentage Rescue -free Days 
using Diary Data up to Month 6Include raw and change from baseline StInt, SAC
2.512.39 PP Analysis of Change from Baseline in 
Percentage Rescue -free Days using Diary D ata 
up to Month 6MMRM on Change from Baseline StInt, SAC
CONFIDENTIA L
205724
102Efficacy: Tables
StInt
No.SAC
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.40 PP
PD4Summary of Baseline Mean Number of 
Occasions of Rescue Medication per Day using 
Sensor DataInclude total column SAC
2.41 PP
PD4Summary of Monthly Mean Number of 
Occasions of Rescu e Medication per Day using 
Sensor Data up to Month 6Include raw and change from baseline SAC
2.42 PP Analysis of Change from Baseline Monthly 
Mean Number of Occasions of Rescue 
Medication per Day using Sensor Data up to 
Month 6MMRM on Change from Base line SAC
2.43 P[COMPANY_003]4Summary of Baseline Percentage Rescue -free 
Days using Sensor DataInclude total column SAC
2.44 P[COMPANY_003]4Summary of Percentage Rescue -free Days 
using Sensor Data up to Month 6Include raw and change from baseline SAC
2.45 PP Analysis of Change from Baseline Percentage 
Rescue -free Days using Sensor Data up to 
Month 6MMRM on Change from Baseline SAC
Physical Activity
2.46
PP PD4 Summary of Baseline PROactive ScoreInclude total column
Endpoints: PROactive Total Score and 
domain scoresSAC
2.47
PP PD4 Summary of PROactive Score up to Month 6Include raw and change from baseline
Endpoints: PROactive Total Score and 
domain scoresSAC
CONFIDENTIA L
205724
103Efficacy: Tables
StInt
No.SAC
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.[ADDRESS_984646] Global Assessments at 
BaselineInclude total column
Endpoints: severity, activity limitationSAC
2.[ADDRESS_984647] Global AssessmentsEndpoints: severity, change in severity, 
activity limitation and c hange in activity 
limitationSAC
14.11.6. Efficacy  Figures
Efficacy: Figures
StInt
No.SAC No.
PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
E-RS: COPD
2.1PP Daily Mean E -RS: COPD Scores over TimeTotal and subscale scores
Day -[ADDRESS_984648] SAC
2.2
[COMPANY_003]aily Mean E -RS: COPD Scores over Time by 
[CONTACT_720851] -[ADDRESS_984649] SAC
2.1 2.3[COMPANY_003]aily Mean Change from Baseline in E-RS: COPD 
Scores over TimeTotal and subscale scores StInt, SAC
CONFIDENTIA L
205724
104Efficacy: Figures
StInt
No.SAC No.
PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.2 2.4
[COMPANY_003]aily Mean (SE) Change from Baseline in E -RS: 
COPD over Time by [CONTACT_720852]; one panel for 
each DNX dose to include DNX and 
placebo dataStInt, SAC
2.3
SymptomaticDaily Mean (SE) Change from Baseline in E -RS: 
COPD over Time by [CONTACT_720852]; one panel for 
each DNX dose to include DNX and 
placebo dataStInt
2.5PP Daily Mean (SE) E -RS: COPD over Time by [CONTACT_720853] -[ADDRESS_984650] SAC
2.4 2.6
PPBayesian Dose Response Model for E -RS: COPD 
Scores at Month 6Total and subscale scores; overlaid with 
mean/CI from Bayesian longitudinal 
modelStInt, SAC
2.5SymptomaticBayesian Dose Response Model for E -RS: COPD 
Total Score at Month 6Total score; overlaid with mean/CI from 
Bayesian longitudinal modelStInt
2.6 2.7PPPosterior Mean (90% CrI) Change from Baseline in E -
RS: COPD Scores over TimeTotal and subscale scores StInt, SAC
2.7SymptomaticPoster ior Mean (90% CrI) Change from Baseline in E -
RS: COPD Total Score over TimeTotal score StInt
2.8ITTPosterior Mean (90% CrI) Change from Baseline in E -
RS: COPD Total Score over TimeTotal score StInt
2.9 2.8PPAdjusted Mean (90% CI) Change from Bas eline in E -
RS: COPD Total Score over TimeTotal score StInt, SAC
2.9PPAdjusted Mean (90% CI) E -RS: COPD Total Score 
over TimeTotal score Post SAC
CONFIDENTIA L
205724
105Efficacy: Figures
StInt
No.SAC No.
PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.[ADDRESS_984651] Squares Mean (90% CI) Change from Baseline 
in E-RS:COPD Total Score at Month 6 by [CONTACT_720854] E -
RS: COPD Total Score (<10, >=10)One panel for each factor on the same 
pageStInt
2.[ADDRESS_984652] Squares Mean (90% CI) Change from Baseline 
in E-RS: COPD Total Score at Month 6 by [CONTACT_720855] (Current, Former)One panel for each factor on the same 
pageStInt, SAC
2.[ADDRESS_984653] Squares Mean (90% CI) Change from Baseline 
in E-RS: COPD Total Score at Month [ADDRESS_984654] Squares Mean (90% CI) Change from Baseli ne 
in E-RS: COPD Total Score at Month 6 by % 
Predicted FEV1 at Screening (<50, >=50)One panel for each factor on the same 
pageStInt, SAC
2.[ADDRESS_984655] Squares Mean (90% CI) Change from Baseline 
in E-RS: COPD Total Score at Month 6 by [CONTACT_720856] (<10, >=10)One panel for each factor on the same 
pageStInt, SAC
2.[ADDRESS_984656] Squares Mean (90% CI) Change from Baseline 
in E-RS: COPD Total Score at Month 6 by 
[CONTACT_720849] (>=2 moderate/severe vs. <2 
moderate/severe, prior year)One pa nel for each factor on the same 
pageStInt
2.[ADDRESS_984657] Squares Mean (90% CI) Change from Baseline 
in E-RS: COPD Total Score at Month 6 by [CONTACT_720857][INVESTIGATOR_720811] (ICS+LABA+LAMA, 
ICS+LABA, LABA+LAMA, Other)One panel for each factor on the same 
pageStInt
2.[ADDRESS_984658] Squares Mean (90% CI) Change from Baseline 
in E-RS: COPD Total Score at Month 6 by [CONTACT_720858] L
205724
106Efficacy: Figures
StInt
No.SAC No.
PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.[ADDRESS_984659] Squares Mean (90% CI) Change from Baseline 
in E-RS: COPD Total Score at Month 6 by [CONTACT_720859]
2.13 PP Empi[INVESTIGATOR_720813] E -RS: COPD 
Total Scores at BaselineTotal and subscale scores Post SAC
2.14 PP Empi[INVESTIGATOR_720813] E-RS: COPD 
Total Scores at Month 6Total and subscale scores Post SAC
Exacerbations
2.192.15PPMedian Rate Ratio (90% CrI) of On -treatment 
Moderate/Severe HCRU ExacerbationsStInt, SAC
2.20ITTMedian Rate Ratio (90% CrI) of On -treatment 
Moderate/Severe HCRU ExacerbationsStInt
2.[ADDRESS_984660] On -treatment 
Moderate/Severe HCRU ExacerbationStInt, SAC
2.[ADDRESS_984661] Events
2.18PPMedian Rate Ratio (90% CrI) of On -treatment EXACT 
EventsSAC
2.19PPKaplan -Meier Plot of Time to First On -treatment 
EXACT EventSAC
SGRQ
2.232.20PPPosterior Mean (90% CrI) Change from Baseline in 
SGRQ Total Score over TimeStInt, SAC
2.21 PP Mean (90% CI) SGRQ Total Score over Time Baseline, Day [ADDRESS_984662] SAC
CONFIDENTIA L
205724
107Efficacy: Figures
StInt
No.SAC No.
PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
CAT
2.24 2.22PPPosterior Mean (90% CrI) Change from Baseline in 
CAT Score over TimeStInt, SAC
2.23 PP Mean (90% CI) CAT Score over Time Baseline, Day [ADDRESS_984663] Squares Mean (90% CI) Change from Baseline 
in CAT Score at Month 6 by [INVESTIGATOR_31975] E -RS: COPD 
Total Score (<10, >=10)One panel for each factor
StInt
2.[ADDRESS_984664] Squares Mean (90% CI) Change from Baseline 
in CAT Score at Month 6 by [CONTACT_720860] (Current, Former)One panel for each factor
StInt, SAC
2.[ADDRESS_984665] Squares Mean (90% CI) Change from Baseline 
in CAT Score at Month [ADDRESS_984666] Squares Mean (90% CI) Chang e from Baseline 
in CAT Score at Month 6 by % Predicted FEV1 at 
Screening (<50, >=50)One panel for each factor
StInt, SAC
2.[ADDRESS_984667] Squares Mean (90% CI) Change from Baseline 
in CAT Score at Month 6 by [CONTACT_720848] 
(<10, >=10)One panel fo r each factor
StInt, SAC
2.[ADDRESS_984668] Squares Mean (90% CI) Change from Baseline 
in CAT Score at Month 6 by [CONTACT_720849] 
(>=2 moderate/severe vs. 1 moderate/severe, prior 
year)One panel for each factor
StInt
CONFIDENTIA L
205724
108Efficacy: Figures
StInt
No.SAC No.
PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
2.[ADDRESS_984669] Squares Mean (90% CI) Change from Baseline 
in CAT Score at Month 6 by [CONTACT_720861][INVESTIGATOR_720811] (ICS+LABA+LAMA, ICS+LABA, 
LABA+LAMA, Other)One panel for each factor
StInt
2.[ADDRESS_984670] Squares Mean (90% CI) Change from Baseline 
in CAT Score at Month [ADDRESS_984671] Squares Mean (90% CI) Change from Baseline 
in CAT Score at Month [ADDRESS_984672] Squares Mean (90% CI) Change from Baseline 
in Mean Number of Puffs of Rescue Use per Day 
using Diary Data over TimeStInt, SAC
2.[ADDRESS_984673] Squares Mean (90% CI) Change from Baseline 
in Percentage of Rescue -free Days using Diary Data
over TimeStInt, SAC
2.[ADDRESS_984674] Squares Mean (90% CI) Change fr om Baseline 
in Mean Number of Occasions of Rescue Use per 
Day using Sensor Data over TimeSAC
2.[ADDRESS_984675] Squares Mean (90% CI) Change from Baseline 
in Percentage of Rescue -free Days using Sensor 
Data over TimeSAC
CONFIDENTIA L
205724
109Efficacy: Figures
StInt
No.SAC No.
PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Conditional E -RS: COPD
2.36-
2.432.33-
2.[ADDRESS_984676] Squares Mean (90% CI) Change from Baseline 
in E-RS: COPD Total Score over Time by [CONTACT_720862] 
10% level Where Factor is defined in 
Section 7.3.[ADDRESS_984677] Squares Mean (90% CI) Change from Baseline 
in CAT Score over Time by [CONTACT_720863] 
10% level Where Factor is defined in 
Section 7.3.1
One pa nelfor each factorStInt, SAC
14.11.7. Safety Tables
Safety : Tables
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Adverse Events (AEs)
3.1 3.1mITT AE1Summary of On -treatment Adverse Events by [CONTACT_720864] E3 StInt, SAC
3.2 3.2mITT AE3Summary of Common (>=5%) On -treatment Adverse 
Events by [CONTACT_312483] E3 StInt, SAC
CONFIDENTIA L
205724
110Safety : Tables
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.3 3.3
mITT AE1/AE3Summary All On-treatment Drug -Related Adverse Events 
by [System Organ Class and ]Preferred TermICH E3
Use AE1 for interim with text in [] in title
Use AE3 for final reporting with text in [] 
omitted.StInt, SAC
3.4
mITT AE15Summary of Common (>=5%) Non -serious On-treatment 
Adverse Events by [CONTACT_136491] (Number of Subject and Occurrences)FDAAA, EudraCT SAC
3.[ADDRESS_984678] -treatment Adverse Events SAC
3.6ALLSUB AE2Relationsh ip of Adverse Event System Organ Class, 
Preferred Term and Verbatim TextSAC
3.7mITT AE5ASummary of All On-treatment Adverse Events by [CONTACT_720865] E3 SAC
3.8
mITT AE5ASummary of On-treatment Drug -Related Adverse Events 
by [CONTACT_720866] E3 SAC
Serious and Other Significant Adverse Events
3.9
mITT AE16Summary of On-treatment Serious Adverse Events by 
[CONTACT_39960] (Number of 
Subjects and Occurrences)FDAAA, EudraCT SAC
3.10ALLSUB AE1/AE3Summary of Pre -treatment Serious Adverse Events by 
[System Organ Class and ]Preferred TermSAC
3.4 3.11
mITT AE1/AE3Summary of On -treatment Serious Adverse Events by 
[System Organ Class and]Preferred TermUse AE1 for interim with text in [] in title
Use AE3 for final reporting with text in [] 
omitted.StInt, SAC
CONFIDENTIA L
205724
111Safety : Tables
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.5 3.12
mITT AE1/AE3Summary of On -treatment Fatal Serious Adverse Events 
by [System Organ Class and ]Preferred TermUse AE1 for interim with text in [] in title
Use AE3 for final reporting with text in [] 
omitted.StInt, SAC
3.63.13
mITT AE1/AE3Summary of On-treatment Adverse Events Leading to 
Permanent Discontinuation of Study Treatment or 
Withdrawal from Study by [System O rgan Class and ]
Preferred TermIDSL
Use AE1 for interim with text in [] in title
Use AE3 for final reporting with text in [] 
omitted.StInt, SAC
3.73.14mITTSummary of On -treatment Adverse Events of Special 
InterestStInt, SAC
3.15
mITTSummary of On-treatment Pneumonia (AE and SAE) by 
[CONTACT_720867] 
‘Infective pneumonia’ SMQ
By [CONTACT_720868] [ADDRESS_984679] SAC
Laboratory: Chemistry 
3.83.16mITT LB1 Summary of C hemistry Changes from Baseline ICH E3, include change from baseline of 
min/max valueStInt, SAC
3.93.17mITT LB17Summary of Worst Case Chemistry Results by [CONTACT_720869] E3StInt, SAC
Laboratory: Hematology
3.103.18mITT LB1 Summary of Hematology Changes from BaselineICH E3, include change from baseline of 
min/max valueStInt, SAC
3.113.19mITT LB17Summary of Worst Case Hematology by [CONTACT_720870] E3 StInt, SAC
CONFIDENTIA L
205724
112Safety : Tables
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Laboratory: Hepatobiliary (Liver)
3.123.20
mITT LIVER1Summary/Listing of Liver Monitoring/Stoppi[INVESTIGATOR_720814] –if there are very small number of 
events this summary will be replaced 
with a listing. Table title to be 
determined by [CONTACT_375262].StInt, SAC
3.133.21
mITT LIVER10 Summary/Listing of Hepatobiliary Laboratory AbnormalitiesIDSL –if there are very small number of 
events this summary will be replaced 
with a listing. Table title to be 
determined by [CONTACT_375262].StInt, SAC
ECG
3.22 mITT EG1 Summary of ECG Findings IDSL, include min/max value SAC
3.23mITT EG2 Summary of Change from Baseline in ECG Values by [CONTACT_720871]/max valueSAC
3.143.24mITT EG10Summary of Maximum QTcF Values Post -Baseline 
Relative to Baseline by [CONTACT_720872], SAC
3.153.25mITT EG11Summary of Maximum Increase in QTcF Values Post -
Baseline Relative to Baseline by [CONTACT_720872], SAC
Vital Signs
3.26mITT VS1 Summary of Change from Baseline in Vital SignsICH E3, include change from baseli ne of 
min/max valueSAC
3.27mITT VS7Summary of Worst Case Vital Signs Results by [CONTACT_720873] L
205724
113Safety : Tables
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Spi[INVESTIGATOR_038]
3.163.28mITT Summary of Baseline Post -Bronchodilator FEV1 (L)Post bronchodilator FEV1 
Include total colum nStInt, SAC
3.[ADDRESS_984680] -Bronchodilator FEV1 (L)Post bronchodilator FEV1 
Include raw and change from baselineStInt, SAC
3.[ADDRESS_984681]-Bronchodilator 
FEV1 (L) up to Month 6Frequentist MMRM 
Endpoints: Post bronchodilator FEV1StInt, SAC
3.[ADDRESS_984682]-Bronchodilator FEV1 (L)Frequentist MMRM 
Endpoints: Post bronchodilator FEV1StInt, SAC
3.[ADDRESS_984683] -Bronchodilator FVC (L)Post bronchodilator FVC 
Include total columnStInt, SAC
3.[ADDRESS_984684] -Bronchodilator FVC (L)Post bronchodilator FVC 
Include raw and change from baselineStInt, SAC
3.[ADDRESS_984685]-Bronchodilator 
FVC (L) up to Month 6Frequentist MMRM 
Endpoints: Post bronchodilator FVCStInt, SAC
3.[ADDRESS_984686]-Bronchodilator FVC (L)Frequentist MMRM 
Endpoints: Post bronchodilator FVCStInt, SAC
3.36mITT Summary of Baseline Post -Bronchodilator FEV1/FVCPost bronchodilator FEV1/FVC 
Include total columnPost SAC
3.[ADDRESS_984687] -Bronchodilator FEV1/FVCPost bronchodilator FEV1 
Include ra w and change from baseline
Day [ADDRESS_984688] SAC
CONFIDENTIA L
205724
[ZIP_CODE].11.8. Safety  Figures
Safety : Figures
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Adverse Events
3.1
mITT AE10Plot of Common (>=5%) On -Treatment Adverse Events and 
Relative RiskIDSL
One page per active 
treatment compared to 
placebo
Include AEs which have 
>=5% incidence in any 
treatment groupSAC
Laboratory
3.[ADDRESS_984689]-
Baseline Total BilirubinIDSL StInt, SAC
3.3 3.4 mITT Plot of Mean (95% CI) Neutrophil Count s over Time StInt, SAC
3.5mITTPlot of Mean (95% CI) Neutrophil Counts over Ti me for Subjects 
with PneumoniaPost SAC
Spi[INVESTIGATOR_038]
3.6 mITT Mean (90% CI) Post -Bronchodilator FEV1 (L) over Time Baseline, Day [ADDRESS_984690] SAC
3.43.7 mITTAdjusted Mean (90% CI) Change from Baseline Post-
Bronchodilator FEV1 (L) over TimeStInt, SAC
3.8 mITT Mean (90% CI) Post -Bronchodilator FVC (L) over Time Baseline, Day [ADDRESS_984691] SAC
3.53.9 mITTAdjusted Mean (90% CI) Change from Baseline Post-
Bronchodilator FVC (L) over TimeStInt, SAC
CONFIDENTIA L
205724
115Safety : Figures
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
3.10 mITT Mean (90% CI) Post -Bronchodila tor FEV1/FVC Ratio over Time Baseline, Day [ADDRESS_984692] SAC
ECG
3.6 3.11 mITT Boxplot of Change from Baseline in QTcF by [CONTACT_720874], SAC
14.11.9. Pharmacokinetic Tables
SAC 
No.PopulationIDSL / 
Example ShellTitle Programming NotesDelivera ble 
[Priority]
4.1
PK PKCT1Summary of Danirixin Whole Blood Pharmacokinetic 
Concentration -Time Data (Dry Blood Spot)Include geometric mean and 90%  
CI for the summary of blood 
concentration dataSAC
4.2PK PKPT4Summary of Derived Danirixin Whole Blood Pharmacokinetic 
Parameters (Dry Blood Spot)SAC
4.3 PK2Table 3.10
Study 201037Summary of Statistical Analysis of Log -Transformed Danirixin 
Concentration -Time Data
Dry Blood Spot vs Wet Whole Blood Samples -Bland Altman 
AnalysisSAC
4.4 PK2Table 3.1 2
Study 201037Summary of Statistical Analysis of Log -Transformed Danirixin 
Pharmacokinetic Parameters
Dry Blood Spot vs Wet Whole Blood Samples -Bland Altman 
AnalysisSAC
4.5 PK2Table 3.11
Study 201037Summary of Statistical Analysis of Log -Transforme d Danirixin 
Pharmacokinetic Parameters
Dry Blood Spot vs Wet Whole Blood SamplesSAC
CONFIDENTIA L
205724
116SAC 
No.PopulationIDSL / 
Example ShellTitle Programming NotesDelivera ble 
[Priority]
4.6 PK2Table 3.10
Study 201037Summary of Statistical Analysis of Log -Transformed Danirixin 
Concentration -Time Data
Sensitivity Analysis: Dry Blood Spot vs Wet Whole Bl ood 
Samples -Bland Altman Analysisexcluding dry blood spot 
concentrations above the assay 
HLOQ of 1000 ng/mLSAC
4.7
PK2Table 3.12
Study 201037Summary of Statistical Analysis of Log -Transformed Danirixin 
Pharmacokinetic Parameters
Sensitivity Analysis : Dry Blood Spot vs Wet Whole Blood 
Samples -Bland Altman Analysisexcluding dry blood spot 
concentrations above the assay 
HLOQ of 1000 ng/mLSAC
4.8
PK2Table 3.11
Study 201037Summary of Statistical Analysis of Log -Transformed Danirixin 
Pharmacokinetic Parameters
Sensitivity Analysis: Dry Blood Spot vs Wet Whole Blood 
Samplesexcluding dry blood spot 
concentrations above the assay 
HLOQ of 1000 ng/mLSAC
14.11.10. Pharmacokinetic Figures
SAC 
No.PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable
[Priority]
4.[ADDRESS_984693] (Linear and Semi -log) (Dry Blood Spot)1. X-axis displays actual relative 
time
2. Include line for LLQ along with 
footnote defining LLQ value
3. Include values below LLQ
4. Overlay Visit 3, 6, 7 and 10.SAC
4.2
PK PKCF6Individual Whole Blood Danirixin Concentration -Time Plots by 
[CONTACT_2006] (Linear and Semi -log) (Dry Blood Spot)1. X-axis displays actual relative 
time
2. Include line for LLQ along with 
footnote definin g LLQ value
3. Include values below LLQSAC
CONFIDENTIA L
205724
117SAC 
No.PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable
[Priority]
4.3
PK PKCF4Mean ( SD) Whole Blood Danirixin Concentration -Time Plots 
(Linear and Semi -log) (Dry Blood Spot)1. Include the full SD bars at each 
time point
2. X-axis displays planned relative 
time
3. Include li ne for LLQ along with 
footnote defining LLQ value
4. Overlay Visit 3, 6, 7 and 10.SAC
4.4
PK PKCF5Median (Range) Whole Blood Danirixin Concentration -Time 
Plots (Linear and Semi -log) (Dry Blood Spot)1. Include bars for range at each 
time point
2. X-axisdisplays planned relative 
time
3. Include like for LLQ along with 
footnote defining LLQ value
4. Overlay Visit 3, 6, 7 and 10.SAC
4.5
PK PK27Median (Range) Pre -Dose Whole Blood Danirixin 
Concentration Versus Day (Linear and Semi -log) (Dry Blood 
Spot)1. Include bars for range at each 
time point
2. X-axis displays Visit
3. Include like for LLQ along with 
footnote defining LLQ value
4. Visit include 3, 6, 7 and 10.SAC
4.6
PKFigure 11.206
Study 200163Individual Whole Blood Pharmacokinetic Parameters 
(+Geometric Mean and 95% CI) versus DemographicsDemographics: Age, Weight, 
Gender.
By [CONTACT_4475].SAC
4.7PKScatter Plot of Whole Blood Danirixin Concentration -by [CONTACT_2006] 
(Dry Blood Spot)Post SAC
4.[ADDRESS_984694] Danirixin Bloo d Concentration -Time Plot 
(Linear and Semi -Log) by [CONTACT_720875] L
205724
118SAC 
No.PopulationIDSL / 
Example ShellTitle Programming NotesDeliverable
[Priority]
4.[ADDRESS_984695] Danirixin Blood Concentration -Time Plot 
(Linear and Semi -Log) by [CONTACT_720876]: Dry Blood Spot vs Wet Whole Blood 
Samplesexcluding dry blood spot 
concentrations above the assay 
HLOQ of 1000 ng/mLSAC
4.[ADDRESS_984696] Danirixin Blood 
Concentrations 
Sensitivity Analysis: Dry Blood Spot vs Wet Whole Blood 
Samplesexcluding dry blood spot 
concentrations above the assay 
HLOQ of 1000 ng/mLSAC
4.[ADDRESS_984697] Log -Transformed 
Danirixin Blood Concentrations
Sensitivity Analysis: Dry Blood Spot vs Wet Whole Blood 
Samplesexcluding dry blood spot 
concentrations above the assay 
HLOQ of 1000 ng/mLSAC
CONFIDENTIA L
205724
[ZIP_CODE].11.11. Pharmacokinetic / Pharmacodynamic Figure
Pharmacokinetic / Pharmacod ynamic : Figures
SAC
No.PopulationIDSL /
Example ShellTitle Programming NotesDeliverable 
[Priority]
5.1 PKScatter plot of PD endpoint versus Danirixin Concentration
(Trough)CAT Total Score 
Include Placebo imputed as DNX 
conc=0ng/mL, include DNX 
conc=NQ imputed as LLOQ/2, 
where LLOQ=5ng/mL
By [CONTACT_720877]
5.2 PK Scatter plot of Safety versus Danirixin Concentration (Trough)Blood Neutrophil Count and C -
reactive Protein (CRP)
Highlight subjects with an on -
treatm ent event in the ‘Infective 
pneumonia’ SMQ . Add footnote 
‘Note: Pneumonia may have 
occurred at any time during the 
study’
Include Placebo imputed as DNX 
conc=0ng/mL, include DNX 
conc=NQ imputed as LLOQ/2, 
where LLOQ=5ng/mL
By [CONTACT_720877]
5.[ADDRESS_984698] SAC
5.4 PK Quartile plot of Danirixin Concentration versus Safety endpointBlood Neutrophil Count and C -
reactive Protein (CRP)Post SAC
CONFIDENTIA L
205724
[ZIP_CODE].11.12. Biomark er Tables
Biomarker: Tables
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Biomarkers
6.1 6.1mITT LB1Summary of C -reactive Protein (CRP) Changes from 
BaselineICH E3 StInt, SAC
6.2 6.2 mITT LB1 Summa ry of Fibrinogen Changes from Baseline ICH E3 StInt, SAC
6.3
mITTSummary of C -reactive Protein (CRP) for Subjects with 
PneumoniaScreening, Baseline, Day [ADDRESS_984699] an event in 
the ‘Infective pneumonia’ SMQPost SAC
6.[ADDRESS_984700] an event in 
the ‘Infective pneumonia’ SMQPost SAC
CONFIDENTIA L
205724
[ZIP_CODE].11.13. Biomarker Figures
Biomarker: Figures
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Progr amming NotesDeliverable 
[Priority]
Biomarkers
6.1 6.1mITTBoxplot of C -reactive Protein (CRP) by [CONTACT_720878], Baseline, Day 84 
and 168StInt, SAC
6.2 6.2mITT Boxplot of Fibrinogen by [CONTACT_720879], Baseline, Day 84 
and 168StInt, SAC
6.2
mITTBoxplot of C -reactive Protein (CRP) over Time for 
Subjects with PneumoniaScreening, Baseline, Day [ADDRESS_984701] an event in 
the ‘Infective pneumonia’ SMQPost SAC
6.[ADDRESS_984702] an event in 
the ‘Infective pneumonia’ SMQPost SAC
CONFIDENTIA L
205724
[ZIP_CODE].11.14. ICH Listings
ICH: Listings
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority ]
Subject Disposition
[ADDRESS_984703] s with Inclusion/Exclusion 
Criteria DeviationsICH E3 SAC
8mITT IE3Listing of Subject s with Inclusion/Exclusion Criteria 
DeviationsICH E3 SAC
CONFIDENTIA L
205724
123ICH: Listings
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority ]
Populations Analysed
[ADDRESS_984704] s Excluded from Any PopulationICH E3
ITT(Strategic interim only) , 
mITT, PP, Symptomatic
(Strategic interim only) , PK and 
PK2 populationSAC
Demographic and Baseline Characteristics
[ADDRESS_984705] Scores
15 mITT Listing of E -RS: COPD Daily Scores Total and subscale scores SAC
Adverse Events
[ADDRESS_984706] Numb ers for Individual Adverse Events ICH E3 SAC
18 mITTAE2Listing of Relationship Between Adverse Event System 
Organ Classes, Preferred Terms, and Verbatim TextIDSL SAC
CONFIDENTIA L
205724
124ICH: Listings
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority ]
Serious and Other Significant Adverse Events
19mITTAE8 / 
AE8CPaListing of Fatal Serious Adverse Events ICH E3 SAC
20mITTAE8 / 
AE8CPaListing of Non -Fatal Serious Adverse Events ICH E3 SAC
21mITT AE14Listing of Reasons for Considering as a Serious Adverse 
EventICH E3 SAC
22mITT AE8 / AECP8 Listing of Adverse Events Leadin g to Withdrawal from 
Study / Permanent Discontinuation of Study TreatmentICH E3 SAC
23 mITT AE8 / AECP8 Listing of Drug -Related Adverse Events ICH E3 SAC
24 mITT AE8 / AECP8 Listing of Adverse Events of Special Interest ICH E3 SAC
Hepatobiliary (Li ver)
25mITT MH2Listing of Medical Conditions for Subject s with Liver 
Stoppi[INVESTIGATOR_720815]
26mITT SU2Listing of Substance Use for Subject s with Liver Stoppi[INVESTIGATOR_720816]
27mITT LB5 Listing of Chemistry Data for Subject s with Any Value of 
Potential Clinical ImportanceICH E3 SAC
28mITT LB5 Listing of Haematology Data for Subject s with Any Value of 
Potential Clinical ImportanceICH E3 SAC
29mITT LB5 Listing of Chemistry Values of Potential Clinical 
ImportanceSAC
CONFIDENTIA L
205724
125ICH: Listings
StInt
No.SAC 
No. PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority ]
30mITT LB5 Listing of Haematology Values of Potential Clinical 
ImportanceSAC
[ADDRESS_984707] s with Any Value 
of Potential Clinical ImportanceIDSL SAC
CONFIDENTIA L
205724
[ZIP_CODE].11.15. Non-ICH Listings
Non-ICH: Listings
StInt 
No.SAC
No.PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
Subject Disposi tion
37. ALLSUB ES9 Listing of Subjects Who Were RescreenedInclude Inclusion/ Exclusion/ 
Randomization Criteria 
DeviationsSAC
38. ALLSUB Listing of Study Treatment Misallocations SAC
Demographic and Baseline Characteristics
39. mITT Listing of Smoking H istory and Smoking Status SAC
40. mITT Listing of COPD History and Exacerbation History SAC
41. mITTListing of Screening Spi[INVESTIGATOR_720817] % predicted category 
(</>=50%)SAC
42. mITT Listing of Baseline Symptomatic Characteristics Contents as for table SAC
Past and Current Medical History
43. mITT Listing of Medical Conditions SAC
44. mITT Listing of Family History of Cardiovascular Risk Factors SAC
45. mITT Listing of Percent Oxygen in Blood SAC
Treatment Comp liance
46. mITT Listing of Treatment Compliance SAC
CONFIDENTIA L
205724
127Non-ICH: Listings
StInt 
No.SAC
No.PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
E-RS: COPD 
47. mITTListing of E -RS: COPD Baseline and Monthly Mean 
ScoresInclude baseline and baseline 
category (</>=10) 
Total and subscale scores
Include change from baseline 
and seasonSAC
Exacer bations
48. mITT Listing of HCRU Exacerbation Data SAC
EXACT Events
49. mITT Listing of EXACT Event Data SAC
SGRQ
50. mITT Listing of SGRQ ScoresTotal and domain scores
Baseline, absolute and change 
from baselineSAC
CAT
51. mITT Listing of CAT Score sTotal score
Baseline, absolute and change 
from baseline and seasonSAC
Rescue Use
52. mITT Listing of Derived Rescue Use from Diary Monthly means
Absolute, baseline and change 
from baselineSAC
CONFIDENTIA L
205724
128Non-ICH: Listings
StInt 
No.SAC
No.PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
53. mITT Listing of Derived Rescue Use from Sensor Monthl y means
Baseline, absolute and change 
from baselineSAC
Physical Activity
54. mITT Listing of C -PPAC Questionnaire Responses SAC
55. mITT Listing of Activity Monitor Data SAC
56. mITT Listing of PROactive ScoresTotal and domain scores
Baseline, absolut e and change 
from baselineSAC
Subject Global Assessments
57. mITT Listing of Subject Global Assessments SAC
Biomarkers
58. mITT Listing of Biomarkers SAC
ECG
2.59. mITTListing of Subjects with Maximum Post -Baseline QTcF 
increasing to over 500msec or by 60 msec from BaselineStInt, SAC
PK
60. PK PKCL1PListing of Danirixin Blood Concentration -Time Data –Dry 
Blood Spot SamplesSAC
61. PK PKPL1PListing of Danirixin Blood Pharmacokinetic Parameter –
Dry Blood Spot SamplesSAC
62. PK2 PKCL1PListing o f Danirixin Blood Concentration -Time Data –Wet 
Whole Blood SamplesSAC
CONFIDENTIA L
205724
129Non-ICH: Listings
StInt 
No.SAC
No.PopulationIDSL / 
Example 
ShellTitle Programming NotesDeliverable 
[Priority]
63. PK2 PKPL1PListing of Danirixin Blood Pharmacokinetic Parameter –
Wet Whole Blood SamplesSAC
64. PK2Listing 40
Study 
201037Supportive SAS Output from Statistical Analysis of Log -
Transformed Danirixin Blood Pharmacokinetic 
Concentration Data -Bland Altman AnalysisSAC
65. PK2Listing 42
Study 
2101037Supportive SAS Output from Statistical Analysis of Log -
Transformed Danirixin Pharmacokinetic Parameters -
Bland Altman AnalysisSAC
66. PK2Listing 41
Study 
201037Supportive SAS Output from Statistical Analysis of Log -
Transformed Danirixin Pharmacokinetic ParametersSAC
67. PK2Listing 40
Study 
201037Supportive SAS Output from Statistical Analysis of Log -
Transformed Sensitivity Anal ysis: Danirixin Blood 
Pharmacokinetic Concentration Data -Bland Altman 
Analysisexcluding dry blood spot 
concentrations above the assay 
HLOQ of 1000 ng/mLSAC
68. PK2Listing 42
Study 
2101037Supportive SAS Output from Statistical Analysis of Log -
Transform ed Sensitivity Analysis: Danirixin
Pharmacokinetic Parameters -Bland Altman Analysisexcluding dry blood spot 
concentrations above the assay 
HLOQ of 1000 ng/mLSAC
69. PK2Listing 41
Study 
201037Supportive SAS Output fr om Statistical Analysis of Log -
Trans formed Sensitivity Analysis: Danirixin
Pharmacokinetic Parametersexcluding dry blood spot 
concentrations above the assay 
HLOQ of 1000 ng/mLSAC
CONFIDENTIA L
205724
[ZIP_CODE].12. Appendix 12: Example Mock Shells for Data Display s
Mock shells will be created in a separate document.